

**ALKERMES PUBLIC LIMITED COMPANY**  
**DIRECTORS' REPORT AND CONSOLIDATED FINANCIAL STATEMENTS**  
**For the Financial Year Ended December 31, 2020**  
**Registered Company Number: 498284**

**ALKERMES PUBLIC LIMITED COMPANY**  
**DIRECTORS' REPORT AND CONSOLIDATED FINANCIAL STATEMENTS**  
**TABLE OF CONTENTS**

<a href="#">Directors' Report</a> .....	3
<a href="#">Statement of Directors' Responsibilities</a> .....	57
<a href="#">Independent Auditors' Report—Group and Company</a> .....	58
<a href="#">Consolidated Profit and Loss Account</a> .....	64
<a href="#">Consolidated Statement of Comprehensive Loss</a> .....	65
<a href="#">Consolidated Balance Sheet</a> .....	66
<a href="#">Consolidated Statement of Cash Flows</a> .....	67
<a href="#">Consolidated Reconciliation of Movement in Shareholders' Funds</a> .....	68
<a href="#">Notes to the Consolidated Financial Statements</a> .....	69
<a href="#">Company Balance Sheet</a> .....	111
<a href="#">Company Reconciliation of Movement in Shareholders' Funds</a> .....	112
<a href="#">Notes to the Company Financial Statements</a> .....	113

## DIRECTORS' REPORT

### For the Financial Year Ended December 31, 2020

The directors present their report and the audited consolidated financial statements and related notes of Alkermes Public Limited Company ("Alkermes plc") for the year ended December 31, 2020. Irish law requires the directors to prepare financial statements for each financial year that give a true and fair view of the consolidated and company's assets, liabilities and financial position as at the end of the financial year and of the profit or loss of the group for the financial year. Under that law, the directors have prepared the consolidated financial statements in accordance with U.S. accounting standards, as defined in Section 279(1) of the Companies Act 2014, as amended (the "Companies Act"), to the extent that the use of those principles in the preparation of the financial statements does not contravene any provision of the Companies Act or of any regulations made thereunder and the parent company financial statements in accordance with generally accepted accounting practice in Ireland (accounting standards issued by the Financial Reporting Council and Irish law).

#### NOTE REGARDING COMPANY AND PRODUCT REFERENCES

Use of terms such as "us," "we," "our," "Alkermes" or the "Company" in this Directors' Report is meant to refer to Alkermes plc and its consolidated subsidiaries. Except as otherwise suggested by the context, (a) references to "products" or "our products" in this Directors' Report include our marketed products, marketed products using our proprietary technologies, our product candidates and product candidates using our proprietary technologies (b) references to the "biopharmaceutical industry" in this Directors' Report are intended to include reference to the "biotechnology industry" and/or the "pharmaceutical industry" and (c) references to "licensees" in this Directors' Report are used interchangeably with references to "partners."

#### NOTE REGARDING TRADEMARKS

We are the owner of various United States ("U.S.") federal trademark registrations ("®") and other trademarks ("™"), including ALKERMES®, ARISTADA®, ARISTADA INITIO®, LinkeRx®, LYBALVI™, NanoCrystal®, and VIVITROL®.

The following are trademarks of the respective companies listed: ABILIFY® and ABILIFY MAINTENA®—Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharm. Co."); AMPYRA® and FAMPYRA®—Acorda Therapeutics, Inc. ("Acorda"); ANTABUSE®—Teva Women's Health, Inc.; AUBAGIO® and LEMTRADA®—Sanofi Societe Anonyme France; AVONEX®, PLEGRIDY®, TECFIDERA®, TYSABRI® and VUMERITY®—Biogen MA Inc. (together with its affiliates, "Biogen"); BETASERON®—Bayer Pharma AG; BUNAVAIL™—BioDelivery Sciences; CAMPRAL®—Merck Sante; CAPLYTA®—Intra-Cellular Therapies, Inc.; COPAXONE®—Teva Pharmaceutical Industries Ltd.; EXTAVIA®, GILENYA®, and MAYZENT®—Novartis AG; INVEGA SUSTENNA®, INVEGA TRINZA®, TREVICTA®, XEPLION® and RISPERDAL CONSTA®—Johnson & Johnson (or its affiliates); LATUDA®—Sumitomo Dainippon Pharma Co., Ltd.; MAVENCLAD®—Merck KGaA, REBIF®—Ares Trading S.A.; OCREVUS®—Genentech, Inc. ("Genentech"); REXULTI®—H. Lundbeck A/S plc; PERSERIS®, SUBOXONE®, SUBUTEX® and SUBLOCADE®—Indivior plc (or its affiliates); VRAYLAR®—Forest Laboratories, LLC; ZEPOSIA®—Bristol-Myers Squibb Company; ZUBSOLV®—Orexo US, Inc.; and ZYPREXA® and ZYPREXA RELPREVV®—Eli Lilly and Company ("Lilly"). Other trademarks, trade names and service marks appearing in this Directors' Report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Directors' Report are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

#### CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS

This document contains and incorporates by reference "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, these statements can be identified by the use of forward-looking terminology such as "may," "will," "could," "should," "would," "expect," "anticipate," "continue," "believe," "plan," "estimate," "intend," or other similar words. These statements discuss future expectations and contain projections of results of operations or of financial condition, or state trends and known uncertainties or other forward-looking information. Forward-looking statements in this Directors' Report include, without limitation, statements regarding:

- our expectations regarding our financial performance, including revenues, expenses, liquidity, capital expenditures and income taxes;
- our expectations regarding our products, including those expectations related to product development, regulatory filings, regulatory approvals and regulatory timelines, therapeutic and commercial scope and potential, and the costs and expenses related to such activities;
- our expectations regarding the initiation, timing and results of clinical trials of our products;

- our expectations regarding the competitive, payer, legislative, regulatory and policy landscapes, and changes therein, related to our products, including competition from generic forms of our products or competitive products and competitive development programs, barriers to access or coverage of our products and changes in reimbursement of our products, and legislation, regulations, executive orders, guidance or other measures that may limit pricing and reimbursement of, and access to, our products;
- our expectations regarding the financial impact of currency exchange rate fluctuations and valuations;
- our expectations regarding future amortization of intangible assets;
- our expectations regarding our collaborations, licensing arrangements and other significant agreements with third parties relating to our products, including our development programs;
- our expectations regarding the impact of new legislation, rules, regulations and the adoption of new accounting pronouncements;
- our expectations regarding near-term changes in the nature of our market risk exposures or in management’s objectives and strategies with respect to managing such exposures;
- our expectations regarding our ability to comply with restrictive covenants of our indebtedness and our ability to fund our debt service obligations;
- our expectations regarding future capital requirements and capital expenditures and our ability to finance our operations and capital requirements;
- our expectations regarding the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our products and intellectual property (“IP”), including our patents;
- our expectations regarding the impact of the ongoing novel coronavirus (“COVID-19”) pandemic on our business and operations; and
- other factors discussed elsewhere in this Directors’ Report.

Actual results might differ materially from those expressed or implied by these forward-looking statements because these forward-looking statements are subject to risks, assumptions and uncertainties. In light of these risks, assumptions and uncertainties, the forward-looking events discussed in this Directors’ Report might not occur. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this Directors’ Report. All subsequent written and oral forward-looking statements concerning the matters addressed in this Directors’ Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Except as required by applicable law or regulation, we do not undertake any obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For more information regarding the risks, assumptions and uncertainties of our business, see the “Principal Risks” section of this Directors’ Report.

This Directors’ Report includes data that we obtained from industry publications and third-party research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. This Directors’ Report also includes data based on our own internal estimates and research. Our internal estimates and research have not been verified by any independent source, and, while we believe the industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Such third-party data and our internal estimates and research are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the “Principal Risks” section of this Directors’ Report. These and other factors could cause results to differ materially from those expressed in this Directors’ Report.

### **Principal Activities**

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Headquartered in Dublin, Ireland, Alkermes has a research

and development (“R&D”) center in Waltham, Massachusetts; an R&D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

## **COVID-19 Update**

In March 2020, COVID-19 was declared a global pandemic by the World Health Organization. To date, COVID-19 has surfaced in nearly all regions around the world and resulted in travel restrictions and business slowdowns and/or shutdowns in affected areas. All U.S. states, and many local jurisdictions and countries around the world, including Ireland, have, at times during the pandemic, issued “shelter-in-place” orders, quarantines, executive orders and similar government orders, restrictions, and recommendations for their residents to control the spread of COVID-19. Such orders, restrictions and/or recommendations, and/or the perception that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses, including healthcare systems that serve people living with opioid dependence, alcohol dependence and schizophrenia, work stoppages, slowdowns and/or delays, work-from-home policies and travel restrictions, among other effects.

We continue to closely monitor and rapidly respond to the ongoing impact of COVID-19 on our employees, our communities and our business operations. We have adopted a series of precautionary measures and will continue to do so as the circumstances warrant, in an effort to protect our employees and mitigate the potential spread of COVID-19 in a community setting. For example, we instituted a global remote work policy for those of our employees who are able to work remotely. Certain of our field-based employees have since resumed in-person interactions, as appropriate and on a voluntary basis, in accordance with location-specific guidance.

At the same time, we have worked to continue our critical business functions, including continued operation of our manufacturing facilities and our laboratories, and have continued to conduct our discovery efforts and supply our medicines. For those of our employees who work in our manufacturing facilities and laboratories or who otherwise enter any of our sites, we have instituted, and will continue to institute as we deem appropriate and as required, additional safety precautions, including increased sanitization of our facilities, use of personal protective equipment, implementation of a daily health screening application and physical distancing practices to help protect their health and safety. We have also taken actions to support people living with schizophrenia, opioid dependence and alcohol dependence to help assure that they have access to the information, resources and medicines that may assist in their treatment.

The marketed products from which we derive revenue, including manufacturing and royalty revenue, are primarily injectable medications administered by healthcare professionals. Given developments that have transpired to date, and may continue to transpire, in response to the pandemic, including the implementation of “shelter-in-place” policies, social distancing requirements and other restrictive measures, commercial sales of these marketed products have been adversely impacted to varying degrees and we expect commercial sales of these marketed products to continue to be adversely impacted while the pandemic persists.

During the year ended December 31, 2020, we took actions to support uninterrupted access to our proprietary marketed products. However, we currently expect commercial sales of our marketed products, particularly VIVITROL, to be impacted by the COVID-19 pandemic into 2021. The impact COVID-19 had on our proprietary marketed products during the year ended December 31, 2020 is discussed in greater detail later in the “Results of Operations” section of this Directors’ Report.

While we continue to conduct R&D activities, including our ongoing clinical trials, the COVID-19 pandemic has impacted, and may continue to impact, the timelines of certain of our early-stage discovery efforts and clinical trials. We are working with our internal teams, our clinical investigators, R&D vendors and critical supply chain vendors to continually assess, and mitigate, the potential impact of COVID-19 on our manufacturing operations and R&D activities.

Due to numerous uncertainties surrounding the ongoing COVID-19 pandemic, the actual impact on our financial condition and operating results resulting from the pandemic may differ from our current projections. These uncertainties include, among other things, the ultimate severity and duration of the pandemic; governmental, business or other actions that have been, are being, or will be, taken in response to the pandemic, including restrictions on travel and mobility, business closures and operating restrictions and imposition of social distancing measures; impacts of the pandemic on our employees, the vendors or distribution channels in our supply chain and on our ability to continue to manufacture our products; impacts of the pandemic on the conduct of our clinical trials, including with respect to enrollment rates, availability of investigators and clinical trial sites, and monitoring of data; impacts of the pandemic on healthcare systems that serve people living with opioid dependence, alcohol dependence and schizophrenia; impacts of the pandemic on the regulatory agencies with which we interact in the development, review, approval and commercialization of our medicines; impacts of the pandemic on reimbursement for our products, including our Medicaid rebate liability, and for services related to the use of our products; and impacts of the pandemic on the U.S., Irish and global economies more broadly. For additional information about risks

and uncertainties related to the COVID-19 pandemic that may impact our business, our financial condition or our results of operations, see “Principal Risks” of this Directors’ Report.

## Business Overview

### Marketed Products

The key marketed products discussed below are expected to generate significant revenues for us. Refer to the “Patents and Proprietary Rights” section of this Directors’ Report for information with respect to the IP protection for these marketed products.

The following provides summary information regarding our proprietary products that we commercialize:

Product	Indication(s)	Territory
ARISTADA INITIO	Initiation or re-initiation of ARISTADA for the treatment of Schizophrenia	U.S.
ARISTADA	Schizophrenia	U.S.
VIVITROL	Alcohol dependence and Opioid dependence	U.S.

The following provides summary information regarding our key licensed products, and key third-party products using our proprietary technologies under license that are commercialized by our licensees:

### Third-Party Products Using Our Proprietary Technologies

Product	Indication(s)	Licensee	Licensed Territory
RISPERDAL CONSTA	Schizophrenia and Bipolar I disorder	Janssen Pharmaceutica Inc. (“Janssen, Inc.”) and Janssen Pharmaceutica International, a division of Cilag International AG (“Janssen International”)	Worldwide
INVEGA SUSTENNA / XEPLION	INVEGA SUSTENNA: Schizophrenia and Schizoaffective disorder  XEPLION: Schizophrenia	Janssen Pharmaceutica N.V. (together with Janssen, Inc. Janssen International and their affiliates “Janssen”) Janssen	Worldwide
INVEGA TRINZA / TREVICTA	Schizophrenia	Janssen	Worldwide

### Our Licensed Products

Product	Indication(s)	Licensee	Licensed Territory
VIVITROL	Alcohol dependence and Opioid dependence	Cilag GmbH International (“Cilag”)	Russia and Commonwealth of Independent States (“CIS”)
VUMERITY	Multiple sclerosis	Biogen	Worldwide

### Proprietary Products

We have developed and commercialize products designed to address the unmet needs of patients suffering from opioid dependence, alcohol dependence and schizophrenia. Refer to the “Patents and Proprietary Rights” section of this Directors’ Report for information with respect to the IP protection for our proprietary products.

### ARISTADA

ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA is the first of our products to utilize our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is available in four dose strengths with once-monthly dosing options (441 mg, 662 mg and 882 mg), a six-week dosing option (882 mg) and a two-month dosing option (1064 mg). ARISTADA is packaged in a ready-to-use, pre-filled product format. We developed ARISTADA and exclusively manufacture and commercialize it in the U.S.

## **ARISTADA INITIO**

ARISTADA INITIO (aripiprazole lauroxil) leverages our proprietary NanoCrystal technology and provides an extended-release formulation of aripiprazole lauroxil in a smaller particle size compared to ARISTADA thereby enabling faster dissolution and more rapid achievement of relevant levels of aripiprazole in the body. ARISTADA INITIO, combined with a single 30 mg dose of oral aripiprazole, is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults. The first ARISTADA dose may be administered on the same day as the ARISTADA INITIO regimen or up to 10 days thereafter. We developed ARISTADA INITIO and exclusively manufacture and commercialize it in the U.S.

### *What is schizophrenia?*

Schizophrenia is a serious brain disorder marked by positive symptoms (hallucinations and delusions, disorganized speech and thoughts, and agitated or repeated movements) and negative symptoms (depression, blunted emotions and social withdrawal). Approximately 2.4 million adults are diagnosed with schizophrenia in the U.S., with men and women affected equally. Worldwide, it is estimated that one person in every 100 develops schizophrenia. Studies have demonstrated that as many as 75% of patients with schizophrenia have difficulty taking their oral medication on a regular basis, which can lead to worsening of symptoms.

## **VIVITROL (U.S.)**

VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We developed and exclusively manufacture VIVITROL and we commercialize VIVITROL in the U.S.

For a discussion of legal proceedings related to VIVITROL, see Note 20, *Commitments and Contingent Liabilities* in the “Notes to Consolidated Financial Statements” in this Directors’ Report, and for information about risks relating to such legal proceedings, see “Principal Risks” in this Directors’ Report and specifically the sections entitled “—Patent and other IP protection for our products is key to our business and our competitive position but is uncertain,” “—Uncertainty over IP in the biopharmaceutical industry has been the source of litigation, which is inherently costly and unpredictable, could significantly delay or prevent approval or negatively impact commercialization of our products, and could adversely affect our business” and “—Litigation or arbitration filed against Alkermes, including securities litigation or regulatory actions (such as citizens petitions) filed against regulatory agencies in respect of our products, may result in financial losses, harm our reputation, divert management resources, negatively impact the approval of our products, or otherwise negatively impact our business.”

### *What are opioid dependence and alcohol dependence?*

Opioid dependence is a serious and chronic brain disease characterized by compulsive, prolonged self-administration of opioid substances that are not used for a medical purpose. According to the 2019 U.S. National Survey on Drug Use and Health, an estimated 1.5 million people aged 18 or older in the U.S. had an opioid use disorder in the past year. Alcohol dependence is a serious and chronic brain disease characterized by cravings for alcohol, loss of control over drinking, withdrawal symptoms and an increased tolerance for alcohol. According to the 2019 U.S. National Survey on Drug Use and Health, an estimated 14.1 million people aged 18 or older in the U.S. had an alcohol use disorder in the past year. Adherence to medication is particularly challenging with these patient populations.

In 2013, with the publication of the Diagnostic Statistical Manual (“DSM”) 5, the DSM IV diagnoses of substance use disorders as either dependence or abuse (i.e., opioid dependence or alcohol dependence), which reflects the approved indication of VIVITROL, were combined into one diagnostic category of “substance use disorders” (i.e., opioid use disorder or alcohol use disorder) with three categories of disorder severity—mild, moderate or severe.

## **Licensed Products and Products Using Our Proprietary Technologies**

We have licensed products to third parties for commercialization and have licensed our proprietary technologies to third parties to enable them to develop, commercialize and/or manufacture products. See “Patents and Proprietary Rights” section of this Directors’ Report for information with respect to the IP protection for these products. We receive royalties and/or manufacturing and other revenues from the commercialization of these products. Such arrangements include the following:

### ***INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and RISPERDAL CONSTA***

INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate 3-month injection) and RISPERDAL CONSTA (risperidone long-acting injection) are long-acting atypical antipsychotics owned and commercialized worldwide by Janssen that incorporate our proprietary technologies.

INVEGA SUSTENNA is approved in the U.S. for the treatment of schizophrenia and for the treatment of schizoaffective disorder as either a monotherapy or adjunctive therapy. Paliperidone palmitate extended-release injectable suspension is approved in the European Union (“EU”) and other countries outside of the U.S. for the treatment of schizophrenia and is marketed and sold under the trade name XEPLION. INVEGA SUSTENNA/XEPLION uses our nanoparticle injectable extended-release technology to increase the rate of dissolution and enable the formulation of an aqueous suspension for once-monthly intramuscular administration. INVEGA SUSTENNA/XEPLION is manufactured by Janssen.

INVEGA TRINZA is approved in the U.S. for the treatment of schizophrenia in patients who have been adequately treated with INVEGA SUSTENNA for at least four months. TREVICTA is approved in the EU for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION. INVEGA TRINZA/TREVICTA is dosed once every three months. INVEGA TRINZA/TREVICTA uses our proprietary technology and is manufactured by Janssen.

For a discussion of legal proceedings related to the patents covering INVEGA SUSTENNA and INVEGA TRINZA, see Note 20, *Commitments and Contingent Liabilities* in the “Notes to Consolidated Financial Statements” in this Directors’ Report and for information about risks relating to such legal proceedings, see “Principal Risks” in this Directors’ Report and specifically the section entitled “—We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.”

RISPERDAL CONSTA is approved in the U.S. for the treatment of schizophrenia and as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA is approved in numerous countries outside of the U.S. for the treatment of schizophrenia and the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one intramuscular injection every two weeks. RISPERDAL CONSTA microspheres are exclusively manufactured by us. For a discussion of legal proceedings related to certain of the patents covering RISPERDAL CONSTA, see Note 20, *Commitments and Contingent Liabilities* in the “Notes to Consolidated Financial Statements” in this Directors’ Report and for information about risks relating to such legal proceedings, see “Principal Risks” in this Directors’ Report and specifically the section entitled “—We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.”

#### *What is bipolar I disorder?*

Bipolar I disorder is a brain disorder that causes unusual shifts in a person’s mood, energy and ability to function. Patients with this brain disorder may experience debilitating mood swings, from extreme highs (mania) to extreme lows (depression). Bipolar I disorder is characterized based on the occurrence of at least one manic episode, with or without the occurrence of a major depressive episode and affects approximately one percent of the American adult population in any given year. The median age of onset for bipolar I disorder is 25 years.

#### *What is schizoaffective disorder?*

Schizoaffective disorder is a condition in which a person experiences a combination of schizophrenia symptoms, such as delusions, hallucinations or other symptoms characteristic of schizophrenia, and mood disorder symptoms, such as mania or depression. Schizoaffective disorder is a serious mental illness that affects about one in 300 people.

### ***VIVITROL (Russia and CIS)***

VIVITROL is described more fully above under the heading “Proprietary Products” in “Business Overview” in this Directors’ Report. We developed and exclusively manufacture VIVITROL for Cilag. Cilag exclusively commercializes VIVITROL in Russia and certain countries of the CIS.

### ***VUMERITY***

VUMERITY (diroximel fumarate) is a novel, oral fumarate with a distinct chemical structure that was approved in the U.S. in October 2019 for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.



Under our license and collaboration agreement with Biogen, Biogen holds the exclusive, worldwide license to develop and commercialize VUMERITY. For more information about the license and collaboration agreement with Biogen, see “Collaborative Arrangements—Biogen” in “Business Overview” in this Directors’ Report.

#### *What is multiple sclerosis?*

Multiple sclerosis, or MS, is an unpredictable, often disabling disease of the central nervous system (“CNS”), which interrupts the flow of information within the brain, and between the brain and body. MS symptoms can vary over time and from person to person. Symptoms may include extreme fatigue, impaired vision, problems with balance and walking, numbness or pain and other sensory changes, bladder and bowel symptoms, tremors, problems with memory and concentration and mood changes, among others. Approximately 2.5 million people worldwide have MS, and most are diagnosed between the ages of 15 and 50.

#### Key Development Programs

Our R&D is focused on the development of novel, competitively advantaged medications designed to enhance patient outcomes. As part of our ongoing R&D efforts, we have devoted, and will continue to devote, significant resources to conducting preclinical work and clinical studies to advance the development of new pharmaceutical products. The discussion below highlights our current key R&D programs. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in “Principal Risks” in this Directors’ Report. See “Patents and Proprietary Rights” in “Business Overview” in this Directors’ Report for information with respect to the intellectual property protection for our development candidates.

#### ***LYBALVI (formerly referred to as ALKS 3831)***

LYBALVI (olanzapine/samidorphan) is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. LYBALVI is composed of samidorphan, a novel, new molecular entity, co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.

LYBALVI is designed to provide the robust antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. The ENLIGHTEN clinical development program for LYBALVI includes two key phase 3 studies in patients with schizophrenia: ENLIGHTEN-1, a four-week study which evaluated the antipsychotic efficacy of LYBALVI compared to placebo, and ENLIGHTEN-2, a six-month study which assessed weight gain with LYBALVI compared to ZYPREXA® (olanzapine). The program also includes supportive studies to evaluate the pharmacokinetic (“PK”) and metabolic profile and long-term safety of LYBALVI, and PK bridging studies comparing LYBALVI and ZYPREXA.

In November 2020, we received a Complete Response Letter (“CRL”), which included a request for information, from the U.S. Food and Drug Administration (“FDA”) regarding the LYBALVI New Drug Application (“NDA”), following its remote review of manufacturing records requested under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the “FDCA”) relating to the manufacture of LYBALVI at our Wilmington, Ohio facility. In December 2020, we resubmitted the NDA, and the FDA acknowledged receipt of our NDA resubmission and assigned the NDA a Prescription Drug User Fee Act (“PDUFA”) target action date of June 1, 2021. Following our NDA resubmission, the FDA issued a new request for records under Section 704(a)(4) of the FDCA to supplement the information that we previously provided.

The LYBALVI NDA is a 505(b)(2) NDA and includes data from the ENLIGHTEN clinical development program in patients with schizophrenia, as well as PK bridging data comparing LYBALVI and ZYPREXA. For more information about 505(b)(2) NDAs, see the “Regulatory, Hatch-Waxman Act” section of “Item 1—Business” in our Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 11, 2020 (our “2020 Form 10-K”). We are seeking approval of LYBALVI for the treatment of schizophrenia and for the treatment of manic and mixed episodes associated with bipolar I disorder as a monotherapy or adjunct to lithium or valproate and for maintenance treatment of bipolar I disorder, and of fixed dosage strengths of LYBALVI composed of 10 mg of samidorphan co-formulated with 5 mg, 10 mg, 15 mg or 20 mg of olanzapine.

### ***nemvaleukin alfa (formerly referred to as ALKS 4230)***

Nemvaleukin alfa (“nemvaleukin”) is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (“IL-2”) and the high affinity IL-2 alpha receptor chain, designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven antitumor effects of existing IL-2 therapy while mitigating certain limitations.

ARTISTRY is our clinical development program evaluating nemvaleukin in patients with advanced solid tumors. ARTISTRY-1 and ARTISTRY-2 are phase 1/2 studies evaluating the safety, tolerability, efficacy and pharmacokinetic and pharmacodynamic effects of nemvaleukin in patients with refractory advanced solid tumors, in both monotherapy and combination settings with the PD-1 inhibitor pembrolizumab. Nemvaleukin is being evaluated with intravenous administration in ARTISTRY-1 and with subcutaneous administration in ARTISTRY-2. ARTISTRY-3 is a phase 2 study evaluating the clinical and immunologic effects of nemvaleukin monotherapy administered intravenously on the tumor microenvironment in a variety of advanced, malignant solid tumors.

### **Collaborative Arrangements**

We have entered into several collaborative arrangements to develop and commercialize products and, in connection with such arrangements, to access technological, financial, marketing, manufacturing and other resources.

#### ***Janssen***

##### **INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA**

Under our license agreement with Janssen Pharmaceutica N.V., we granted Janssen a worldwide exclusive license under our NanoCrystal technology to develop, commercialize and manufacture INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA and related products.

Under this license agreement, we received milestone payments upon the achievement of certain development goals from Janssen; there are no further milestones to be earned under this agreement. We receive tiered royalty payments between 3.5% and 9% of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA end-market net sales in each country where the license is in effect, with the exact royalty percentage determined based on aggregate worldwide net sales. The tiered royalty payments consist of a patent royalty and a know-how royalty, both of which are determined on a country-by-country basis. The patent royalty, which equals 1.5% of net sales, is payable in each country until the expiration of the last of the patents with valid claims applicable to the product in such country. The know-how royalty is a tiered royalty of 3.5% on calendar year net sales up to \$250 million, 5.5% on calendar year net sales of between \$250 million and \$500 million and 7.5% on calendar year net sales exceeding \$500 million. The know-how royalty rate resets to 3.5% at the beginning of each calendar year and is payable until 15 years from the first commercial sale of a product in each individual country, subject to the expiry of the license agreement. These royalty payments may be reduced in any country based on patent litigation or on competing products achieving certain minimum sales thresholds. The license agreement expires upon the expiration of the last of the patents subject to the agreement. After expiration, Janssen retains a non-exclusive, royalty-free license to develop, manufacture and commercialize the products.

Janssen may terminate the license agreement in whole or in part upon three months’ notice to us. We and Janssen have the right to terminate the agreement upon a material breach of the other party, which is not cured within a certain time period, or upon the other party’s bankruptcy or insolvency.

##### **RISPERDAL CONSTA**

Under a product development agreement, we collaborated with Janssen on the development of RISPERDAL CONSTA. Under the development agreement, Janssen provided funding to us for the development of RISPERDAL CONSTA, and Janssen is responsible for securing all necessary regulatory approvals for the product.

Under two license agreements, we granted Janssen and an affiliate of Janssen exclusive worldwide licenses to use and sell RISPERDAL CONSTA. Under our license agreements with Janssen, we receive royalty payments equal to 2.5% of Janssen’s end-market net sales of RISPERDAL CONSTA in each country where the license is in effect based on the quarter when the product is sold by Janssen. This royalty may be reduced in any country based on lack of patent coverage and significant competition from generic versions of the product. Janssen can terminate the license agreements upon 30 days’ prior written notice to us. Either party may terminate the license agreements by written notice following a breach which continues for 90 days after the delivery of written notice thereof or upon the other party’s insolvency. The licenses granted to Janssen expire on a country-by-country basis upon the later of (i) the expiration of the last patent claiming the product in such country or (ii) 15 years after the date of the first commercial sale of the product in such country, provided that in no event

will the license granted to Janssen expire later than the twentieth anniversary of the first commercial sale of the product in each such country, with the exception of Canada, France, Germany, Italy, Japan, Spain and the United Kingdom, in each case, where the fifteen-year minimum shall pertain regardless. After expiration, Janssen retains a non-exclusive, royalty-free license to manufacture, use and sell RISPERDAL CONSTA.

We exclusively manufacture RISPERDAL CONSTA for commercial sale. Under our manufacturing and supply agreement with Janssen, we receive manufacturing revenue based on a percentage of Janssen's net unit sales price for RISPERDAL CONSTA for the applicable calendar year. This percentage is determined based on Janssen's unit demand for such calendar year and varies based on the volume of units shipped, with a minimum manufacturing fee of 7.5%. Either party may terminate the manufacturing and supply agreement upon a material breach by the other party, which is not resolved within 60 days after receipt of a written notice specifying the material breach or upon written notice in the event of the other party's insolvency or bankruptcy. Janssen may terminate the agreement upon six months' written notice to us. In the event that Janssen terminates the manufacturing and supply agreement without terminating the license agreements, the royalty rate payable to us on Janssen's net sales of RISPERDAL CONSTA would increase from 2.5% to 5.0%.

Revenues from our collaborative arrangements with Janssen accounted for approximately 33% and 28% of our consolidated revenues for the years ended December 31, 2020 and 2019, respectively.

### *Acorda*

Under an amended and restated license agreement, we granted Acorda an exclusive worldwide license to use and sell and, solely in accordance with our supply agreement, to make or have made, AMPYRA/FAMPYRA. We receive certain commercial and development milestone payments, license revenues and a royalty of approximately 10% based on net selling price of AMPYRA and FAMPYRA by Acorda and its sub-licensee, Biogen. This royalty payment may be reduced in any country based on lack of patent coverage, competing products achieving certain minimum sales thresholds, and whether we manufacture the product.

In June 2009, we entered into an amendment of the amended and restated license agreement and the supply agreement with Acorda and, pursuant to such amendment, consented to the sublicense by Acorda to Biogen of Acorda's rights to use and sell FAMPYRA in certain territories outside of the U.S. (to the extent that such rights were to be sublicensed to Biogen pursuant to its separate collaboration and license agreement with Acorda). Under this amendment, we agreed to modify certain terms and conditions of the amended and restated license agreement and the supply agreement with Acorda to reflect the sublicense by Acorda to Biogen.

Acorda has the right to terminate the amended and restated license agreement upon 90 days' written notice. We have the right to terminate the amended and restated license agreement for countries in which Acorda fails to launch a product within a specified time after obtaining the necessary regulatory approval or fails to file regulatory approvals within a commercially reasonable time after completion of, and receipt of positive data from, all pre-clinical and clinical studies required for filing a marketing authorization application. Either party has the right to terminate the amended and restated license agreement by written notice following a material breach of the other party, which is not cured within a certain time period, or upon the other party's entry into bankruptcy or dissolution proceedings. If we terminate Acorda's license in any country, we are entitled to a license from Acorda of its patent rights and know-how relating to the product as well as the related data, information and regulatory files, and to market the product in the applicable country, subject to an initial payment equal to Acorda's cost of developing such data, information and regulatory files and to ongoing royalty payments to Acorda. Subject to the termination of the amended and restated license agreement, licenses granted under the license agreement terminate on a country-by-country basis upon the expiration of the last to expire of our patents or the existence of a threshold level of competition in the marketplace.

Under our commercial manufacturing supply agreement with Acorda, we manufacture and supply AMPYRA/FAMPYRA for Acorda (and its sub-licensee, Biogen). Under the terms of the agreement, Acorda may obtain up to 25% of its total annual requirements of product from a second-source manufacturer. We receive manufacturing royalties equal to 8% of net selling price (or higher under certain circumstances) for all product manufactured by us and a compensating payment for product manufactured and supplied by a third party. We may terminate the commercial manufacturing supply agreement upon 12 months' prior written notice to Acorda, and either party may terminate the commercial manufacturing supply agreement following a material and uncured breach of the commercial manufacturing supply agreement or amended and restated license agreement or the entry into bankruptcy or dissolution proceedings by the other party. In addition, subject to early termination of the commercial manufacturing supply agreement noted above, the commercial manufacturing supply agreement terminates upon the expiry or termination of the amended and restated license agreement.

We are entitled to receive each of the following payments under our amended and restated license agreement with Acorda for achievement of the following milestones with respect to each of the third and fourth new indications for which the product is developed thereunder: (i) \$1.0 million upon initiation of a phase 3 clinical trial; (ii) \$1.0 million upon acceptance of an NDA by the FDA; (iii) \$1.5 million upon approval of the NDA by the FDA; and (iv) \$1.5 million upon the first commercial sale.

Revenues from Acorda related to this license and collaboration agreement accounted for approximately 5% and 3% of our consolidated revenues for the years ended December 31, 2020 and 2019, respectively.

### ***Biogen***

Under a license and collaboration agreement with Biogen, which we entered into in November 2017 and amended in October 2018, January 2019 and October 2019, we granted Biogen a worldwide, exclusive, sublicensable license to develop, manufacture and commercialize VUMERITY and other products covered by patents licensed to Biogen under that agreement.

Under this license and collaboration agreement, we received an upfront cash payment of \$28.0 million in November 2017, and milestone payments of \$50.0 million, \$150.0 million and \$5.0 million in June 2018, November 2019 and December 2019, respectively, upon the achievement of certain developmental milestones, including FDA approval of the NDA for VUMERITY in October 2019, and amendment of the license and collaboration agreement in October 2019. We are also eligible to receive additional payments upon achievement of certain milestones, including milestones relating to the first two products, other than VUMERITY, covered by patents licensed to Biogen under the license and collaboration agreement.

In addition, we receive a 15% royalty on worldwide net sales of VUMERITY, subject to, under certain circumstances, minimum annual payments for the first five years following FDA approval of VUMERITY. We are also entitled to receive royalties on net sales of products other than VUMERITY covered by patents licensed to Biogen under the license and collaboration agreement, at tiered royalty rates calculated as percentages of net sales ranging from high-single digits to sub-teen double digits. All royalties are payable on a product-by-product and country-by-country basis until the later of (i) the last-to-expire patent right covering the applicable product in the applicable country and (ii) a specified period of time from the first commercial sale of the applicable product in the applicable country. Royalties for all products and the minimum annual payments for VUMERITY are subject to customary reductions, as set forth in the license and collaboration agreement.

Except in limited circumstances, we were responsible for the development of VUMERITY until it was approved by the FDA. Following FDA approval of VUMERITY in October 2019 and except for the manufacturing responsibilities discussed below, Biogen is now responsible for all development and commercialization activities for VUMERITY and all other products covered by the patents that we licensed to Biogen.

Under the license and collaboration agreement, Biogen appointed us as the toll manufacturer of clinical and commercial supplies of VUMERITY, subject to Biogen's right to manufacture or have manufactured commercial supplies as a back-up manufacturer and subject to good faith agreement by the parties on the terms of such manufacturing arrangements. In October 2019, we entered into a commercial supply agreement with Biogen for the commercial supply of VUMERITY, an amendment to such commercial supply agreement and an amendment to the November 2017 license and collaboration agreement with Biogen. Biogen has elected to initiate a technology transfer and, following a transition period, assume responsibility for the manufacture (itself or through a designee) of clinical supplies of VUMERITY and up to 100% of commercial supplies of VUMERITY in exchange for an increase in the royalty rate to be paid by Biogen to us on net sales of that portion of product that is manufactured by Biogen or its designee.

If VUMERITY discontinuations due to gastrointestinal adverse events in VUMERITY's long-term safety clinical trial exceed a certain pre-defined threshold, then "GI Inferiority" shall be deemed to exist, and (i) Biogen shall have the right to recapture from us its \$50.0 million option payment through certain temporary reductions in royalty rates, and (ii) the minimum annual payments Biogen owes to us shall terminate.

Unless earlier terminated, the license and collaboration agreement will remain in effect until the expiry of all royalty obligations. Biogen has the right to terminate the license and collaboration agreement at will, on a product-by-product basis or in its entirety upon 180 days' prior notice to us. Either party has the right to terminate the license and collaboration agreement following any governmental prohibition of the transactions effected by the agreement, or in connection with an insolvency event involving the other party. Upon termination of the license and collaboration agreement by either party, then, at our request, the VUMERITY program will revert to us.

Revenues from Biogen related to this license and collaboration agreement accounted for approximately 2% and 17% of our consolidated revenues for the years ended December 31, 2020 and 2019, respectively.

## **Proprietary Technology Platforms**

We have used our proprietary technology platforms, which include technologies owned and exclusively licensed to us, to establish drug development, clinical development and regulatory expertise and in the development of our products.

### ***Injectable Extended-Release Microsphere Technology***

Our injectable extended-release microsphere technology allows us to encapsulate small-molecule pharmaceuticals, peptides and proteins in microspheres made of common medical polymers. The technology is designed to enable novel formulations of pharmaceuticals by providing controlled, extended release of drugs over time. Drug release from the microsphere is controlled by diffusion of the drug through the microsphere and by biodegradation of the polymer. These processes can be modulated through a number of formulation and fabrication variables, including drug substance and microsphere particle sizing and choice of polymers and excipients.

### ***LinkeRx Technology***

The long-acting LinkeRx technology platform is designed to enable the creation of extended-release injectable versions of antipsychotic therapies and may also be useful in other disease areas in which extended duration of action may provide therapeutic benefits. The technology uses proprietary linker-tail chemistry to create new molecular entities derived from known agents.

### ***NanoCrystal Technology***

Our NanoCrystal technology is applicable to poorly water-soluble compounds and involves formulating and stabilizing drugs into particles that are nanometers in size. A drug in NanoCrystal form can be incorporated into a range of common dosage forms and administration routes, including tablets, capsules, inhalation devices and sterile forms for injection, with the potential for enhanced oral bioavailability, increased therapeutic effectiveness, reduced/eliminated fed/fasted variability and sustained duration of intravenous/intramuscular release.

### ***Oral Controlled Release Technology***

Our oral controlled release (“OCR”) technologies are used to formulate, develop and manufacture oral dosage forms of pharmaceutical products with varied drug release profiles.

## **Manufacturing and Product Supply**

We own and occupy an R&D and manufacturing facility in Athlone, Ireland and a manufacturing facility in Wilmington, Ohio. We either purchase active pharmaceutical ingredients (“API”) from third parties or receive it from our third-party licensees to formulate products using our technologies. The manufacture of our products for clinical trials and commercial use is subject to Current Good Manufacturing Practices (“cGMP”) regulations and other regulations. Our manufacturing and development capabilities include formulation through process development, scale-up and full-scale commercial manufacturing and specialized capabilities for the development and manufacturing of controlled substances.

Although some materials and services for our products are currently only available from a single source or a limited number of qualified sources, we attempt to acquire an adequate stock of such materials, establish alternative sources and/or negotiate long-term supply arrangements. However, we cannot be certain that we will continue to be able to obtain long-term supplies of our manufacturing materials.

Our supply chain is growing with an expanding external network of third-party service providers involved in the manufacture of our products who are subject to inspection by the FDA or comparable agencies in other jurisdictions. Any delay, interruption or other issues that arise in the acquisition of API, raw materials, or components, or in the manufacture, fill-finish, packaging, or storage of our marketed or development products, including as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection, could significantly impair our ability to sell our products or advance our development efforts, as the case may be. For information about risks relating to the manufacture of our marketed products and product candidates, see “Principal Risks” in this Directors’ Report and specifically those sections entitled “—We rely on third parties to provide services in connection with the manufacture and distribution of the products we manufacture” and “—We are subject to risks related to the manufacture of our products.”

### ***Marketed Products***

We manufacture ARISTADA and ARISTADA INITIO, and microspheres for RISPERDAL CONSTA and VIVITROL, in our Wilmington, Ohio facility. We are currently operating one RISPERDAL CONSTA line, two VIVITROL lines, two ARISTADA lines and one ARISTADA INITIO line at commercial scale. We outsource our packaging operations for VIVITROL, ARISTADA and ARISTADA INITIO to third-party contractors. Janssen is responsible for packaging

operations for RISPERDAL CONSTA and, in Russia and certain countries of the CIS, VIVITROL. Our Wilmington, Ohio facility has been inspected by U.S., European (including the UK Medicines and Healthcare products Regulatory Agency), Chinese, Japanese, Brazilian, Turkish and Saudi Arabian regulatory authorities for compliance with required cGMP standards for continued commercial manufacturing.

We manufacture several products in our Athlone, Ireland facility that are marketed by third parties, including AMPYRA, FAMPYRA and VUMERITY. This facility has been inspected by U.S., Irish, Brazilian, Turkish, Saudi Arabian, Korean, Belarusian, Russian and Chinese regulatory authorities for compliance with required cGMP standards for continued commercial manufacturing.

### ***Clinical Products***

We have established, and are operating, facilities with the capability to manufacture clinical supplies of injectable extended-release products, solid dosage form products and biologics products at our Wilmington, Ohio facility and solid dosage form products at our Athlone, Ireland facility. We have also contracted with third-party manufacturers to formulate certain products for clinical use. We require that our contract manufacturers adhere to cGMP in the manufacture of products for clinical use.

### ***Research & Development***

We devote significant resources to R&D programs. We focus our R&D efforts on developing novel therapeutics in areas of high unmet medical need. Our R&D efforts include, but are not limited to, areas such as pharmaceutical formulation, analytical chemistry, process development, engineering, scale-up and drug optimization/delivery. Please see “Results of Operations” in this Directors’ Report for additional information relating to our R&D expenditures.

### **Permits and Regulatory Approvals**

We hold various licenses in respect of our manufacturing activities conducted in Wilmington, Ohio and Athlone, Ireland. The primary licenses held in this regard are FDA Registrations of Drug Establishment and Drug Enforcement Administration of the U.S. Department of Justice (“DEA”). We also hold a Manufacturers Authorization (No. M1067), an Investigational Medicinal Products Manufacturers Authorization (No. IMP074) and Certificates of Good Manufacturing Practice Compliance of a Manufacturer (Ref. 2014/7828/IMP074 and 2014/7828/M1067) from the Health Products Regulatory Authority in Ireland (“HPRA”) in respect of our Athlone, Ireland facility, and a number of Controlled Substance Licenses granted by HPRA. Due to certain U.S. state law requirements, we also hold state licenses to cover distribution activities conducted in certain states and not in respect of any manufacturing activities conducted in those states.

We do not generally act as the marketing authorization holder for products incorporating our drug delivery technologies that have been developed on behalf of a licensee of such technologies. In such cases, our licensee usually holds the relevant marketing authorization from the FDA or other relevant regulatory authority, and we would support this authorization by furnishing a copy of the product’s Drug Master File, or chemistry, manufacturing and controls data, to the relevant regulator. We generally update this information annually with the relevant regulator. In other cases where we have developed proprietary products, such as VIVITROL, ARISTADA and ARISTADA INITIO, we hold the marketing authorization and related regulatory documentation ourselves.

### **Marketing, Sales and Distribution**

We are responsible for the marketing of VIVITROL, ARISTADA and ARISTADA INITIO in the U.S. We focus our sales and marketing efforts on physicians in private practice and in public treatment systems. We believe that we use customary pharmaceutical company practices to market our products, including through advertisements, professional symposia, selling initiatives and other methods, and to educate individual physicians, nurses, social workers, counselors and other stakeholders involved in the treatment of opioid dependence, alcohol dependence and schizophrenia. We provide, and contract with third-party vendors to provide, customer service and other related programs for our products, such as product-specific websites, insurance research services and order, delivery and fulfillment services.

Our sales force for VIVITROL in the U.S. consists of approximately 100 individuals. VIVITROL is primarily sold to pharmaceutical wholesalers, pharmacies, specialty distributors and treatment providers. Product sales of VIVITROL during the year ended December 31, 2020 to Cardinal Health, McKesson Corporation and AmerisourceBergen Corporation (“AmerisourceBergen”) represented approximately 23%, 21% and 13%, respectively, of total VIVITROL gross sales.

Our sales force for ARISTADA and ARISTADA INITIO in the U.S. consists of approximately 250 individuals. ARISTADA and ARISTADA INITIO are primarily sold to pharmaceutical wholesalers. Product sales of ARISTADA and ARISTADA INITIO during the year ended December 31, 2020 to Cardinal Health, McKesson Corporation and AmerisourceBergen represented approximately 48%, 24% and 21%, respectively, of total ARISTADA and ARISTADA INITIO gross sales.

ICS, a division of AmerisourceBergen, provides warehousing, shipping and administrative services for VIVITROL, ARISTADA and ARISTADA INITIO.

Under our license agreements with Janssen, Biogen and other licensees and sublicensees, they are each responsible for the commercialization of any products developed under their respective agreement if and when regulatory approval is obtained.

## Competition

We face intense competition in the development, manufacture, marketing and commercialization of our products from many and varied sources, such as research institutions and biopharmaceutical companies, including other companies with similar technologies. Some of these competitors are also our licensees, who control the commercialization of products from which we receive manufacturing and royalty revenues. These competitors are working to develop and market other systems, products and other methods of preventing or reducing disease, and new small molecule and other classes of drugs that can be used with or without a drug delivery system.

The biopharmaceutical industry is characterized by intensive research, development and commercialization efforts and rapid and significant technological change. In many cases, there are already products on the market that may be in direct competition with our commercial products or products in development. In addition, there are many companies developing products with similar technologies to ours or for use in similar indications with whom we and our licensees compete, many of whom are larger and have significantly greater financial and other resources than we do. Other smaller or earlier stage companies may also prove to be significant competitors, particularly through focused development programs and collaborative arrangements with large, established companies. Some of the products being developed by our competitors are being designed to work differently than our products and may turn out to be safer or more effective than our products, which may render our products or technology platforms obsolete or noncompetitive. With respect to our products, we believe that our ability to successfully compete will depend on, among other things, the existence of competing or alternative products in the marketplace, including generic competition, and the relative price of those products; the efficacy, safety and reliability of our products compared to competing or alternative products; product acceptance by, and preferences of, physicians, other health care providers and patients; our ability to comply with applicable laws, regulations and regulatory requirements with respect to the commercialization of our products, including any changes or increases to regulatory restrictions; protection of our proprietary rights relating to our products; our ability to obtain reimbursement for our products in approved indications; our ability to complete clinical development and obtain regulatory approvals for our products, and the timing and scope of regulatory approvals; our ability to provide a reliable supply of commercial quantities of a product to the market; and our ability to recruit, retain and develop skilled employees.

With respect to our proprietary injectable product platform, we are aware that there are other companies developing extended-release delivery systems for pharmaceutical products, including but not limited to, Teva Pharmaceuticals Industries Ltd., which is developing a risperidone extended-release injectable suspension for subcutaneous use and a once every two weeks injectable microsphere formulation, in each case for the treatment of schizophrenia and has filed an Abbreviated New Drug Application (“ANDA”) seeking approval to commercialize a generic version of VIVITROL (naltrexone for extended-release injectable suspension).

In the treatment of schizophrenia, ARISTADA, INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and RISPERDAL CONSTA compete with each other and a number of other injectable products including ZYPREXA RELPREVV (olanzapine for extended release injectable suspension), which is marketed and sold by Lilly; ABILIFY MAINTENA (aripiprazole for extended release injectable suspension), a once-monthly injectable formulation of ABILIFY (aripiprazole) developed by Otsuka Pharm. Co.; PERSERIS (risperidone for extended release injectable suspension), a once-monthly formulation of risperidone marketed by Indivior plc; CAPLYTA (lumateperone), an oral, once-daily antipsychotic developed by Intra-Cellular Therapies, Inc.; other oral compounds currently on the market; and generic versions of branded oral and injectable products. In the treatment of bipolar disorder, RISPERDAL CONSTA competes with antipsychotics such as oral aripiprazole; REXULTI, which is co-marketed by Otsuka Pharm Co. and H. Lundbeck A/S plc; LATUDA, which is marketed and sold by Sunovion Pharmaceuticals Inc.; VRAYLAR, which is marketed and sold by Abbvie Inc.; ABILIFY MAINTENA; risperidone; quetiapine; olanzapine; ziprasidone and clozapine.

In the treatment of alcohol dependence, VIVITROL competes with generic acamprosate calcium (also known as CAMPRAL) and generic disulfiram (also known as ANTABUSE) as well as currently marketed drugs, including generic

drugs, also formulated from naltrexone. Other pharmaceutical companies are developing products that have shown some promise in treating alcohol dependence that, if approved by the FDA, would compete with VIVITROL.

In the treatment of opioid dependence, VIVITROL competes with SUBOXONE (buprenorphine HCl/naloxone HCl dehydrate sublingual tablets), SUBOXONE (buprenorphine/naloxone) Sublingual Film, SUBUTEX (buprenorphine HCl sublingual tablets) and SUBLOCADE (once-monthly buprenorphine extended-release injection), each of which is marketed and sold by Indivior plc; BUNAVAIL buccal film (buprenorphine and naloxone) marketed by BioDelivery Sciences; and ZUBSOLV (buprenorphine and naloxone) marketed by Orexo US, Inc. VIVITROL also competes with methadone, oral naltrexone and generic versions of SUBUTEX and SUBOXONE sublingual tablets. Other pharmaceutical companies are developing products that have shown promise in treating opioid dependence that, if approved by the FDA, would compete with VIVITROL.

In the treatment of MS, VUMERITY competes with AVONEX, TYSABRI, TECFIDERA, and PLEGRIDY from Biogen; OCREVUS from Genentech; BETASERON from Bayer HealthCare Pharmaceuticals; COPAXONE from Teva Pharmaceutical Industries Ltd.; REBIF and MAVENCLAD from EMD Serono, Inc.; GILENYA, EXTAVIA and MAYZENT from Novartis AG; AUBAGIO and LEMTRADA from Sanofi-Aventis; and ZEPOSIA from Bristol-Myers Squibb Company.

With respect to our NanoCrystal technology, we are aware that other technology approaches similarly address poorly water-soluble drugs. These approaches include nanoparticles, cyclodextrins, lipid based self-emulsifying drug delivery systems, dendrimers and micelles, among others, any of which could limit the potential success and growth prospects of products incorporating our NanoCrystal technology. In addition, there are many competing technologies to our OCR technology, some of which are owned by large pharmaceutical companies with drug delivery divisions and other, smaller drug delivery specific companies.

### **Patents and Proprietary Rights**

Our success will be dependent, in part, on our ability to obtain and maintain patent protection for our products, including those marketed and sold by our licensees, to maintain trade secret protection and to operate without infringing upon the proprietary rights of others. We have a proprietary portfolio of patent rights and exclusive licenses to patents and patent applications, which includes numerous patents in the U.S. and in other countries directed to compositions of matter, methods of treatment and formulations, as well as processes of preparation. In the future, we plan to file additional patent applications in the U.S. and in other countries directed to new or improved products and processes, and we intend to continue to vigorously defend our patent positions. In addition, our licensees may own additional patents that cover those products owned by such licensees that incorporate our proprietary technologies and for which we receive royalties.



### ***ARISTADA and ARISTADA INITIO***

We have several U.S. patents and patent applications, and a number of corresponding non-U.S. counterparts, that cover ARISTADA and/or ARISTADA INITIO. Our principal U.S. patents for ARISTADA and/or ARISTADA INITIO and their expiration dates are as follows:

<b>U.S. Patent No.</b>	<b>Product(s) Covered</b>	<b>Expiration Date</b>
8,431,576	ARISTADA; ARISTADA INITIO	2030
8,796,276	ARISTADA; ARISTADA INITIO	2030
10,112,903	ARISTADA; ARISTADA INITIO	2030
10,023,537	ARISTADA	2030
10,351,529	ARISTADA; ARISTADA INITIO	2030
9,034,867	ARISTADA	2032
10,226,458	ARISTADA	2032
9,193,685	ARISTADA	2033
9,861,699	ARISTADA	2033
10,342,877	ARISTADA	2033
10,639,376	ARISTADA	2033
9,452,131	ARISTADA	2035
9,526,726	ARISTADA	2035
10,064,859	ARISTADA	2035
10,238,651	ARISTADA	2035
10,478,434	ARISTADA	2035
10,813,928	ARISTADA	2035
10,016,415	ARISTADA INITIO	2035
10,688,091	ARISTADA INITIO	2035
10,849,894	ARISTADA INITIO	2035

### ***VIVITROL and RISPERDAL CONSTA***

We have a number of patents and pending patent applications covering our microsphere technology throughout the world, which, to some extent, cover VIVITROL and RISPERDAL CONSTA. The latest to expire of our patents covering RISPERDAL CONSTA expire in the U.S. in 2023 and in the EU in 2021. For a discussion of legal proceedings related to certain of the patents covering RISPERDAL CONSTA, see Note 20, *Commitments and Contingent Liabilities* in the “Notes to Consolidated Financial Statements” in this Directors’ Report.

We own one unexpired Orange-Book listed U.S. patent covering VIVITROL, which expires in the U.S. in 2029 and in the EU in 2021. Under the terms of a settlement and license agreement entered into in July 2019 with Amneal Pharmaceuticals LLC (“Amneal”), we granted Amneal a non-exclusive license under certain patents covering VIVITROL, including the remaining patent covering VIVITROL in the U.S., to market and sell a generic formulation of VIVITROL in the U.S. beginning sometime in 2028 or earlier under certain circumstances. For a discussion of legal proceedings related to the U.S. patent covering VIVITROL, see Note 20, *Commitments and Contingent Liabilities* in the “Notes to Consolidated Financial Statements” in this Directors’ Report.

### ***INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA***

Our NanoCrystal technology patent portfolio, licensed to Janssen in relation to INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA, contains a number of granted patents and pending patent applications throughout the world, including in the U.S. and in countries outside of the U.S. The latest of the patents subject to our license agreement with Janssen covering INVEGA SUSTENNA/XEPLION expires in 2030 in the U.S. and certain other countries and in 2022 in the EU. The latest to expire of the licensed patents covering INVEGA TRINZA/TREVICTA in the U.S. expired in 2017 and in the EU will expire in 2022. In addition, Janssen has other patents not subject to our license agreement, including one that covers INVEGA SUSTENNA in the U.S. and expires in 2031 and one that covers INVEGA TRINZA in the U.S. and expires in 2036. For a discussion of legal proceedings related to one of the patents covering INVEGA SUSTENNA, see Note 20, *Commitments and Contingent Liabilities* in the “Notes to Consolidated Financial Statements” in this Directors’ Report.

## ***VUMERITY***

We have U.S. patents and patent applications, and a number of corresponding non-U.S. counterparts, that cover VUMERITY. U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733, each expiring in 2033, cover compositions of, or methods of treatment for, VUMERITY. We recently received a Paragraph IV certification related to VUMERITY. For a discussion of risks related to this certification, see “Principal Risks” in this Directors’ Report and specifically the section entitled “—We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.”

We also have worldwide patent protection for our Key Development Programs:

## ***LYBALVI***

We own or have a license to U.S. and worldwide patents and patent applications that cover a class of compounds that includes the opioid modulators in LYBALVI. In addition, we own U.S. and worldwide patents and patent applications that claim formulations and methods of treatment that cover LYBALVI. The principal owned or licensed U.S. patents for LYBALVI and their expiration dates are as follows:

<b>U.S. Patent No.</b>	<b>Product(s) Covered</b>	<b>Expiration Date</b>
7,956,187	LYBALVI	2021
8,252,929	LYBALVI	2021
7,262,298	LYBALVI	2025
8,680,112	LYBALVI	2030
9,119,848	LYBALVI	2031
10,005,790	LYBALVI	2031
8,778,960	LYBALVI	2031
9,126,977	LYBALVI	2031
9,517,235	LYBALVI	2031
9,943,514	LYBALVI	2031
10,300,054	LYBALVI	2031
10,716,785	LYBALVI	2031

## ***nemvaleukin alfa***

We have U.S. patents and patent applications, and a number of corresponding non-U.S. counterparts, that cover nemvaleukin. U.S. Patent Nos. 9,359,415 and 10,407,481, each expiring in 2033, cover compositions of nemvaleukin.

### ***Protection of Proprietary Rights and Competitive Position***

We have exclusive rights through licensing agreements with third parties to issued U.S. patents, pending patent applications and corresponding patents or patent applications in countries outside the U.S, subject in certain instances to the rights of the U.S. government to use the technology covered by such patents and patent applications. Under certain licensing agreements, we are responsible for patent expenses, and we pay annual license fees and/or minimum annual royalties. In addition, under these licensing agreements, we are obligated to pay royalties on future sales of products, if any, covered by the licensed patents.

There may be patents issued to third parties that relate to our products or technologies. The manufacture, use, offer for sale, sale or import of some of our products might be found to infringe on the claims of these patents. A third party might file an infringement action against us. The cost of defending such an action is likely to be high, and we might not receive a favorable ruling. There may also be patent applications filed by third parties that relate to some of our products if issued in their present form. The patent laws of the U.S. and other countries are distinct, and decisions as to patenting, validity of patents and infringement of patents may be resolved differently in different countries.

If patents exist or are issued that cover our products or technologies, we or our licensees may not be able to manufacture, use, offer for sale, sell or import some of our products without first getting a license from the patent holder. The patent holder may not grant us a license on reasonable terms, or it may refuse to grant us a license at all. This could delay or prevent us from developing, manufacturing, selling or importing those of our products that would require the license.

We try to protect our proprietary position by filing patent applications in the U.S. and in other countries related to our proprietary technology, inventions and improvements that are important to the development of our business. Because the patent position of biopharmaceutical companies involves complex legal and factual questions, enforceability of patents cannot be predicted with certainty. The ultimate degree of patent protection that will be afforded to products and processes, including ours, in the U.S. and in other important markets, remains uncertain and is dependent upon the scope of protection

decided upon by the patent offices, courts and lawmakers in these countries. Patents, if issued, may be challenged, invalidated or circumvented. Thus, any patents that we own or license from others may not provide any protection against competitors. Our pending patent applications, those we may file in the future, or those we may license from third parties, may not result in patents being issued. If issued, they may not provide us with proprietary protection or competitive advantages against competitors with similar technology. Furthermore, others may independently develop similar technologies or duplicate any technology that we have developed outside the scope of our patents. The laws of certain countries do not protect our IP rights to the same extent as the laws of the U.S.

We also rely on trade secrets, know-how and inventions, which are not protected by patents, to maintain our competitive position. We try to protect this information by entering into confidentiality agreements with parties that have access to it, such as our corporate partners, collaborators, licensees, employees and consultants. However, any of these parties may breach such agreements and may disclose our confidential information or our competitors might learn of the information in some other way. If any trade secret, know-how or other invention not protected by a patent were to be disclosed to, or independently developed by, a competitor, such event could materially adversely affect our business, financial condition, cash flows and results of operations. For more information, see “Principal Risks” in this Directors’ Report.

Our trademarks, including VIVITROL, ARISTADA, ARISTADA INITIO and LYBALVI, are important to us and are generally covered by trademark applications or registrations with the U.S. Patent and Trademark Office and the patent or trademark offices of other countries. Our licensed products and products using our proprietary technologies also use trademarks that are owned by our licensees, such as the trademarks INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and RISPERDAL CONSTA, which are registered trademarks of Johnson & Johnson, VUMERITY, which is a registered trademark of Biogen (and used by Alkermes under license) and AMPYRA and FAMPYRA, which are registered trademarks of Acorda. Trademark protection varies in accordance with local law and continues in some countries as long as the trademark is used and in other countries as long as the trademark is registered. Trademark registrations generally are for fixed but renewable terms.

## **Review of the Performance of the Business**

### **Overview**

We earn revenue on net sales of VIVITROL, ARISTADA and ARISTADA INITIO, which are proprietary products that we manufacture, market and sell in the U.S., and manufacturing and/or royalty revenues on net sales of products commercialized by our licensees. Our key marketed products are expected to generate significant revenues for us in the near- and medium-term and we believe are singular or competitively advantaged products in their classes. In 2020, these key marketed products consisted of VIVITROL; ARISTADA and ARISTADA INITIO; INVEGA SUSTENNA/XEPLION; INVEGA TRINZA/TREVICTA; and RISPERDAL CONSTA.

In 2020, we incurred an operating loss of \$112.4 million, as compared to \$175.5 million in 2019. Revenues decreased by 11% in 2020, as compared to 2019, which was primarily due to revenue earned in 2019 under our license and collaboration agreement with Biogen for VUMERITY and reduced net sales of VIVITROL in 2020 due to the impact of COVID-19. This was partially offset by increased net sales of ARISTADA in 2020. Also contributing to the decrease in our operating loss in 2020 as compared to 2019, was a 15% decrease in operating expenses, which was primarily due to a \$60.6 million decrease in SG&A expense in 2020, a \$86.6 million charge related to the IPR&D acquired as part of the acquisition of Rodin Therapeutics, Inc. (“Rodin”) in 2019 and a \$13.4 million charge in 2019 related to approval from our board of directors (the “Board”) of a restructuring plan following a review of our operations, cost structure and growth opportunities (the “Restructuring”). These items are discussed in further detail within the “Results of Operations” section below.

In December 2020, we announced a value enhancement plan designed to drive growth, improve operational and financial performance and enhance shareholder value. The value enhancement plan includes a commitment to certain multi-year profitability targets, a review and optimization of our cost structure, potential monetization of our non-core assets, and continued governance enhancements. A newly formed committee of our board of directors is responsible for overseeing achievement of the profitability targets and the potential monetization of our non-core assets.

We have already undertaken several important initiatives to support this plan, including a reorganization of our commercial infrastructure in November 2020 and an ongoing review of our operations and cost structure, both internally and with external advisors, to identify potential areas for improved efficiencies. We are also exploring a broad range of strategic opportunities, including potential strategic collaborations for nemvaleukin and monetization of our non-core assets, whether through divestment or other means. Any such collaboration or monetization, if effected, may impact our financial condition and operating results and may result in impairment charges related to our long-lived assets and/or adverse impacts on our liquidity.

## Results of Operations

### Product Sales, Net

Our product sales, net consist of sales of VIVITROL, ARISTADA and ARISTADA INITIO in the U.S., primarily to wholesalers, specialty distributors and pharmacies. The following table presents the adjustments deducted from product sales, gross to arrive at product sales, net for sales of VIVITROL, ARISTADA and ARISTADA INITIO in the U.S. during the years ended December 31, 2020 and 2019:

(In millions, except for % of Sales)	Year Ended December 31,			
	2020	% of Sales	2019	% of Sales
Product sales, gross	\$ 1,136.2	100.0 %	\$ 1,019.4	100.0 %
Adjustments to product sales, gross:				
Medicaid rebates	(291.1)	(25.6) %	(237.0)	(23.3) %
Chargebacks	(100.0)	(8.8) %	(84.4)	(8.3) %
Product discounts	(88.2)	(7.8) %	(78.9)	(7.7) %
Medicare Part D	(56.6)	(5.0) %	(45.2)	(4.4) %
Other	(48.5)	(4.2) %	(49.4)	(4.8) %
Total adjustments	(584.4)	(51.4) %	(494.9)	(48.5) %
Product sales, net	\$ 551.8	48.6 %	\$ 524.5	51.5 %

Our product sales, net for VIVITROL and ARISTADA and ARISTADA INITIO in 2020 were \$310.7 million and \$241.0 million, respectively, as compared to \$335.4 million and \$189.1 million in 2019, respectively.

The increase in product sales, gross was due to a 39% increase in ARISTADA and ARISTADA INITIO gross sales, partially offset by a 4% decrease in VIVITROL gross sales. The increase in ARISTADA and ARISTADA INITIO gross sales was due to a 30% increase in the number of ARISTADA and ARISTADA INITIO units sold and a 6% price increase that went into effect in April 2020. The decrease in VIVITROL gross sales was due to an 8% decrease in the number of VIVITROL units sold, primarily as a result of COVID-19-related disruptions, partially offset by a 6% increase in the selling price of VIVITROL, which went into effect in June 2020. The increase in Medicaid rebates, as a percentage of sales, is primarily due to factors related to the COVID-19 pandemic.

A number of companies, including us, are working to develop products to treat addiction, including alcohol and opioid dependence, that may compete with, and negatively impact, future sales of VIVITROL. Increased competition may lead to reduced unit sales of VIVITROL and increased pricing pressure. The latest to expire of our patents covering VIVITROL in the U.S. will expire in 2029 and the latest to expire of our patents covering VIVITROL in Europe will expire in 2021. Under the terms of a settlement and license agreement, we granted Amneal a license under certain patents covering VIVITROL, including the latest to expire patent covering VIVITROL in the U.S., to market and sell a generic formulation of VIVITROL in the U.S. beginning sometime in 2028 or earlier under certain circumstances. We are currently engaged in Paragraph IV litigation with certain Teva entities in respect of the last to expire patent covering VIVITROL in the U.S. For a discussion of these legal proceedings, see Note 20, *Commitments and Contingent Liabilities* in the “Notes to Consolidated Financial Statements” in this Directors’ Report and for information regarding the risks relating to these legal proceedings, see “Risks Related to our Intellectual Property—We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers”. A number of companies, including us, currently market and/or are developing products to treat schizophrenia that may compete with and negatively impact future sales of ARISTADA and ARISTADA INITIO. Increased competition may lead to reduced unit sales of ARISTADA and ARISTADA INITIO and increased pricing pressure. The latest to expire of our patents covering ARISTADA and ARISTADA INITIO in the U.S. will expire in 2035; and, as such, we do not anticipate any generic versions of this product to enter the market in the near term. We expect our product sales, net will continue to grow as VIVITROL continues to penetrate the opioid and alcohol dependence markets in the U.S., and as ARISTADA and ARISTADA INITIO continue to gain market share in the U.S.

### Manufacturing and Royalty Revenue

Manufacturing revenues for third-party products using our proprietary technologies are mostly recognized over time as products move through the manufacturing process, using an input method based on costs as a measure of progress. Manufacturing revenue from RISPERDAL CONSTA is recognized at the point in time the product has been fully manufactured. Royalties earned on our licensees’ net sales of third-party products using our proprietary technologies are generally recognized in the period such products are sold by our licensees. The following table compares manufacturing and royalty revenues earned in the years ended December 31, 2020 and 2019:

(In millions)	Year Ended December 31,		Change
	2020	2019	2020–2019
Manufacturing and royalty revenues:			
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA	\$ 274.2	\$ 256.9	\$ 17.3
RISPERDAL CONSTA	71.4	66.4	5.0
AMPYRA/FAMPYRA	47.9	37.2	10.7
Other	90.5	87.4	3.1
Manufacturing and royalty revenues	<u>\$ 484.0</u>	<u>\$ 447.9</u>	<u>\$ 36.1</u>

Under our agreements with Janssen related to INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA, we earn tiered royalty payments, which consist of a patent royalty and a know-how royalty, both of which are determined on a country-by-country basis. The patent royalty, which equals 1.5% of net sales, is payable in each country until the expiration of the last of the patents with valid claims applicable to the product in such country. The know-how royalty is a tiered royalty of 3.5% on calendar year net sales up to \$250 million; 5.5% on calendar year net sales of between \$250 million and \$500 million; and 7.5% on calendar year net sales exceeding \$500 million. The know-how royalty rate resets to 3.5% at the beginning of each calendar year and is payable until 15 years from the first commercial sale of a product in each individual country, subject to the expiry of the license agreement. The increase in INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA royalty revenues was due to an increase in Janssen’s end market net sales of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA. Janssen’s end market net sales of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA were \$3.7 billion and \$3.3 billion during the years ended December 31, 2020 and 2019, respectively. The latest of the patents subject to our license agreement with Janssen covering INVEGA SUSTENNA/XEPLION expires in 2030 in the U.S. and certain other countries and in 2022 in the EU. The latest of the licensed patents covering INVEGA TRINZA/TREVICTA expired in 2017 in the U.S. and will expire in 2022 in the EU. In addition, Janssen has other patents not subject to our license agreement, including one that covers INVEGA SUSTENNA in the U.S. and expires in 2031 and one that covers INVEGA TRINZA in the U.S. and expires in 2036. Each of INVEGA SUSTENNA and INVEGA TRINZA are currently subject to Paragraph IV litigation in response to companies seeking to market generic versions of such products. For a discussion of these legal proceedings, see Note 20, *Commitments and Contingent Liabilities* in the “Notes to Consolidated Financial Statements” in this Directors’ Report, and for information about risks relating to these legal proceedings, see “Principal Risks” in this Directors’ Report, and specifically the section entitled “Risks Related to Intellectual Property—We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.”

We recognize manufacturing revenue, equal to 7.5% of Janssen’s unit net sales price of RISPERDAL CONSTA, at the point in time when RISPERDAL CONSTA has been fully manufactured, which is deemed to have occurred when the product is approved for shipment by both us and Janssen. We record royalty revenue, equal to 2.5% of end-market net sales, in the period that the end-market sale of RISPERDAL CONSTA occurs. The increase in RISPERDAL CONSTA revenue was due to a 13% increase in manufacturing revenue, partially offset by a 9% decrease in royalty revenue. The increase in manufacturing revenue was primarily due to an increase in the number of units of RISPERDAL CONSTA manufactured for Janssen. The decrease in royalty revenue was due to a decline in Janssen’s end-market net sales of RISPERDAL CONSTA. Janssen’s end market net sales of RISPERDAL CONSTA were \$642.0 million and \$688.0 million during the years ended December 31, 2020 and 2019, respectively. The latest to expire patent covering RISPERDAL CONSTA will expire in 2021 in the EU and 2023 in the U.S. For a discussion of legal proceedings related to patents covering RISPERDAL CONSTA, see Note 20, *Commitments and Contingent Liabilities* in the “Notes to Consolidated Financial Statements” in this Directors’ Report, and for risks relating to such legal proceedings, see “Principal Risks” in this Directors’ Report and specifically the section entitled “Risks Related to our Intellectual Property—We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.”

We expect revenues from our long acting, atypical franchise to decrease over time. While we expect continued growth from sales of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA in the near term, we are aware of potential generic competition for RISPERDAL CONSTA that may lead to reduced unit sales and increased pricing pressure in 2021. We are also aware of generic challenges to INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA. For a discussion of legal proceedings related to RISPERDAL CONSTA, INVEGA SUSTENNA and INVEGA TRINZA, see Note 20, *Commitments and Contingent Liabilities* in the “Notes to Consolidated Financial Statements” in this Directors’ Report. In addition, a number of companies, including us, are working to develop new products to treat schizophrenia and/or bipolar disorder that may compete with INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and RISPERDAL CONSTA. Increased competition from new products or generic versions of INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA or RISPERDAL CONSTA may lead to reduced unit sales of INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and RISPERDAL CONSTA, and increased pricing pressure.

We record manufacturing and royalty revenue for AMPYRA as the product is being manufactured, rather than when it is shipped to Acorda. For FAMPYRA, we record manufacturing revenue as the product is being manufactured and record royalty revenue when the end-market sale of FAMPYRA occurs. The increase in the amount of manufacturing and royalty revenue from AMPYRA and FAMPYRA was primarily due to an \$11.3 million increase in AMPYRA revenue in 2020, \$6.7 million of which was manufacturing revenue and \$4.6 million of which was royalty revenue, in each case related to increased batches of AMPYRA manufactured in 2020, compared to 2019 in which we did not manufacture any batches of AMPYRA due to the entry of generic forms of AMPYRA into the U.S. market in 2018. We expect revenues from AMPYRA to decline due to the availability of generic forms of AMPYRA in the U.S. The latest of the patents covering FAMPYRA expires in 2025 in the EU.

Certain of our manufacturing and royalty revenues are earned in countries outside of the U.S. and are denominated in currencies in which the product is sold. See “Currency Exchange Rate Risk” in this Directors’ Report for information on currency exchange rate risk related to our revenues and “Principal Risks” in this Directors’ Report, and specifically the section entitled “Risks Related to our Financial Condition and Tax Matters—Currency exchange rates may affect revenues and expenses” for risks related to currency exchange rates.

### ***License Revenue***

(In millions)	Year Ended December 31,		Change
	2020	2019	2020 - 2019
License revenue	\$ 1.1	\$ 145.8	\$ (144.7)

The decrease in license revenue in 2020 was primarily due to the absence in 2020 of any milestone payments under our license and collaboration agreement with Biogen for VUMERITY, as compared to the \$150.0 million milestone payment we received under such agreement in 2019 upon FDA approval of the NDA for VUMERITY, of which \$145.8 million was allocated to the delivery of the license and the remaining \$4.2 million was allocated to R&D services.

### ***Research and Development Revenue***

(In millions)	Year Ended December 31,		Change
	2020	2019	2020 - 2019
Research and development revenue	\$ 1.9	\$ 52.8	\$ (50.9)

The decrease in R&D revenue was primarily due to a decrease in the revenue earned under our license and collaboration agreement with Biogen for VUMERITY, as discussed in further detail within the “Critical Accounting Estimates” section below. R&D revenues earned under our license and collaboration agreement with Biogen for VUMERITY were \$0.7 million and \$50.0 million in the years ended December 31, 2020 and 2019, respectively, and the decrease in revenue was due to a decrease in services performed given FDA approval of VUMERITY in October 2019.

### **Costs and Expenses**

#### ***Cost of Goods Manufactured and Sold***

(In millions)	Year Ended December 31,		Change
	2020	2019	2020 - 2019
Cost of goods manufactured and sold	\$ 178.3	\$ 180.4	\$ (2.1)

The decrease in cost of goods manufactured and sold was primarily due to a 6% decrease in cost of goods manufactured and sold related to VIVITROL, which was primarily due to a decrease in VIVITROL units sold, partially offset by a 10% increase in cost of goods manufactured and sold related to ARISTADA, primarily due to an increase in ARISTADA units sold, as described in the Product Sales, net section, above.

#### ***Research and Development Expenses***

For each of our R&D programs, we incur both external and internal expenses. External R&D expenses include clinical and non-clinical activities performed by CROs, consulting fees, laboratory services, purchases of drug product materials and third-party manufacturing development costs. Internal R&D expenses include employee related expenses, occupancy costs, depreciation and general overhead. We track external R&D expenses for each of our development programs; however, internal R&D expenses are not tracked by individual program as they benefit multiple programs or our technologies in general.

The following table sets forth our external R&D expenses for the years ended December 31, 2020 and 2019 listed by the nature of such expenses:

(In millions)	Year Ended December 31,		Change
	2020	2019	2020 - 2019
<b>External R&amp;D Expenses:</b>			
Development programs:			
nemvaleukin	\$ 74.6	\$ 45.2	\$ 29.4
LYBALVI	35.3	33.4	1.9
ALKS 5461	6.0	21.3	(15.3)
VUMERITY	0.1	27.7	(27.6)
IPR&D acquired from Rodin	—	86.6	(86.6)
Other external R&D expenses	66.5	72.7	(6.2)
Total external R&D expenses	182.5	286.9	(104.4)
<b>Internal R&amp;D expenses:</b>			
Employee-related	158.8	175.8	(17.0)
Occupancy	20.8	12.3	8.5
Depreciation	15.1	14.0	1.1
Other	17.4	23.8	(6.4)
Total internal R&D expenses	212.1	225.9	(13.8)
Research and development expenses	\$ 394.6	\$ 512.8	\$ (118.2)

These amounts are not necessarily predictive of future R&D expenses. In an effort to allocate our spending most effectively, we continually evaluate our products under development based on the performance of such products in preclinical and/or clinical trials and our expectations regarding the likelihood of their regulatory approval and commercial viability, among other factors.

The increase in expenses related to nemvaleukin was primarily due to the advancement of the ARTISTRY development program for the product. The increase in expenses related to LYBALVI was primarily due to the write-off of approximately \$7.7 million of stock that was expected to be sold commercially but, in the fourth quarter of 2020 we determined that certain lots were no longer probable of being sold commercially, partially offset by a decrease in clinical activity across the LYBALVI program following original submission of the NDA in November 2019. The decrease in expenses related to ALKS 5461 was primarily due to a decrease in activity within the program following receipt in January 2019 of a CRL from the FDA relating to our NDA seeking marketing approval of ALKS 5461 for the adjunctive treatment of major depressive disorder, and subsequent winding down of ongoing clinical activity in the development program. The decrease in expenses related to VUMERITY was primarily due to the completion of our elective, randomized, head-to-head phase 3 study in 2019. The FDA approved the NDA for VUMERITY in the fourth quarter of 2019. For additional detail on the status of our key development programs, see “Business Overview” in this Directors’ Report and specifically the section entitled “Key Development Programs”.

Included in external R&D expenses in 2019 was a charge of \$86.6 million related to IPR&D acquired when we acquired Rodin in the fourth quarter of 2019. The acquisition of Rodin was treated as an asset acquisition and not a business combination for accounting purposes as substantially all of the fair value of the assets acquired in the acquisition of Rodin was tied to their IPR&D, which is largely in the preclinical stage. As the IPR&D was determined to have no alternative future use, the value ascribed to the IPR&D was charged to R&D expense upon its acquisition.

The decrease in employee-related expenses was primarily due to a decrease in R&D headcount of 10% from December 31, 2019 to December 31, 2020, as a result of the Restructuring. The increase in occupancy expenses in the year ended December 31, 2020, as compared to the year ended December 31, 2019, was primarily due to the commencement of the 900 Winter Street Lease in January 2020.

### ***Selling, General and Administrative Expenses***

(In millions)	Year Ended December 31,		Change
	2020	2019	2020 - 2019
Selling and marketing expense	\$ 338.5	\$ 389.5	\$ (51.0)
General and administrative expense	200.3	209.9	(9.6)
Selling, general and administrative expense	\$ 538.8	\$ 599.4	\$ (60.6)

The decrease in selling and marketing expense was primarily due to a decrease in marketing expense of \$40.4 million, a decrease in employee-related expenses of \$7.6 million and a decrease in professional service fees of \$4.2 million. The

decrease in marketing expense was primarily due to cost saving measures taken in 2020 and a reduction in the number of speaker programs and speaker trainings and a reduction in conference-related spend primarily due to the impacts of the COVID-19 pandemic. The decrease in employee-related expenses was primarily due to a decrease in employee travel related to the impacts of the COVID-19 pandemic. The decrease in professional service fees was primarily due to an overall reduction in external consultant-related fees in 2020, as compared to 2019.

The decrease in general and administrative expense was primarily due to a decrease in employee-related expenses of \$14.1 million and a decrease in professional service fees of \$4.0 million, partially offset by an increase in overhead costs of \$9.5 million. The decrease in employee-related expenses was primarily due to a decrease in share-based compensation expense and in salaries and benefits, due to a decrease in general and administrative headcount of 2% from December 31, 2019 to December 31, 2020 and the impact of the Restructuring, and due to a decrease in employee travel related to the impacts of the COVID-19 pandemic. The decrease in professional service fees was primarily due to expense management measures taken in response to COVID-19-related disruptions to the business. The increase in overhead expenses was primarily related to the commencement of the 900 Winter Street Lease and an increase in insurance costs.

### *Amortization of Acquired Intangible Assets*

(In millions)	Year Ended December 31,		Change
	2020	2019	2020 - 2019
Amortization of acquired intangible assets	\$ 39.5	\$ 40.4	\$ (0.9)

Our amortizable intangible assets consist of technology and collaborative arrangements acquired as part of the acquisition of EDT in September 2011, which are being amortized over 12 to 13 years. We amortize our amortizable intangible assets using the economic use method, which reflects the pattern that the economic benefits of the intangible assets are consumed as revenue is generated from the underlying patent or contract.

Based on our most recent analysis, amortization of intangible assets included within our consolidated balance sheet at December 31, 2020 is expected to be approximately \$40.0 million, \$35.0 million, \$35.0 million, \$1.0 million and none in the years ending December 31, 2021 through 2025, respectively.

### *Restructuring*

(In millions)	Year Ended December 31,		Change
	2020	2019	2020 - 2019
Restructuring expense	\$ —	\$ 13.4	\$ (13.4)

In the fourth quarter of 2019, our board of directors approved the Restructuring, which included a reduction in headcount of approximately 160 employees across the Company. We recorded a charge of \$13.4 million in the fourth quarter of 2019 as a result of the Restructuring, which consisted of one-time termination benefits for employee severance, benefits and related costs, all of which are expected to result in cash expenditures and substantially all of which were paid out by the end of 2020. We paid \$8.7 million and \$4.2 million of the total \$13.4 million accrued for the Restructuring during the years ended December 31, 2020 and 2019, respectively.

### *Other Income (Expense), Net*

(In millions)	Year Ended December 31,		Change
	2020	2019	2020 - 2019
Interest income	\$ 7.0	\$ 14.0	\$ (7.0)
Interest expense	(8.7)	(13.6)	4.9
Change in the fair value of contingent consideration	3.9	(22.8)	26.7
Other income, net	13.7	0.8	12.9
Total other income (expense), net	\$ 15.9	\$ (21.6)	\$ 37.5

The decreases in interest income and interest expense in 2020, as compared to 2019, were primarily due to a decrease in interest rates. Interest income consists primarily of interest earned on our available-for-sale investments. Interest expense consists primarily of interest incurred on the term loan under our credit agreement, which bear interest at a LIBOR of our choosing (one, three or six months), plus 2.25% with a 0% LIBOR floor. (the "2023 Term Loans"). During the years ended December 31, 2020 and 2019, the Company's average LIBOR rates were 0.51% and 2.27%, respectively.



In April 2015, we sold certain of our business assets to Recro Pharma, Inc. (“Recro”) and Recro Gainesville LLC, which included as part of the purchase price contingent consideration tied to low double digit royalties on net sales of the IV/IM and parenteral forms of Meloxicam and any other product with the same active ingredient as Meloxicam IV/IM that is discovered or identified using certain of our IP to which Recro was provided a right of use, through license or transfer (such products, the “Meloxicam Products”), and milestone payments to be paid upon the achievement of certain regulatory and sales milestones related to the Meloxicam Products (such transaction, the “Gainesville Transaction”). In November 2019, Recro spun out its acute care segment to Baudax Bio, Inc. (“Baudax”), a publicly-traded pharmaceutical company. As part of this transaction, Recro’s obligations to pay certain contingent consideration from the Gainesville Transaction were assigned and/or transferred to Baudax.

We determined the fair value of the contingent consideration through three valuation approaches, which are described in greater detail in the “Critical Accounting Estimates” section in this Directors’ Report. At each reporting date, we update our assessment of the fair value of this contingent consideration and reflect any changes to the fair value within the consolidated statements of operations and comprehensive loss and will continue to do so until the milestones and/or royalties included in the contingent consideration have been settled.

During the years ended December 31, 2020 and 2019, we determined that the fair value of the contingent consideration increased by \$3.9 million and decreased by \$22.8 million, respectively. The increase in the fair value of the contingent consideration in 2020, as compared to 2019, was primarily due to the approval by the FDA of ANJESO in February 2020, partially offset by an increase in the discount rate due to an increase in the risk of non-payment. In Baudax’s Quarterly Report on Form 10-Q for the period ended September 30, 2020, Baudax included disclosures around its ability to continue as a going concern.

The increase in other income, net in the year ended December 31, 2020, as compared to the year ended December 31, 2019, was primarily due to an \$8.3 million gain on our equity method investment as a result of the sale of two of the companies within the Fountain Healthcare Partners II (“Fountain”) portfolio. Our investment in Fountain is discussed in greater detail in Note 15, *Investments*, in the “Notes to Consolidated Financial Statements” in this Directors’ Report.

***(Provision) Benefit for Income Taxes***

(In millions)	Year Ended December 31,		Change
	2020	2019	2020 - 2019
Income tax (provision) benefit	\$ (14.3)	\$ 0.4	\$ 14.7

The income tax provision in 2020 and the income tax benefit in 2019 were primarily due to U.S. federal and state taxes. The unfavorable change in income taxes in 2020, as compared to 2019, was primarily due to a significant benefit recorded in 2019 related to the foreign derived intangible income (“FDII”) proposed regulations issued by the U.S. Department of the Treasury and the U.S. Internal Revenue Service in March 2019.

No provision for income tax has been provided on undistributed earnings of the Company’s foreign subsidiaries because such earnings are indefinitely reinvested in the foreign operations. Cumulative unremitted earnings of overseas subsidiaries totaled approximately \$369.0 million at December 31, 2020. In the event of a repatriation of those earnings in the form of dividends or otherwise, the Company may be liable for income taxes, subject to adjustment, if any, for foreign tax credits and foreign withholding taxes payable to foreign tax authorities. The Company estimates that approximately \$38.0 million of income taxes would be payable on the repatriation of the unremitted earnings to Ireland.

As of December 31, 2020, the Company had \$1.6 billion of Irish net operating loss (“NOL”) carryforwards, \$33.3 million of U.S. federal NOL carryforwards, \$43.2 million of state NOL carryforwards, \$48.6 million of federal R&D credits and \$23.0 million of state tax credits which will either expire on various dates through 2040 or can be carried forward indefinitely. These loss and credit carryforwards are available to reduce certain future Irish and foreign taxable income and tax. These loss and credit carryforwards are subject to review and possible adjustment by the appropriate taxing authorities and may be subject to limitations based upon changes in the ownership of the Company's ordinary shares.

## Liquidity and Capital Resources

Our financial condition is summarized as follows:

(In millions)	December 31, 2020			December 31, 2019		
	U.S.	Ireland	Total	U.S.	Ireland	Total
Cash and cash equivalents	\$ 152.8	\$ 120.2	\$ 273.0	\$ 63.3	\$ 140.5	\$ 203.8
Investments—short-term	293.5	68.5	362.0	285.3	45.9	331.2
Investments—long-term	23.2	1.6	24.8	40.3	39.1	79.4
Total cash and investments	<u>\$ 469.5</u>	<u>\$ 190.3</u>	<u>\$ 659.8</u>	<u>\$ 388.9</u>	<u>\$ 225.5</u>	<u>\$ 614.4</u>
Outstanding borrowings—short and long-term	<u>\$ 275.0</u>	<u>\$ —</u>	<u>\$ 275.0</u>	<u>\$ 277.1</u>	<u>\$ —</u>	<u>\$ 277.1</u>

At December 31, 2020, our investments consisted of the following:

(In millions)	Amortized Cost	Gross Unrealized		Allowance for Credit Losses	Estimated Fair Value
		Gains	Losses		
Investments—short-term available-for-sale	\$ 359.3	\$ 1.9	\$ —	\$ (1.0)	\$ 360.2
Investments—short-term held-to-maturity	1.7	0.1	—	—	1.8
Investments—long-term available-for-sale	23.0	—	—	—	23.0
Investments—long-term held-to-maturity	1.8	—	—	—	1.8
Total	<u>\$ 385.8</u>	<u>\$ 2.0</u>	<u>\$ —</u>	<u>\$ (1.0)</u>	<u>\$ 386.8</u>

### Sources and Uses of Cash

We generated \$82.8 million and \$72.0 million of cash from operating activities during the years ended December 31, 2020 and 2019, respectively. We expect that our existing cash and investments will be sufficient to finance our anticipated working capital and other cash requirements, such as capital expenditures and principal and interest payments on our long-term debt, for at least the twelve months following the date from which our financial statements were issued. Subject to market conditions, interest rates and other factors, we may pursue opportunities to obtain additional financing in the future, including debt and equity offerings, corporate collaborations, bank borrowings, arrangements relating to assets or other financing methods or structures. In addition, the 2023 Term Loans have an incremental facility capacity in an amount of \$175.0 million, plus additional amounts as long as we meet certain conditions, including a specified leverage ratio.

Our investment objectives are, first, to preserve liquidity and conserve capital and, second, to generate investment income. We mitigate credit risk in our cash reserves by maintaining a well-diversified portfolio that limits the amount of investment exposure as to institution, maturity and investment type. Our available for sale investments consist primarily of short- and long-term U.S. government and agency debt securities and corporate debt securities. We classify available for sale investments in an unrealized loss position, which do not mature within 12 months, as long-term investments. We have the intent and ability to hold these investments until recovery, which may be at maturity, and it is more likely than not that we would not be required to sell these securities before recovery of their amortized cost. At December 31, 2020, we performed an analysis of our investments with unrealized losses for impairment and determined that they were temporarily impaired.

Information about our cash flows, by category, is presented in the accompanying consolidated statements of cash flows. The following table summarizes our cash flows for the years ended December 31, 2020 and 2019:

(In millions)	Year Ended December 31,	
	2020	2019
Cash and cash equivalents, beginning of period	\$ 203.8	\$ 266.8
Cash flows provided by operating activities	82.8	72.0
Cash flows used in investing activities	(11.5)	(141.8)
Cash flows (used in) provided by financing activities	(2.1)	6.8
Cash and cash equivalents, end of period	<u>\$ 273.0</u>	<u>\$ 203.8</u>

### Operating Activities

The increase in cash flows provided by operating activities was primarily due to an increase in the cash provided from our net loss, net of adjustments to reconcile net loss to cash flows from operating activities. This was partially offset by a decrease in the cash provided from working capital, primarily due to increases in receivables and stock, partially offset by an increase in amounts owed to creditors.

### Investing Activities

The decrease in cash used in investing activities was primarily due to the net sale of investments of \$23.5 million in 2020 as compared to the net purchase of investments of \$52.9 million in 2019. We also had a decrease in property, plant and equipment additions of \$48.7 million in 2020 primarily due to a decrease in expenses related to leasehold improvements related to the 900 Winter Street Lease commencement in January 2020.

We expect to spend approximately \$40.0 million during the year ended December 31, 2021 for capital expenditures. We continue to evaluate our manufacturing capacity based on expectations of demand for our products and will continue to record such amounts within construction in progress until such time as the underlying assets are placed into service, or we determine we have sufficient existing capacity and the assets are no longer required, at which time we would recognize an impairment charge. We continue to periodically evaluate whether facts and circumstances indicate that the carrying value of these long-lived assets to be held and used may not be recoverable.

In the fourth quarter of 2019, we acquired Rodin for an upfront cash payment of approximately \$100.0 million and potential future milestone payments of up to \$850.0 million. We accounted for the transaction as an asset acquisition, as substantially all of the fair value of the assets acquired in the acquisition of Rodin were tied to their IPR&D, which was largely in the preclinical stage. As the IPR&D was determined to have no alternative future use, the value ascribed to the IPR&D, \$86.6 million, was charged to R&D expense upon its acquisition and was included in our net loss in 2019. The remaining \$8.9 million of net assets acquired, net of cash transferred as part of the acquisition of \$2.7 million, was included as an investing activity in the 2019 cash flow statement.

### Financing Activities

The change in cash flows from financing activities was due to an \$8.9 million decrease in the net cash provided from stock option exercises by our employees.

### Borrowings

At December 31, 2020, our borrowings consisted of \$276.4 million outstanding under the 2023 Term Loans. Please refer to Note 7, *Long-Term Debt*, in the accompanying “Notes to Consolidated Financial Statements” in this Directors’ Report for a discussion of our outstanding term loans.

### Contractual Obligations

The following table summarizes our obligations to make future payments under our current contracts at December 31, 2020:

Contractual Obligations (In thousands)	Total	Less Than One Year (2021)	One to Three Years (2022 - 2023)	Three to Five Years (2024 - 2025)	More than Five Years (After 2025)
2023 Term Loans—Principal	\$ 276,434	\$ 2,843	\$ 273,591	\$ —	\$ —
2023 Term Loans—Interest	23,700	10,602	13,098	—	—
Operating lease obligations	195,806	16,882	34,267	35,346	109,311
Purchase obligations <sup>(1)</sup>	208,743	208,743	—	—	—
Total contractual cash obligations	<u>\$ 704,683</u>	<u>\$ 239,070</u>	<u>\$ 320,956</u>	<u>\$ 35,346</u>	<u>\$ 109,311</u>

(1) Purchase obligations represent open purchase orders for the acquisition of goods and services in the ordinary course of business and purchase orders for capital expenditures primarily related to certain planned capital spend. Our obligation to pay certain of these amounts may be reduced based on certain future events.

As interest on the 2023 Term Loans is based on a one, three or six-month LIBOR rate of our choosing, for the purposes of this disclosure, we are using the one-month LIBOR rate, which was 0.16% at December 31, 2020 and is the rate we were using at December 31, 2020 for interest payments under the 2023 Term Loans.

This table excludes up to \$850.0 million in milestone payments that we would be obligated to make upon achievement by the platform of development candidates acquired in the acquisition of Rodin of certain specified clinical and regulatory milestones, and attainment of certain sales thresholds, as we cannot make a reliable estimate of the period of payment. At December 31, 2020, we have not recorded a liability related to these milestone payments, as none of the future events which would trigger a milestone payment are considered probable of occurring.

This table also excludes any liabilities pertaining to uncertain tax positions as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. At December 31, 2020, we had \$7.7 million of net liabilities associated with uncertain tax positions. We do not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease within the next 12 months.

### **Off-Balance Sheet Arrangements**

At December 31, 2020, we were not a party to any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

### **Financial Risk Management**

We hold securities in our investment portfolio that are sensitive to market risks. Our securities with fixed interest rates may have their market value adversely impacted by a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectations due to a fall in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates. However, because we classify our investments in debt securities as available for sale, no gains or losses are recognized due to changes in interest rates unless such securities are sold prior to maturity or declines in fair value are determined to be other than temporary. Should interest rates fluctuate by 10%, our interest income would change by an immaterial amount over an annual period. We do not believe that we have a material exposure to interest rate risk as our investment policies specify credit quality standards for our investments and limit the amount of credit exposure from any single issue, issuer or type of investment.

We do not believe that inflation and changing prices have had a material impact on our results of operations, and as approximately 48% and 27% of our investments at December 31, 2020 were in corporate debt securities with a minimum rating of Aa2 (Moody's)/AA (Standard and Poor's) and debt securities issued by the U.S. government or its agencies, respectively, our exposure to liquidity and credit risk is not believed to be significant.

At December 31, 2020, our borrowings consisted of \$276.4 million outstanding under the 2023 Term Loans. The 2023 Term Loans bear interest at a LIBOR rate of our choosing (one, three or six months), plus 2.25% with a 0% LIBOR floor. We are currently using the one-month LIBOR rate, which was 0.16% at December 31, 2020. A 10% increase in the one-month LIBOR rate would have increased the amount of interest we owe under this agreement during the year ended December 31, 2020 by approximately \$0.4 million. At December 31, 2019, a 10% increase in the one-month LIBOR rate, which was the LIBOR rate in use at the time, would have increased the amount of interest we owed by approximately \$0.5 million. For a discussion about risks relating to LIBOR, see "Principal Risks" in this Directors' Report and specifically the section entitled "Risks Related to our Financial Condition and Tax Matters—Discontinuation, reform or replacement of LIBOR, or uncertainty related to the potential for any of the foregoing, may adversely affect us."

### **Currency Exchange Rate Risk**

Manufacturing and royalty revenues we receive on certain of our products and services are a percentage of the net sales made by our licensees, and a portion of these sales are made in countries outside the U.S. and are denominated in currencies in which the product is sold, which is predominantly the euro. The manufacturing and royalty payments on these non-U.S. sales are calculated initially in the currency in which the sale is made and are then converted into USD to determine the amount that our licensees pay us for manufacturing and royalty revenues. Fluctuations in the exchange ratio of the USD and these non-U.S. currencies will have the effect of increasing or decreasing our revenues even if there is a constant amount of sales in non-U.S. currencies. For example, if the USD weakens against a non-U.S. currency, then our revenues will increase given a constant amount of sales in such non-U.S. currency. For the year ended December 31, 2020, an average 10% strengthening of the USD relative to the currencies in which these products are sold would have resulted in revenues being reduced by approximately \$28.9 million, as compared to a reduction in revenues of approximately \$26.5 million for the year ended December 31, 2019.

We incur significant operating costs in Ireland and face exposure to changes in the exchange ratio of the USD and the euro arising from expenses and payables at our Irish operations that are settled in euro. The impact of changes in the exchange ratio of the USD and the euro on our USD denominated revenues earned in countries other than the U.S. is partially offset by the opposite impact of changes in the exchange ratio of the USD and the euro on operating expenses and payables incurred at our Irish operations that are settled in euro. For the year ended December 31, 2020, an average 10% weakening in the USD relative to the euro would have resulted in an increase to our expenses denominated in euro of approximately \$7.3 million, as compared to an increase in our expenses of approximately \$7.1 million in the year ended December 31, 2019.

## **Principal Risks**

*You should consider carefully the risks described below in addition to the financial and other information contained in this Directors' Report, including the matters addressed under the caption "Cautionary Note Concerning Forward-Looking Statements." If any events described by the following risks actually occur, they could materially adversely affect our business, financial condition, cash flows or results of operations. This could cause the market price of our ordinary shares to decline.*

### **Risks Related to Our Business and our Industry**

***Our business, financial condition and results of operations have been, and may continue to be, adversely affected by the COVID-19 pandemic or other similar outbreaks of contagious diseases.***

Outbreaks of contagious diseases and other adverse public health developments affecting us and/or the third parties on which we rely, could have a material and adverse effect on our business, financial condition and results of operations. The COVID-19 pandemic has impacted, and is continuing to impact, many aspects of society, including the operation of the healthcare system and other business and economic activity worldwide. Almost all U.S. states, many local jurisdictions and countries across the world have, at various times throughout the pandemic, issued "shelter-in-place" orders, quarantines, and restrictions and recommendations for their residents to control the spread of COVID-19, resulting in widespread closures of businesses, work stoppages, slowdowns and delays, work-from-home policies and travel restrictions, among other effects.

The COVID-19 pandemic has had, and may continue to have, an adverse impact on our financial condition and results of operations. For example, commercial sales of the medicines from which we derive revenue—consisting primarily of injectable medications administered by healthcare professionals—have been, and we expect will continue to be, adversely impacted as a result of developments that have transpired, and may continue to transpire, related to this pandemic, including travel restrictions and social distancing measures, many of which have contributed to limited access to healthcare providers and locations where injectable medications may be administered. Further, this pandemic and measures to mitigate the spread of COVID-19 have had, and may continue to have, an adverse effect on global economic conditions, which could have an adverse effect on our business and financial condition, including the demand for, and ability of patients to access, our and our licensees' medicines, or our ability to obtain financing, if needed, on favorable terms or at all.

The COVID-19 pandemic has, to varying degrees, disrupted our business operations and the business operations of the third parties on which we rely, including our suppliers, packagers, distributors, contract research organizations, customers, clinical site investigators, community advocacy partners, and others, and may continue to do so for so long as the pandemic and its impacts persist. For example, the third-party sites and investigators involved in our clinical trials have experienced, and may continue to experience, interruptions which have impacted, and may continue to impact, the conduct of our clinical trials and our ability to complete them in a timely manner or at all. If our clinical programs are significantly delayed as a result of such impacts, there could be adverse effects on our expected timelines for regulatory review and potential approval of our product candidates.

The COVID-19 pandemic has also impacted, and may continue to impact, the regulatory agencies with which we interact in the development, manufacture, regulatory review and commercialization of our medicines. For example, travel restrictions and social distancing measures have impacted the manner in which the FDA, the HPRC and other regulatory agencies conduct their pre- or post-approval inspections of manufacturing facilities, relying more heavily on remote record reviews than in-person interactions. If such regulatory agencies do not find the results of such remote reviews to be sufficient for their regulatory purposes, our manufacturing activities or expected timelines for regulatory review and approval of our product candidates may be delayed, which could have an adverse effect on our business and the market price for our ordinary shares. For example, we received a CRL from the FDA, which included a request for information, regarding the NDA for LYBALVI following the FDA's remote review of records relating to the manufacture of LYBALVI at our Wilmington, Ohio facility. We subsequently resubmitted our NDA, and the FDA assigned the application a PDUFA target action date of June 1, 2021. Following our resubmission, the FDA issued a new request for records to supplement information that we previously provided. There is no guarantee that the FDA's remote review of our resubmission and additional records will be sufficient to meet the FDA's requirements for approval of LYBALVI without the conduct of a pre-approval inspection.

Despite the spread of COVID-19 across the U.S., we have begun to observe, and expect to continue to observe, a gradual normalization in patient and healthcare provider practices, as providers and patients have adapted their behaviors and procedures to the evolving circumstances and as COVID-19 vaccines continue to be administered. However, the degree to which the ongoing COVID-19 pandemic may continue to impact our business, financial condition and results of operations will depend on the ultimate severity and duration of this pandemic and the manner in which it continues to evolve, and future developments in response thereto, which are highly uncertain and cannot be predicted as of the date of this Directors' Report

and which may include, among other things, governmental, business or other actions that have been, or will be, taken in response to this pandemic, including continued restrictions on travel and mobility, business closures and imposition of social distancing measures; impacts of the pandemic on our employees, the vendors or distribution channels in our supply chain and on our ability to continue to manufacture and supply our products; impacts of the pandemic on the conduct of our clinical trials, including with respect to enrollment rates, availability of investigators and clinical trial sites, and monitoring of data; impacts of the pandemic on healthcare systems that serve people living with opioid dependence, alcohol dependence and schizophrenia; impacts of the pandemic on the regulatory agencies with which we interact in the development, review, approval and commercialization of our medicines; impacts of the pandemic on reimbursement for our products, including our Medicaid rebate liability, and for services related to the use of our products; and impacts of the pandemic on the U.S., Irish and/or global economies more broadly. For example, if the U.S. Consumer Price Index—Urban (CPI-U) becomes negative, this would increase our Medicaid rebate liability. For a discussion of the Medicaid rebate liability, please see the “Pricing and Reimbursement” section in “Item 1—Business” in our 2020 Form 10-K.

***We receive substantial revenue from our key proprietary products and our success depends on our ability to maintain or increase sales of such products.***

Sales of our proprietary products comprise an increasingly significant portion of our revenues. We developed and exclusively manufacture VIVITROL for the treatment of alcohol dependence and opioid dependence, ARISTADA for the treatment of schizophrenia, and ARISTADA INITIO for initiation onto ARISTADA for the treatment of schizophrenia, and we exclusively commercialize these products in the U.S. Our success depends in large part on our ability to continue to successfully manufacture and increase sales of such products in the complex markets into which they are sold. Any significant negative developments relating to these products could have a material adverse effect on our revenues from these products and, in turn, on our business, financial condition, cash flows and results of operations and the market price of our ordinary shares.

***We rely heavily on our licensees in the commercialization and continued development of products from which we receive revenue; and if our licensees are not effective, our revenues could be materially adversely affected.***

Our arrangements with licensees are critical to bringing to market and/or successfully commercializing products using our proprietary technologies and from which we receive manufacturing and/or royalty revenue. We rely on these licensees in various respects, including commercializing such products, conducting development activities with respect to new formulations or new indications for such products, and/or managing the regulatory approval process for such products.

We earn significant royalty and/or manufacturing revenue from sales by our licensees of our licensed products and third-party products incorporating our proprietary technologies. The revenues we receive from such products depend primarily upon the success of our licensees in commercializing such products. For example, we receive substantial revenue from Janssen’s sales of RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA and upon sales of FAMPYRA by Biogen. We have no involvement in the commercialization efforts for these and other products sold by third parties from which we receive revenue, and cannot control the extent or effectiveness of such commercialization efforts.

Disputes may also arise between us and a licensee involving the ownership of technology developed under a license, the terms and amounts of royalty payments to be paid under a license, or other issues arising out of any licenses or other collaborative agreements. Such disputes may delay related development programs, impact commercialization or manufacturing activities for the related products or result in expensive arbitration or litigation, which may not be resolved in our favor and may adversely impact our financial condition. Further, certain of our license agreements may be terminated without cause, or assigned in connection with a change in control, and we cannot guarantee that any of these relationships will continue or that our licensees will be able or willing to continue to perform their obligations under such agreements. Any significant negative developments relating to our relationships with our licensees or our collaborative arrangements could have a material adverse effect on our business, financial condition, cash flows and results of operations.

For these and other reasons that may be outside of our control, our revenues from products sold by our licensees may fall below our expectations, the expectations of our licensees or those of our shareholders, which could have a material adverse effect on our results of operations and the market price of our ordinary shares.

***We face competition in the biopharmaceutical industry.***

We face intense competition in the development, manufacture, marketing and commercialization of our products from many and varied sources, such as research institutions and other biopharmaceutical companies, including companies with similar technologies or medicines, and manufacturers of generic drugs. Some of these competitors are also our licensees, who control the commercialization of products from which we receive manufacturing and/or royalty revenues. For example, our

proprietary product ARISTADA competes directly with RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA, products from which we receive significant manufacturing and/or royalty revenues.

The biopharmaceutical industry is characterized by intensive research, development and commercialization efforts and rapid and significant technological change. In many cases, there are already products on the market that may be in direct competition with our commercial products or products in development. In addition, there are many companies developing generic versions of our products, or products with similar technologies to ours or for use in similar indications with whom we and our licensees compete, many of whom are larger and have significantly greater financial and other resources than we do. Other smaller or earlier stage companies may also prove to be significant competitors, particularly through focused development programs and collaborative arrangements with large, established companies. Some of the products being developed by our competitors are being designed to work differently than our products and may turn out to be safer or more effective than our products, which may render our products or technology platforms obsolete or noncompetitive. For a detailed discussion of the competition that we face with respect to our current marketed products, technology platforms and product indications, please see the section entitled “*Competition*” in this Directors’ Report. If we are unable to compete successfully in this highly competitive biopharmaceutical industry, our business, financial condition, cash flows and results of operations could be materially adversely affected.

***There are many factors that could cause our revenues to decrease or grow at a slower than expected rate.***

We cannot be assured that our products will be, or will continue to be, accepted in the U.S. or markets outside the U.S. or that we will be able to maintain or increase sales of our products. Factors that may cause revenues from our products to grow at a slower than expected rate, decrease or cease all together, include, among others:

- the perception of physicians and other members of the healthcare community as to our products’ safety and efficacy relative to that of competing products and the willingness or ability of physicians and other members of the healthcare community to prescribe, dispense and/or administer, and patients to use, our products, including those that may be scheduled by the DEA;
- unfavorable publicity concerning us, our licensees, our products, similar classes of drugs or the industry generally;
- the cost-effectiveness of our products and reimbursement policies of government and third-party payers that may impact use of our products;
- the cost and availability of raw materials necessary for the manufacture of our products;
- the successful manufacture of our products on a timely and cost-effective basis;
- the size of the markets for our products, and patient and physician satisfaction with our products;
- significant changes in the competitive landscape for our products, including any approval of generic versions of our products or other branded products that may compete with our products;
- adverse event information relating to our products or to similar classes of drugs;
- changes to the product labels of our products, or of products within the same drug classes, to add significant warnings or restrictions on use;
- our continued ability to engage third parties to package and/or distribute our products on acceptable terms;
- the unfavorable outcome of investigations, litigation or other legal proceedings, including government requests for information regarding VIVITROL, securities litigation relating to ALKS 5461, IP litigation, including so-called “Paragraph IV” litigation relating to VIVITROL, INVEGA SUSTENNA and INVEGA TRINZA, and litigation or other proceedings before the U.S. Patent and Trademark Office’s (the “USPTO”) Patent Trial and Appeal Board (the “PTAB”) or its equivalent in other jurisdictions outside of the U.S., including opposition proceedings in the EU relating to RISPERDAL CONSTA and any other litigation related to any of our products;
- regulatory developments and actions related to the manufacture, commercialization or continued use of our products, including FDA actions such as the issuance of a Risk Evaluation and Mitigation Strategy (“REMS”) or warning letter, or conduct of an audit by the FDA or another regulatory authority in which a manufacturing or quality deficiency is identified;
- the extent and effectiveness of the sales, marketing and distribution support for our products, including our licensees’ decisions as to the timing and volume of product orders and shipments, the timing of product launches, and product pricing and discounting;

- disputes with our licensees relating to the marketing and sale of products from which we receive manufacturing and/or royalty revenue and the amounts to be paid with respect to such products;
- exchange rate valuations and fluctuations;
- U.S. and global political changes and/or instability, including the recent change in the U.S. presidential administration and the exit of the United Kingdom from the European Union (commonly referred to as “Brexit”), and any related changes in applicable laws and regulations, that may impact resources and markets for our products outside of the U.S.;
- the impact that the COVID-19 pandemic may have on the manufacture and commercialization of our products; and
- any other material adverse developments with respect to the commercialization of our products.

***Revenues generated by sales of our products depend on the availability from third-party payers of reimbursement for our products and the extent of cost-sharing arrangements for patients (e.g., patient co-payment, co-insurance, deductible obligations), cost-control measures imposed, reductions in payment rate or reimbursement or increases in our financial obligation to payers could result in decreased sales of our products and decreased revenues.***

In both U.S. and non-U.S. markets, sales of our products depend, in part, on the availability of reimbursement from third-party payers such as state and federal governments, including Medicare and Medicaid in the U.S. and similar programs in other countries, managed care providers and private insurance plans. Deterioration in the timeliness, certainty and amount of reimbursement for our products, the existence of barriers to coverage of our products (such as prior authorization, criteria for use or other requirements), increases in our financial obligation to payers, including government payers, limitations by healthcare providers on how much, or under what circumstances, they will prescribe or administer our products or unwillingness by patients to pay any required co-payments, or deductible amounts, could reduce the use of, and revenues generated from, our products and could have a material adverse effect on our business, financial condition, cash flows and results of operations. In addition, when a new product is approved, the availability of government and private reimbursement for that product and coverage restrictions that may be imposed for such product, are uncertain, as is the amount for which that product will be reimbursed. We cannot predict the availability or amount of reimbursement or other access barriers for our products.

In the U.S., federal and state legislatures, health agencies and third-party payers continue to focus on containing the cost of healthcare, including by comparing the effectiveness, benefits and costs of similar treatments. Any adverse findings for our products from such comparisons may reduce the extent of reimbursement for our products. Economic pressure on state budgets may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for drugs, including but not limited to price control initiatives, discounts and other pricing-related actions. Over the past several years, a number of states have enacted drug pricing transparency laws that require companies to report on drug price increases and justify how drug prices were set. We expect additional state drug pricing initiatives to be proposed and enacted in 2021 and beyond. In addition, state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products.

In 2021, we may face uncertainties as a result of continued federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA, the outcome of existing litigation related to PPACA, and potential reforms and changes to government negotiation or regulation of drug pricing. PPACA significantly expanded coverage of mental health and substance use disorders and provided federal parity protections to such coverage benefits. There is no assurance that such efforts and proposed legislation will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform and drug pricing will affect our business.

In addition, the outcome or settlement of litigation could impact the practices of healthcare providers and patients, and the policies and practices of third-party payers, including Medicare, Medicaid, managed care providers and private insurance plans, in a manner detrimental to our products, which in turn could materially and adversely affect our business and financial condition. For example, one or more defendants in the opioid multi-district litigation has offered large volumes of generic buprenorphine free of charge to state plaintiffs as settlement compensation, which, if agreed to and approved, could



negatively impact state reimbursement policies, healthcare provider practices, and patient access to alternative FDA-approved medications to generic buprenorphine, which includes VIVITROL, for the treatment of opioid dependence.

The government-sponsored healthcare systems in Europe and many other countries are the primary payers for healthcare expenditures, including payment for drugs and biologics. We expect that countries may take actions to reduce expenditure on drugs and biologics, including mandatory price reductions, patient access restrictions, suspensions of price increases, increased mandatory discounts or rebates, preference for generic products, reduction in the amount of reimbursement and greater importation of drugs from lower-cost countries. These cost-control measures likely would reduce our revenues. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, the inability to secure adequate prices in a particular country may not only limit the marketing of products within that country, but may also adversely affect the ability to obtain acceptable prices in other markets.

***Clinical trials for our products are expensive, may take several years to complete, and their outcomes are uncertain.***

Before obtaining regulatory approvals for the commercial sale of any products, we or our licensees must demonstrate, through preclinical testing and clinical trials, that our products are safe and effective for use in humans. Designing, conducting and completing a clinical development program is often a lengthy, time-consuming and expensive process. We have incurred, and we will continue to incur, substantial expense for preclinical testing and clinical trials and other activities related to our clinical development programs.

Our preclinical and clinical development efforts may take several years or more, varying substantially with the type, complexity, novelty and intended use of the product and the clinical study designs and methodologies employed, and may not be successfully completed in a timely manner or at all. Timelines for the initiation, conduct and completion of clinical trials may be delayed by many factors, including:

- issues with the opening, operation or inspection of a new or ongoing clinical trial site;
- delays or failures of third-party CROs and other third-party service providers and clinical investigators to manage and conduct the trials, perform oversight of the trials, including data audit and verification procedures, or to meet expected deadlines;
- an inability to recruit clinical trial participants at the expected rate or at all, or to adequately follow participants following treatment;
- unforeseen safety or tolerability issues;
- an inability to manufacture or obtain sufficient quantities of materials used for clinical trials;
- unforeseen governmental or regulatory issues or concerns, including those of the FDA, DEA and other regulatory agencies; and
- global instability, including instability relating to political events or a global pandemic or other contagious disease, such as COVID-19, in or near the countries in which we conduct our clinical trials.

In addition, we are currently conducting and enrolling patients in clinical studies in a number of countries where our experience is more limited. In these instances, we must depend on third parties, including independent clinical investigators, CROs and other third-party service providers, to successfully conduct our clinical trials and to audit, verify and accurately report results from such trials. Though we do not have much control over many aspects of such third-party activities, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Third parties may not complete planned activities on schedule or conduct our trials in accordance with regulatory requirements or our stated protocols.

The outcome of our clinical trials is uncertain. The results from preclinical testing and early clinical trials often have not predicted results of later clinical trials. A number of products have shown promising results in early clinical trials but subsequently failed to establish sufficient safety and efficacy data in later clinical trials to obtain necessary regulatory approvals.

If a product fails to demonstrate safety and efficacy in clinical trials, or if third parties fail to conduct clinical trials in accordance with their obligations, the development, approval and commercialization of our products may be delayed or prevented, and such events could materially adversely affect our business, financial condition, cash flows and results of operations.

***Preliminary, topline or interim data from our clinical trials that we may announce, publish or report from time to time may change as more patient data become available or based on subsequent audit and verification procedures, and may not be indicative of final data from such trials.***

From time to time, we may announce, publish or report preliminary, topline or interim data from our clinical trials, including those we are conducting in oncology. Such data are subject to the risk that one or more of the clinical outcomes may materially change as patients continue progressing through the study (for example, a patient may progress from a complete or partial response to progressive disease), as patient enrollment continues and/or as more patient data become available, and such data may not be indicative of final data from such trials. Such data also remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary, topline or interim data we previously disclose. As a result, all preliminary, topline and interim data should be viewed with caution until the final data are available. Material adverse differences between preliminary, topline or interim data and final data could significantly harm our business, financial condition, cash flows and results of operations.

***The FDA or other regulatory agencies may not approve our products or may delay approval.***

We must obtain government approvals before marketing or selling our products. The U.S. FDA and DEA (to the extent a product is a controlled substance), and comparable regulatory agencies in other jurisdictions, impose substantial and rigorous requirements for the development, manufacture and commercialization of medicines, the satisfaction of which can take a significant number of years and can vary substantially based upon the type, complexity and novelty of the product.

In addition, regulation is not static, and regulatory agencies, including the FDA, evolve in their staff, interpretations and practices and may impose more stringent requirements than currently in effect, which may adversely affect our plans for product development, manufacture and/or commercialization. The approval procedure and the time required to obtain approval also varies among countries. Regulatory agencies may have varying interpretations of the same data, and approval by one regulatory agency does not ensure approval by regulatory agencies in other jurisdictions. In addition, the FDA or regulatory agencies outside the U.S. may choose not to communicate with or update us during clinical testing and regulatory review periods and the ultimate decision by the FDA or other regulatory agencies regarding drug approval may not be consistent with prior communications.

The product approval process can last many years, be very costly and still be unsuccessful. Regulatory approval by the FDA or non-U.S. regulatory agencies can be delayed, limited or not granted at all for many reasons, including:

- a product may not demonstrate safety and efficacy for each target indication in accordance with the FDA's or other regulatory agencies' standards;
- data from preclinical testing and clinical trials may be interpreted by the FDA or other regulatory agencies in different ways than we or our licensees interpret it;
- the FDA or other regulatory agencies may not agree with our or our licensees' regulatory approval strategies, plans for accelerated development timelines, components of our or our licensees' filings such as clinical trial designs, conduct and methodologies, or the sufficiency of our or our licensees' submitted data to meet their requirements for product approval;
- the FDA or other regulatory agencies might not approve our or our licensees' manufacturing processes or facilities, or those of the CROs and contract manufacturing organizations who conduct research or manufacturing work on our or our licensees' behalf;
- any failure by our clinical investigational sites and the records kept at such sites, including any clinical trial data, to be in compliance with the FDA's Good Clinical Practices ("GCP"), or EU legislation governing GCP, or to pass FDA, European Medicines Agency or EU member state inspections of clinical trials;
- the FDA or other regulatory agencies may change their requirements for approval or post-approval marketing; and
- adverse medical events during the trials could lead to requirements that trials be repeated or extended, or that a program be terminated or placed on clinical hold, even if other studies or trials relating to the program are successful.

In addition, disruptions at the FDA and other regulatory agencies that are unrelated to our company or our products, including those relating to COVID-19 or other political or economic conditions, could cause delays to the regulatory approval process for our products. As of June 23, 2020, the FDA noted it is continuing to ensure timely review of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals; however, FDA may not be able

to continue its current pace and approval timelines could be extended, including in instances when a pre-approval inspection or an inspection of clinical trial sites is required and due to COVID-19 pandemic-related restrictions, the FDA may be unable to complete such required inspections during the review period. In addition, if a prolonged U.S. government shutdown occurs as a result of political or economic conditions or if the COVID-19 pandemic increases in severity or impact, the FDA's ability to timely review and process our regulatory submissions could be significantly impacted.

For example, in December 2020, we resubmitted our NDA for LYBALVI for the treatment of adults with schizophrenia and adults with bipolar I disorder, following receipt from the FDA in November 2020 of a CRL, which included an information request, relating to the manufacture of LYBALVI at our manufacturing facility in Wilmington, Ohio. The FDA accepted the NDA resubmission and assigned the application a PDUFA target action date of June 1, 2021 and subsequently issued a new request for records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act to supplement records that we previously provided. The FDA review process for this NDA involves uncertainties and risks, particularly in the current COVID-19 environment, including whether the FDA's remote review of our resubmission and additional records will be sufficient to meet the FDA's requirements for approval of LYBALVI without the conduct of a pre-approval inspection, whether the FDA will have additional requests for records or information in order to complete its review of the NDA, or whether the NDA will be approved in a timely manner, or at all.

Any failure to obtain, or delay in obtaining, regulatory approval for our products will prevent or delay their commercialization and could have a material adverse effect on our business, financial condition, cash flows and results of operations. In addition, any failure to obtain, or delay in obtaining, approval for our products could have a material impact on our shareholders' confidence in the strength of our development capabilities and/or our ability to generate significant revenue from our development program and could result in a significant decline in our share price.

***The FDA or other regulatory agencies may impose limitations or post-approval requirements on any product approval.***

Even if regulatory approval to market a product is granted by the FDA or other regulatory agencies, the approved label may not be consistent with our initial expectations or commercial plans, including limitations on the clinical data that may be included or the indicated uses for which, or the manner in which, the product may be marketed, or the approval may impose additional post-approval requirements, such as a REMS, with which we would need to comply in order to maintain the approval of such product. Our business could be seriously harmed if we do not complete these post-approval requirements and, as a result, the FDA or other regulatory agencies require us to change the label for our products, or if such post-approval requirements significantly restrict the marketing, sale or use of our products.

Further, if a product for which we obtain regulatory approval is a controlled substance, it will not become commercially available until after the DEA provides its final schedule designation, which may take longer and may be more restrictive than we expect or may change after its initial designation. For example, LYBALVI, our product currently under review by the FDA, contains samidorphan, which is currently a scheduled substance. The DEA issued a proposed ruling to deschedule samidorphan in December 2020; however, even if LYBALVI is approved by the FDA, until the DEA issues a final ruling, we will not be able to commercialize LYBALVI as a non-controlled substance. In addition, a final designation that is more restrictive than we expect could adversely affect our ability to commercialize such product and could materially adversely affect our business, financial condition, cash flows and results of operations.

In addition, legislation and regulatory policies relating to post-approval requirements and restrictions on promotional activities for pharmaceutical products, or FDA or DEA regulations, guidance or interpretations with respect to such legislation or regulatory policy, may change, which may impact the development and commercialization of our products.

***We are subject to risks related to the manufacture of our products.***

The manufacture of pharmaceutical products is a highly complex process in which a variety of difficulties may arise from time to time including, but not limited to, the supply and quality of API, drug product and other product components; failures relating to materials, manufacturing equipment or processes, vendor error, operator error, labor shortages or transportation, physical or electronic security breaches; natural disasters or global disruptions such as the current global pandemic; and many other factors. Problems with manufacturing processes, whether at our facilities or those of our licensees or other third parties which manufacture products or components of products on our behalf, could result in product defects, manufacturing failures or products not being manufactured to their applicable specifications, which could require us to delay shipment of products or recall products previously shipped, or could impair our ability to receive regulatory approval for a product, expand into new markets or supply products in existing markets. We may not be able to resolve any such issues in a timely manner, or at all.

We rely solely on our manufacturing facility in Wilmington, Ohio for the manufacture of RISPERDAL CONSTA, VIVITROL, ARISTADA, ARISTADA INITIO and certain of our other products in development, including LYBALVI. We rely solely on our manufacturing facility in Athlone, Ireland for the manufacture of many products, including AMPYRA, FAMPYRA and VUMERITY and other products using our NanoCrystal or OCR technologies. Due to regulatory and technical requirements, we have limited ability to shift production among our facilities or to outsource any part of our manufacturing to third parties. Any need to shift production among our facilities or transition our manufacturing processes to a third party could take a significant amount of time and money, may not be successful, and could cause significant delay in our ability to supply product.

Our manufacturing facilities also require specialized personnel and are expensive to operate and maintain. Any delay in a regulatory approval or commercial launch, or recall or suspension of sales, of products manufactured in our facilities may cause operating losses as we continue to operate these facilities and retain the required specialized personnel. In addition, any interruption in manufacturing, whether resulting from issues with equipment, materials, personnel or manufacturing processes, or internal or external quality audits or reviews, could result in delays in meeting our contractual obligations and could damage our relationships with our licensees, including the loss of manufacturing and supply rights.

We are also dependent in certain cases on third parties who manufacture or distribute certain products from which we receive revenue. For example, in the cases of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA, we do not have manufacturing rights or any control over the manufacturing, supply or distribution of the product. Supply or manufacturing issues related to such products could materially and adversely affect sales of such products, and in turn our revenue from such products.

***We rely on third parties to provide services in connection with the manufacture and distribution of the products we manufacture.***

We rely on third parties for the timely supply of specified raw materials, equipment, contract manufacturing, formulation and packaging services, storage and product distribution services, customer service activities and product returns processing that play a role in our manufacturing activities, and some of these materials and services for our products are currently only available from a single source or a limited number of qualified sources. Although we actively manage these third-party relationships to ensure continuity, quality and compliance with applicable regulations, events beyond our control could result in the complete or partial failure of these goods and services. Any such failure could materially adversely affect our business, financial condition, cash flows and results of operations.

The manufacture of products and product components, including the procurement of bulk drug product and other materials used in the manufacture, packaging, storage and distribution of our products, requires successful coordination among us and multiple third-party providers. Lack of capacity available at such third-party providers or any other issues with the quality or operations of these third-party providers, could require us to delay shipment of saleable products, recall products previously shipped or could impair our ability to supply products at all.

We endeavor to qualify and register new vendors and to develop contingency plans so that production is not materially impacted by third-party issues. Nonetheless, any such issues could increase our costs, cause us to lose revenue or market share and damage our reputation and may have a material adverse effect on our business, financial condition, cash flows and results of operations.

In addition, we rely heavily on the three largest pharmaceutical wholesalers in the U.S. market, Cardinal Health Inc., AmerisourceBergen Corp. and McKesson Corp, in the distribution of the products that we market and sell. If we are unable to maintain our business relationships with these wholesalers on commercially acceptable terms, if the buying patterns of these wholesalers fluctuate due to seasonality or any other reason or if wholesaler buying decisions or other factors outside of our control change, such events could materially adversely affect our business, financial condition, cash flows and results of operations.

***If we or our third-party providers fail to meet the stringent requirements of governmental regulation in the manufacture of our products, we could incur substantial remedial costs and a reduction in sales and/or revenues.***

We and our third-party providers are generally required to comply with cGMP regulations and other applicable non-U.S. standards in the manufacture of our products. In addition, in the U.S., the DEA and state-level agencies heavily regulate the manufacturing, holding, processing, security, recordkeeping and distribution of substances, including controlled substances. Any of our products that are scheduled by the DEA as controlled substances make us subject to the DEA's regulations. We and our third-party providers are subject to unannounced inspections by the FDA, the DEA and comparable U.S. state and non-U.S. agencies in other jurisdictions to confirm compliance with all applicable laws. Any changes to our suppliers or modifications of methods of manufacturing require amendments to our NDAs to the FDA or other regulatory

agencies, and ultimate acceptance by such agencies of such amendments, prior to release of product to the applicable marketplace. Our inability or the inability of our third-party providers to demonstrate ongoing cGMP or other regulatory compliance could require us to withdraw or recall products and interrupt clinical and commercial supply of our products. Any delay, interruption or other issues that may arise in the manufacture, formulation, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third-party providers to pass any regulatory agency inspection could significantly impair our ability to develop, obtain and maintain regulatory authority approval of, and commercialize or supply, products. This could increase our costs, cause us to lose revenue or market share and damage our reputation with our collaboration partners or in the market generally.

In March 2020, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law in the U.S., and served to increase the FDA's existing authority with respect to drug shortage measures. Under the CARES Act, for each facility where marketed products for certain serious diseases or conditions are manufactured, or where components of such products are manufactured, we are required to have a risk management plan in place that identifies and evaluates risks to the supply of such products or product components, which plans may be subject to review during any FDA inspection. Each of our facilities operates in accordance with a comprehensive quality management system, which includes risk assessment, preventive actions and regular review of stock levels for each of the marketed products that we manufacture; however, there is no guarantee that the FDA will consider our risk management program to be sufficient upon inspection or that we will not experience shortages in the supply of marketed products that we manufacture, which could materially adversely impact the patients who rely on such marketed products and our business, financial condition, cash flows and results of operations. The FDA and various regulatory agencies outside the U.S. have inspected and approved our commercial manufacturing facilities. We cannot guarantee that the FDA or any other regulatory agencies will approve any other facility we or our third-party providers may operate or, once approved, that any of these facilities will remain in compliance with cGMP and other regulations. Any third party we use to manufacture bulk drug product must be licensed by the FDA and, for controlled substances, the DEA. Failure by us or our third-party providers to gain or maintain regulatory compliance with the FDA or other regulatory agencies could materially adversely affect our business, financial condition, cash flows and results of operations.

***Adverse financial market conditions may exacerbate certain risks inherent to our business, including risk of payment from licensees and reimbursement for our products.***

Due to volatility in the financial markets, there may be disruptions or delays in the performance of our third-party contractors, suppliers or licensees, or reductions in the availability or extent of reimbursement available to us. For example, we depend on our licensees for significant portions of our revenue. The contracts with our licensees pursuant to which we supply product, or under which we are eligible for certain development or sales milestones, or royalties, related to products that incorporate our proprietary technologies, may not be secured by collateral or other security. Accordingly, we bear the risk that our licensees may not be able to pay amounts due to us under such contracts.

In addition, as a result of adverse financial market conditions, organizations that reimburse for use of our products, such as government health administration authorities and private health insurers, may be unable to satisfy such obligations or may delay payment. In addition, U.S. federal and state health authorities may reduce reimbursements (including Medicare and Medicaid reimbursements in the U.S.) or payments, and private insurers may increase their scrutiny of claims. If such licensees or other third parties are unable to pay amounts owed to us or satisfy their commitments to us, or if there are reductions to such payments or commitments, our business, financial condition, cash flows and results of operations would be adversely affected.

***Our business strategy may involve future transactions which may harm the market price of our ordinary shares or require us to seek additional funds, and such funding may not be available on commercially favorable terms or at all and may cause dilution to our existing shareholders.***

In order to achieve our business strategy, we regularly review potential transactions related to technologies, products or product rights, and businesses that are complementary to our business, including mergers, acquisitions, licensing agreements and co-promotion agreements, among others. We may choose to enter into one or more of these transactions at any time, which may cause substantial fluctuations in the market price of our ordinary shares. Moreover, depending upon the nature of any transaction, we may experience a charge to earnings, which could also materially adversely affect our results of operations and could harm the market price of our ordinary shares.

In order to finance such transactions, we may require additional funds, and we may seek such funds through various sources, including debt and equity offerings, corporate collaborations, bank borrowings, arrangements relating to assets, monetization of royalty streams or other financing methods or structures. The source, timing and availability of any financings will depend on market conditions, interest rates and other factors. If we issue additional equity securities or securities convertible into equity securities, our shareholders will suffer dilution of their investment, and it may adversely

affect the market price of our ordinary shares. In addition, future investors or lenders may demand, and may be granted, rights superior to those of existing shareholders. If we issue additional debt securities, our existing debt service obligations will increase further. If we are unable to generate sufficient cash to meet these obligations and need to use existing cash or liquidate investments in order to fund our debt service obligations or to repay our debt, we may be forced to curtail our operations. We cannot be certain that additional financing will be available from any of these sources when needed or, if available, will be on acceptable terms. If we fail to obtain additional capital when we need it, we may not be able to execute our business strategy successfully and may have to give up rights to our product platforms, and/or products, or grant licenses on terms that may not be favorable to us.

***Our future success largely depends upon our ability to attract and retain key personnel.***

Our ability to compete and succeed in the highly competitive biopharmaceutical industry and in the disease states in which we market and sell products depends largely upon the continued service of our management, scientific and commercial teams and our ability to attract, retain and motivate highly skilled technical, scientific, manufacturing, management, regulatory, compliance and selling and marketing personnel. Each of our executive officers and all of our employees are employed “at will,” meaning we or each officer or employee may terminate the employment relationship at any time. The loss of key personnel or our inability to hire and retain personnel who have technical, scientific, manufacturing, management, regulatory, compliance or commercial backgrounds could materially adversely impact our business, including the achievement of our manufacturing, research and development, commercial and other business objectives.

***The increasing use of social media platforms presents new risks and challenges.***

Social media is increasingly being used to communicate about our products and the diseases our medicines are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve, as do the regulations relating to such use. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public’s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.

**Risks Related to Intellectual Property**

***Patent and other IP protection for our products is key to our business and our competitive position but is uncertain.***

Receiving and maintaining patent and/or trademark protection for our products and technologies, including those that are subject to our licensing arrangements, maintaining our trade secrets, not infringing on the proprietary rights of others, and preventing others from infringing our proprietary rights are each key to our success and our competitive position.

Patent protection provides rights of exclusivity for the term of the patent. We are able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. In this regard, we try to protect our proprietary position by filing patent applications in the U.S. and elsewhere related to our proprietary product inventions and improvements that are important to our business and products. Our pending patent applications, together with those we may file in the future, or those we may license to or from third parties, may not result in patents being issued. Even if issued, such patents may not provide us with sufficient proprietary protection or competitive advantages against competitors with similar products or technology. The development of new technologies or products may take a number of years, and there can be no assurance that any patents which may be granted in respect of such technologies or products will not have expired or be due to expire by the time such products are commercialized, or that such patents will successfully withstand any challenges during their respective terms.

Because the patent positions of biopharmaceutical companies involve complex legal and factual questions, enforceability of patents cannot be predicted with certainty. The ultimate degree of patent protection that will be afforded to products and processes, including ours, and those of our licensees, in the U.S. and in other important markets, remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts and lawmakers in these countries. Patents, if issued, may be challenged, invalidated or circumvented. As our products achieve greater commercial sales, potential competitors are more likely to seek to challenge our patents. The laws of certain countries may not protect our IP rights to the same extent as the laws of the U.S., and any patents that we own or license from others may not provide any protection against competitors. In addition, in the case of certain of our licensed products or products incorporating our licensed technology, our licensees are responsible for prosecuting, maintaining, enforcing and defending the IP related to the product(s) from which we derive revenue. Their failure to secure, maintain, enforce and defend this IP could materially and adversely affect our business, financial condition, cash flows, and results of operations.

Although we make reasonable efforts to protect our IP rights and to ensure that our proprietary technology does not infringe the rights of third parties, we cannot ascertain the existence of all potentially conflicting IP claims. Therefore, there is a risk that third parties may make claims of infringement against our products or technologies. If patents exist or are issued that cover our products or technologies, we may not be able to manufacture, use, offer for sale, sell or import such products without first getting a license from the patent holder. The patent holder may not grant us a license on reasonable terms, or it may refuse to grant us a license at all. This could delay or prevent us from developing, manufacturing, selling or importing those of our products that would require the license. Claims of IP infringement may also require that we redesign affected products, enter into costly settlement or license agreements, pay costly damage awards, or face a temporary or permanent injunction prohibiting us from marketing or selling certain of our products. Even if we have an agreement that may serve to indemnify us against such costs, the indemnifying party may be unable to uphold its contractual obligations. If we cannot, or do not, license the infringed technology on reasonable terms or at all, or substitute similar technology from another source, our business, financial condition, cash flows and results of operations could be materially adversely affected.

We also rely on trade secrets, know-how and inventions, which are not protected by patents, to maintain our competitive position. We try to protect this information by entering into confidentiality agreements with parties that have access to it, such as our licensees, licensors, contract manufacturers, potential business partners, employees and consultants. However, any of these parties may breach such agreements and may disclose our confidential information, or our competitors might learn of the information in some other way. To the extent that our employees, consultants or contractors use IP owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. If any trade secret, know-how or other invention not protected by a patent were to be disclosed to, or independently developed by, a competitor, such event could materially and adversely affect our business, financial condition, cash flows and results of operations.

***Uncertainty over IP in the biopharmaceutical industry has been the source of litigation, which is inherently costly and unpredictable, could significantly delay or prevent approval or negatively impact commercialization of our products, and could adversely affect our business.***

There is considerable uncertainty within the biopharmaceutical industry about the validity, scope and enforceability of many issued patents in the U.S. and elsewhere in the world. We cannot currently determine the ultimate scope, validity and enforceability of patents which may be granted to third parties in the future or which patents might be asserted to be infringed by the manufacture, use or sale of our products.

Stemming in part from this uncertainty, there has been, and we expect that there may continue to be, significant litigation and an increasing number of *inter partes* reviews (“IPRs”) and administrative proceedings in the pharmaceutical industry regarding patents and other IP rights. A patent holder might file an IPR, interference and/or infringement action against us, including in response to patent certifications required under the Hatch-Waxman Act, claiming that certain claims of one or more of our issued patents are invalid or that the manufacture, use, offer for sale, sale or import of our products infringed one or more of such party’s patents. We may have to expend considerable time, effort and resources to defend such actions, and litigation may be necessary in some instances to determine the validity and scope of certain of our proprietary rights.

In addition, we may need to enforce our IP rights against third parties who infringe our patents and other IP or challenge our patents, patent applications or trademark applications. Litigation and trial proceedings, such as so-called Paragraph IV litigation and IPRs, concerning patents and other intellectual property rights may be expensive, protracted with no certainty of success, and distracting to management. As a result, we may at times give up certain rights with respect to our IP in order to avoid or resolve timely and costly litigation or IPR proceedings. For example, in July 2019, in order to resolve an IPR instituted by Amneal with the PTAB, we granted Amneal a non-exclusive license under certain patents covering VIVITROL, including the latest to expire patent covering VIVITROL in the U.S., to market and sell a generic formulation of VIVITROL in the U.S. beginning sometime in 2028 or earlier under certain circumstances. Ultimately, the outcome of such litigation and proceedings, or any settlement arrangement with respect thereto, could adversely affect our business and the validity and scope of our patents or other proprietary rights or delay or prevent us from manufacturing and marketing our products.

***We or our licensees may face claims against IP rights covering our products and competition from generic drug manufacturers.***

In the U.S., generic manufacturers of innovator drug products may file ANDAs and, in connection with such filings, certify that their products do not infringe the innovator’s patents and/or that the innovator’s patents are invalid. This often results in litigation between the innovator and the ANDA applicant. This type of litigation is commonly known in the U.S. as “Paragraph IV” litigation.

For example, Teva entities filed an ANDA seeking approval to engage in the commercial manufacture, use or sale of a generic version of VIVITROL and alleging that one of our Orange-Book patents related to VIVITROL is invalid, unenforceable and/or will not be infringed by Teva's proposed product. In September 2020, we initiated a Paragraph IV lawsuit against Teva to dispute such claims. Janssen is similarly involved in Paragraph IV litigation with companies seeking approval to market generic versions of INVEGA SUSTENNA and INVEGA TRINZA, products from which we receive significant revenue.

Although we intend to vigorously defend our IP rights, and we expect our licensees to do the same, there can be no assurance that we or our licensees will prevail. Our and our licensees' existing patents could be invalidated, found unenforceable or found not to cover generic forms of our or our licensees' products. If Teva or other ANDA filers were to receive FDA approval to sell a generic version of our products or the products from which we receive revenue and/or prevail in any patent litigation with respect to such products, such products would become subject to increased competition, and our business, financial condition, cash flows and results of operations could be materially adversely affected.

### **Risks Related to Regulatory or Legal Matters**

***Litigation or arbitration filed against Alkermes, including securities litigation, or regulatory actions (such as citizens petitions) filed against regulatory agencies in respect of our products, may result in financial losses, harm our reputation, divert management resources, negatively impact the approval of our products, or otherwise negatively impact our business.***

We are, and may in the future become, involved in various legal proceedings, including those asserting violations of securities and/or fraud and abuse laws and those asserting claims related to product liability, intellectual property and/or contractual arrangements. Such proceedings may involve claims for, or the possibility of, damages or fines and penalties involving substantial amounts of money or other relief, including but not limited to civil or criminal fines and penalties. For example, in December 2018 and January 2019, two purported stockholders of ours filed putative class actions against us and certain of our officers on behalf of a putative class of purchasers of our securities alleging violations of Sections 10(b) and 20(a) of the Exchange Act based on allegedly false or misleading statements and omissions regarding our regulatory submission for ALKS 5461, our drug candidate for the adjunctive treatment of major depressive disorder, and the FDA's review and consideration of that submission. This and other legal proceedings, and the preparation therefor, could result in substantial costs and a diversion of management's attention and resources, which could harm our business. Moreover, if any of these legal proceedings were to result in an adverse outcome, it could have a material adverse effect on our results of operations and harm our business.

We have been, and may continue to be, the subject of certain government inquiries or requests for documentation. For example, we have received a subpoena and civil investigative demands from U.S. state and federal authorities for documents related to VIVITROL. We are cooperating with the government in each instance. If, as a result of government requests, proceedings are initiated, including under the U.S. federal anti-kickback statute and False Claims Act and state False Claims Acts, and we are found to have violated one or more applicable laws, we may be subject to significant liability, including without limitation, civil fines, criminal fines and penalties, civil damages and exclusion from U.S. federal funded healthcare programs such as Medicare and Medicaid, and may be required to enter into a corporate integrity or other settlement with the government, any of which could materially affect our reputation, business, financial condition, cash flows and results of operations. Conduct giving rise to such liability could also form the basis for private civil litigation by third-party payers or other persons allegedly harmed by such conduct. In addition, if some of our existing business practices are challenged as unlawful, we may have to change those practices, including those of our sales force, which could have a material adverse effect on our business, financial condition, cash flows and results of operations.

Further, our liability insurance coverage may not be sufficient to satisfy, or may not cover, any expenses or liabilities that may arise. Additionally, regardless of whether or not there is merit to the claims underlying any lawsuits or government inquiries of which we are subject, or whether or not we are found as a result of such lawsuits or inquiries to have violated any applicable laws, such lawsuits and inquiries can be expensive to defend or respond to, may divert the attention of our management and other resources that would otherwise be engaged in managing our business, and may further cause significant and potentially irreparable harm to our public reputation.

We have been, and may again be, the subject of citizen petitions that request that the FDA refuse to approve, delay approval of, or impose additional approval requirements for our NDAs. If successful, such petitions can significantly delay, or even prevent, the approval of the NDA in question. Even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition, or may impose additional approval requirements as a result of such petition. These outcomes and others could adversely affect our share price as well as our ability to generate revenues from the commercialization and sale of our products and products using our proprietary technologies.



***The clinical study or commercial use of our products may cause unintended side effects or adverse reactions, or incidents of misuse may occur, which could adversely affect our products, business and share price.***

We cannot predict whether the clinical or commercial use of our products will produce undesirable or unintended side effects that have not been evident in the use of, or in clinical trials conducted for, such products to date. The administration of drugs in humans carries the inherent risk of product liability claims whether or not the drugs are actually the cause of an injury. Our products may cause, or may appear to have caused, injury or dangerous drug interactions, and we may not learn about or understand those effects until the products have been administered to study participants or patients for a prolonged period of time. Additionally, incidents of product misuse may occur.

These events, among others, could result in product recalls or additional regulatory controls (including additional regulatory scrutiny, REMS programs, and requirements for additional labeling) or product liability actions. As our development activities progress and we continue to have commercial sales, our product liability insurance coverage may be inadequate to satisfy liabilities that arise, we may be unable to obtain adequate coverage at an acceptable cost or at all, or our insurer may disclaim coverage as to a future claim. This could prevent or limit the development or commercialization of our products. In addition, the reporting of adverse safety events involving our products, including instances of product misuse, and public rumors about such events could cause our product sales or share price to decline or experience periods of volatility. These types of events could have a material adverse effect on our business, financial condition, cash flows and results of operations.

***If there are changes in, or we fail to comply with the extensive legal and regulatory requirements affecting the healthcare industry, we could face costs, penalties and a loss of business.***

Our activities, and the activities of our licensees and third-party providers, are subject to extensive government regulation. Government regulation by various national, state and local agencies includes detailed inspection of, and controls over, research and laboratory procedures, clinical investigations, product approvals and manufacturing, marketing and promotion, adverse event reporting, sampling, distribution, recordkeeping, storage, and disposal practices. Achieving compliance with these regulations substantially increases the time, difficulty and costs incurred in obtaining and maintaining approvals to market newly developed and existing products. Government regulatory actions, including audits, records requests and inspections of manufacturing facilities, can result in delay in the release of products, seizure or recall of products, suspension or revocation of the authority necessary for the manufacture and sale of products, and other regulatory enforcement actions, including the levying of civil fines or criminal penalties, the issuance of a warning letter, or the imposition of an injunction. Biopharmaceutical companies also have been the target of government lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of healthcare business, submission of false claims for government reimbursement, antitrust violations and violations related to environmental matters.

While we have implemented numerous risk mitigation measures, we cannot guarantee that we, our employees, our licensees, our consultants or our contractors are, or will be, in compliance with all applicable laws and regulations, and interpretations of the applicability of these laws to our products, operations and marketing practices. If we or our agents fail to comply with any of those regulations or laws, a range of actions could result, including the termination of clinical trials, the failure to approve a product, restrictions on our products or manufacturing processes, withdrawal of our products from the market, significant fines, exclusion from government healthcare programs or other sanctions or litigation.

Changes affecting the healthcare industry, including new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to patent protection and enforcement, access to healthcare, and product pricing and marketing, could also adversely affect our revenues and our potential to be profitable. For example, the costs of prescription pharmaceuticals in the U.S. has been the subject of considerable discussion in the U.S. and the new administration may seek to address such costs through new legislative and/or administrative measures. Such changes in laws, regulations or decisions or in the interpretation of existing laws, regulations and decisions could have a material adverse effect on our business, financial condition, cash flows and results of operations.

***Our business involves environmental, health and safety risks.***

Our business involves the use of hazardous materials and chemicals and is subject to numerous environmental, health and safety laws and regulations and to periodic inspections for possible violations of these laws and regulations. Under certain of these laws and regulations, we could be liable for any contamination at our current or former properties or third-party waste disposal sites. In addition to significant remediation costs, contamination can give rise to third-party claims for fines, penalties, natural resource damages, personal injury and damage (including property damage). The costs of compliance with environmental, health and safety laws and regulations are significant. We have developed and implemented a

proprietary risk mitigation program to preemptively identify and address environmental, health, safety and security risks; however, there can be no assurance that a violation of current or future environmental, health or safety laws or regulations, will not occur. Any violations, even if inadvertent or accidental, or the cost of compliance with any resulting order, fine or liability that may be imposed, could materially adversely affect our business, financial condition, cash flows and results of operations.

## **Risks Related to our Financial Condition and Tax Matters**

### ***We may not become profitable on a sustained basis.***

At December 31, 2020, our accumulated deficit was \$1.5 billion, which was primarily the result of net losses incurred from 1987, the year Alkermes, Inc., was founded, through December 31, 2020, partially offset by net income over certain fiscal periods.

Our ability to achieve sustained profitability in the future will depend on our ability to grow and diversify our revenue and effectively and efficiently manage our costs. Factors that may impact our future revenue, and in turn our future profitability, include our or our licensees' (as applicable) ability to:

- successfully commercialize VIVITROL, the ARISTADA product family, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA, FAMPYRA and any other marketed products for which we earn revenue in the countries in which such products are approved;
- successfully develop, and obtain and maintain regulatory approval for, products both in the U.S. and in other countries;
- manufacture our products and third-party products efficiently and in a cost-effective manner;
- obtain adequate reimbursement coverage for our products from insurance companies, government programs and other third-party payers; and
- achieve certain product development and sales milestones under our collaborative arrangements.

Factors that may impact our future spend, and in turn our future profitability, include:

- the scope of our research and development activities, including the number of products, indications or new technologies that we may pursue, and our ability to share development costs through potential collaborations;
- the time and expense required to pursue FDA and/or other regulatory approvals for our products;
- the time and expense required to prosecute, enforce, defend and/or challenge patent and other IP rights;
- the cost of operating and maintaining our manufacturing and research facilities;
- the costs of doing business with third-party vendors, including suppliers, manufacturers, packagers and distributors;
- the cost of possible licenses or acquisitions of technologies, compounds or product rights or the potential acquisition of other assets, including equipment, facilities or businesses;
- the costs related to potential litigation, arbitration or government requests for information;
- the costs of defending against potential proxy contests or other activist shareholder actions; and
- the costs associated with recruiting, compensating and retaining a highly skilled workforce in an environment where competition for such employees is intense.

### ***Certain U.S. holders of our ordinary shares may suffer adverse tax consequences if any of our non-U.S. subsidiaries are characterized as a "controlled foreign corporation".***

In December 2017, the Tax Cuts and Jobs Act was signed into law. This legislation significantly changed U.S. tax law by, among other things, changing the rules which determine whether a foreign corporation is treated for U.S. tax purposes as a controlled foreign corporation ("CFC") for taxable years ended December 31, 2017 and onwards. The impact of this change on certain holders of our ordinary shares is uncertain and could be adverse, including potential income inclusions and reporting requirements for U.S. persons (as defined in the Internal Revenue Code) who are treated as owning (directly or indirectly) at least 10% of the value or voting power of our shares. The determination of CFC status is complex and includes attribution rules, the application of which are not entirely certain. These changes to the attribution rules relating to the

determination of CFC status make it possible that one or more of our non-U.S. subsidiaries will be classified as a CFC. Existing and prospective investors should consult their tax advisers regarding the potential application of these rules to their investments in us.

See “*Certain Irish and United States Federal Income Tax Considerations – United States Federal Income Tax Considerations*” in our Form S-1/A, filed with the SEC on February 29, 2012, for additional discussion with respect to other potential U.S. federal income tax consequences of investments in us.

***If goodwill or other intangible assets become impaired, we could have to take significant charges against earnings.***

At December 31, 2020, we had \$111.2 million of amortizable intangible assets and \$92.9 million of goodwill. Under accounting principles generally accepted in the U.S., we must assess, at least annually and potentially more frequently, whether the value of goodwill and other indefinite-lived intangible assets have been impaired. Amortizing intangible assets will be assessed for impairment in the event of an impairment indicator. Any reduction or impairment of the value of goodwill or other intangible assets will result in a charge against earnings, which could materially adversely affect our results of operations and shareholders’ equity in future periods.

***Our effective tax rate may increase.***

As a global biopharmaceutical company, we are subject to taxation in a number of different jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of these places. Our effective tax rate may fluctuate depending on a number of factors, including, but not limited to, the distribution of our profits or losses between the jurisdictions where we operate and differences in interpretation of tax laws. In addition, the tax laws of any jurisdiction in which we operate may change in the future, which could impact our effective tax rate. Tax authorities in the jurisdictions in which we operate may audit us. If we are unsuccessful in defending any tax positions adopted in our submitted tax returns, we may be required to pay taxes for prior periods, interest, fines or penalties, and may be obligated to pay increased taxes in the future, any of which could have a material adverse effect on our business, financial condition, cash flows and results of operations.

***Our deferred tax assets may not be realized.***

As of December 31, 2020, we had \$86.2 million in net deferred tax assets in the U.S. Included in this amount was approximately \$2.1 million of U.S. federal NOL carryforwards and \$40.9 million of research and development tax credit carryforwards that can be used to reduce U.S. taxable income or offset federal tax in future periods. These carryforwards will expire within the next twenty years. It is possible that some or all of the deferred tax assets will not be realized, especially if we incur losses in the U.S. in the future. Losses may arise from unforeseen operating events or the occurrence of significant excess tax benefits arising from the exercise of stock options and/or the vesting of restricted stock units. Unless we are able to generate sufficient taxable income in the future, a substantial valuation allowance to reduce the carrying value of our U.S. deferred tax assets may be required, which would materially increase our expenses in the period the valuation allowance is recognized and materially adversely affect our business, financial condition and results of operations.

Furthermore, we have included within our U.S. net deferred tax assets of \$86.2 million an amount of \$40.5 million relating to employee share-based compensation expense. It is possible that a material portion of this deferred tax asset will not be realized, especially if the price of our ordinary shares remains at its current level (refer to “Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities” in our 2020 Form 10-K for details of the price of our ordinary shares). Unless the price of our ordinary shares increases, we will incur a deferred tax expense as our U.S.-based employees exercise or forfeit their stock options and their restricted stock unit awards vest. This could materially increase our tax expense and may materially adversely affect our financial condition and results of operations.

***The business combination of Alkermes, Inc. and the drug technology business (“EDT”) of Elan Corporation, plc may limit our ability to use our tax attributes to offset taxable income, if any, generated from such business combination.***

On September 16, 2011, the businesses of Alkermes, Inc. and EDT were combined under Alkermes plc (this combination is referred to as the “Business Combination”). For U.S. federal income tax purposes, a corporation is generally considered tax resident in the place of its incorporation. Because we are incorporated in Ireland, we should be deemed an Irish corporation under these general rules. However, Section 7874 of the Internal Revenue Code of 1986, as amended (the “Code”) generally provides that a corporation organized outside the U.S. that acquires substantially all of the assets of a corporation organized in the U.S. will be treated as a U.S. corporation (and, therefore, a U.S. tax resident) for U.S. federal income tax purposes if shareholders of the acquired U.S. corporation own at least 80% (of either the voting power or the

value) of the stock of the acquiring foreign corporation after the acquisition by reason of holding stock in the domestic corporation, and the “expanded affiliated group” (as defined in Section 7874) that includes the acquiring corporation does not have substantial business activities in the country in which it is organized.

In addition, Section 7874 provides that if a corporation organized outside the U.S. acquires substantially all of the assets of a corporation organized in the U.S., the taxable income of the U.S. corporation during the period beginning on the date the first assets are acquired as part of the acquisition, through the date which is ten years after the last date assets are acquired as part of the acquisition, shall be no less than the income or gain recognized by reason of the transfer during such period or by reason of a license of property by the expatriated entity after such acquisition to a foreign affiliate during such period, which is referred to as the “inversion gain,” if shareholders of the acquired U.S. corporation own at least 60% (of either the voting power or the value) of the stock of the acquiring foreign corporation after the acquisition by reason of holding stock in the domestic corporation, and the “expanded affiliated group” of the acquiring corporation does not have substantial business activities in the country in which it is organized. If this rule was to apply to the Business Combination, among other things, Alkermes, Inc. would have been restricted in its ability to use the approximately \$274.0 million of U.S. federal NOL carryforwards and \$38.0 million of U.S. state NOL carryforwards that it had as of March 31, 2011. We do not believe that either of these limitations should apply as a result of the Business Combination. However, the U.S. Internal Revenue Service (the “IRS”) could assert a contrary position, in which case we could become involved in tax controversy with the IRS regarding possible additional U.S. tax liability. If we were to be unsuccessful in resolving any such tax controversy in our favor, we could be liable for significantly greater U.S. federal and state income tax than we anticipate being liable for through the Business Combination, which would place further demands on our cash needs.

***Our level of indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business.***

In March 2018, we amended and refinanced the term loan under our credit agreement (previously referred to as “Term Loan B-1”), in order to, among other things, extend the due date of the loan from September 25, 2021 to March 26, 2023, reduce the interest payable thereon from LIBOR plus 2.75% with a LIBOR floor of 0.75% to LIBOR plus 2.25% with a 0% LIBOR floor and increase covenant flexibility. As of December 31, 2020, our borrowings consisted of \$276.4 million outstanding under the 2023 Term Loans.

The 2023 Term Loans are secured by a first priority lien on substantially all of the combined company assets and properties of Alkermes plc and most of its subsidiaries, which serve as guarantors. The agreements governing the 2023 Term Loans include a number of restrictive covenants that, among other things, and subject to certain exceptions and baskets, impose operating and financial restrictions on us.

Our failure to comply with these restrictions or to make these payments could lead to an event of default that could result in an acceleration of the indebtedness. Our future operating results may not be sufficient to ensure compliance with these covenants or to remedy any such default. In the event of an acceleration of this indebtedness, we may not have, or be able to obtain, sufficient funds to make any accelerated payments.

***Discontinuation, reform or replacement of LIBOR, or uncertainty related to the potential for any of the foregoing, may adversely affect us.***

In July 2017, the U.K. Financial Conduct Authority announced that LIBOR could be effectively discontinued after 2023. In addition, other regulators have suggested reforming or replacing other benchmark rates. The discontinuation, reform or replacement of LIBOR or any other benchmark rates may have an unpredictable impact on contractual mechanics in the credit markets or cause disruption to the broader financial markets. Uncertainty as to the nature of such potential discontinuation, reform or replacement may negatively impact the volatility of LIBOR rates, liquidity, our access to funding required to operate our business, or the trading market for our 2023 Term Loans.

Under our 2023 Term Loans, if the administrative agent determines that LIBOR is not reasonably ascertainable, or is notified by our lenders that LIBOR does not adequately and fairly reflect the costs to our lenders of maintaining the loans, we would be required to pay interest under an alternative base rate which could cause the amount of interest payable on the 2023 Term Loans to be materially different than expected. We may choose in the future to pursue an amendment to our 2023 Term Loans to provide for a transition mechanism or other alternative reference rate in anticipation of LIBOR’s discontinuation, but we can give no assurance that we will be able to reach agreement with our lenders on any such amendment.

***Currency exchange rates may affect revenues and expenses.***

We conduct a large portion of our business in international markets. For example, we derive a majority of our RISPERDAL CONSTA revenues and all of our FAMPYRA, XEPLION and TREVICTA revenues from sales in countries other than the U.S., and these sales are denominated in non-U.S. dollar (“USD”) currencies. We also incur substantial operating costs in Ireland and face exposure to changes in the exchange ratio of the USD and the euro arising from expenses and payables at our Irish operations that are settled in euro. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, USD, and the currencies in which we do business will affect our results of operations, often in unpredictable ways. See “Financial Risk Management” and “Currency Exchange Rate Risk” in this Directors’ Report for additional information relating to our foreign currency exchange rate risk.

***If we identify a material weakness in our internal control over financial reporting, our ability to meet our reporting obligations and the trading price of our ordinary shares could be negatively affected.***

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. Accordingly, a material weakness increases the risk that the financial information we report contains material errors.

We regularly review and update our internal controls, disclosure controls and procedures, and corporate governance policies. In addition, we are required under the Sarbanes-Oxley Act of 2002 to report annually on our internal control over financial reporting. Any system of internal controls, however well designed and operated, is based in part on certain assumptions and can provide only reasonable, not absolute, assurances that the objectives of the system are met. If we, or our independent registered public accounting firm, determine that our internal controls over financial reporting are not effective, or we discover areas that need improvement in the future, these shortcomings could have an adverse effect on our business and financial results, and the price of our ordinary shares could be negatively affected.

If we cannot conclude that we have effective internal control over our financial reporting, or if our independent registered public accounting firm is unable to provide an unqualified opinion regarding the effectiveness of our internal control over financial reporting, investors could lose confidence in the reliability of our financial statements, which could lead to a decline in the trading price of our ordinary shares. Failure to comply with reporting requirements could also subject us to sanctions and/or investigations by the SEC, the Nasdaq or other regulatory authorities.

**Risks Related to our Ordinary Shares**

***The market price for our ordinary shares has been volatile and may continue to be volatile in the future, and could decline significantly.***

The market price for our ordinary shares has fluctuated significantly from time to time. During the year ended December 31, 2020, the closing price of our ordinary shares on the Nasdaq Global Select Market ranged from \$13.06 to \$22.00 per share. The market price of our ordinary shares is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and industry factors, our results of operations, our ability to maintain and increase sales of our products, the success of our key development programs, our ability to achieve profitability, and other factors, including the principal risks described in this Directors’ Report. The stock market in general, including the market for biopharmaceutical companies, has experienced extreme price and trading volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. In particular, negative publicity regarding pricing and price increases by pharmaceutical companies, and potential legislation to regulate drug pricing, has negatively impacted, and may continue to negatively impact, the market for biopharmaceutical companies. These broad market and industry factors have harmed, and in the future may seriously harm, the market price of our ordinary shares, regardless of our operating performance. We have also experienced significant volatility in the market price of our ordinary shares based on our business performance, including in relation to our commercial sales and the financial guidance that we issue for such sales, results from our clinical development programs, and events relating to regulatory actions and interactions related to our product candidates and commercial products. For example, a series of adverse actions by the FDA in 2018 relating to our NDA for ALKS 5461, our investigational product for the treatment of major depressive disorder, caused the market price of our ordinary shares to decline significantly.

***Our business could be negatively affected as a result of the actions of activist shareholders.***

Proxy contests and other actions by activist shareholders have been waged against many companies in our industry over the last several years. Activist shareholders may agitate, either publicly or privately, for changes to a company’s board of directors, management, structure, spend or strategic direction, among other things. Such actions may cause significant

disruption to a company's operations and cause a company to expend a significant amount of time and resources in responding to their requests.

In December 2020, we engaged in extensive dialogue with an activist shareholder, resulting in our entry into a cooperation agreement with such activist in which we agreed on certain matters relating to our Board and affirmed our commitment to, and plans for, meeting certain financial targets over a multi-year period. These discussions resulted in the expenditure of significant time and energy by management and our Board and required dedication by the Company of significant resources. We have undertaken, and will continue to implement, several initiatives in order to achieve the financial targets, but there is no assurance that we will achieve these targets, or that doing so will decrease the likelihood of activist shareholder engagement in the future.

If faced with a proxy contest or other activist shareholder request or action in the future, we may not be able or willing to respond successfully to the contest, action, or request, which could be significantly disruptive to our business. Even if we are successful, our business could be adversely affected by any proxy contest or activist shareholder request or action involving us because:

- responding to proxy contests and other actions by activist shareholders can be costly and time-consuming, disrupting operations and diverting the attention of management and employees, and can lead to uncertainty;
- perceived uncertainties as to the future direction of the Company or its business may result in the loss of potential acquisitions, collaborations or in-licensing opportunities, and may make it more difficult to attract and retain qualified personnel and business partners; and
- if individuals are elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our strategic plan in a timely manner and create additional value for our shareholders.

Any such activist shareholder contests, actions or requests, or the mere public presence of activist shareholders among our shareholder base, could cause the market price for our ordinary shares to experience periods of significant volatility.

## **Risks Related to Information Security and Data Privacy**

***Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.***

In the ordinary course of our business, we collect and store sensitive data, including IP, our proprietary business information and that of our suppliers and partners, as well as personally identifiable information of patients, clinical trial participants and employees. In addition, the COVID-19 pandemic has required us to implement a global remote work policy for our employees who are able to work remotely. Our partners and third-party providers also possess certain of our sensitive data. The secure maintenance of all such information and the secure performance of our information technology ("IT") systems are critical to our operations and business strategy.

As the dependency on our IT systems increases, the confidentiality, integrity and availability of systems and the data that they store is critical to managing our business. While we take prudent measures to secure our IT systems, the risk still exists that such systems may become compromised by successful breaches, malfeasance, human error or technological fault. Certain types of attacks or breaches on our IT systems or infrastructure may go undetected for a prolonged period. Any breakdown, invasion, corruption, destruction or breach of our, our partners' or our third-party providers' technology systems could compromise such IT systems and the information stored there could be accessed, modified, publicly disclosed, lost or stolen, which could result in legal claims or proceedings and liability under laws that protect the privacy of personal information, disrupt our operations, damage our reputation and adversely affect our business. Although we retain cybersecurity insurance to cover costs and expenses related to a breach or similar event, any such costs and expenses may exceed the insurance available.

***We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.***

We are subject to laws and regulations covering data privacy and the protection of personal information, including health information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. In the U.S., numerous federal and state laws and regulations, including state security breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of personal information. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues for us. If we fail to comply with applicable laws and regulations, we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered

entity in a manner that is not authorized or permitted by the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HIPAA.

Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. The EU and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. In the EU, for example, the General Data Protection Regulation (EU) 2016/679 (“GDPR”) governs the processing of personal data. The GDPR imposes significant obligations on controllers and processors of personal data, including, high standards for obtaining consent from individuals to process their personal data, robust notification requirements to individuals about the processing of their personal data, a strong individual data rights regime, mandatory data breach notifications, limitations on the retention of personal data and increased requirements pertaining to health data, and strict rules and restrictions on the transfer of personal data outside of the EU, including to the U.S. The GDPR also imposes additional obligations on, and required contractual provisions to be included in, contracts between companies subject to the GDPR and their third-party processors that relate to the processing of personal data. The GDPR allows EU member states to make additional laws and regulations further limiting the processing of genetic, biometric or health data.

Adoption of the GDPR increased our responsibility and liability in relation to personal data that we process and may require us to put in place additional mechanisms to ensure compliance. Any failure to comply with the requirements of GDPR and applicable national data protection laws of EU member states could lead to regulatory enforcement actions and significant administrative and/or financial penalties against us (fines of up to €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher), and could adversely affect our business, financial condition, cash flows and results of operations.

### **Likely Future Developments**

We expect to invest in R&D associated with internal initiatives in conjunction with external acquisitive investments, and to focus these investments on products that we believe will offer the greatest potential for near and long-term growth. We plan to invest in areas in which we can benefit from our core competencies and global infrastructure. We plan to allocate resources to support the product lines that are faster-growing, higher-margin businesses in which we have or can develop a global competitive advantage. In fiscal year 2021, we plan to continue to analyze our business portfolio, which may lead to the acquisition or divestiture of assets and/or businesses.

### **Accounting Records**

The Board is responsible for ensuring that the Company keeps adequate accounting records and appropriate accounting systems to ensure compliance with the requirements of Sections 281 to 285 of the Companies Act. To achieve this, the Chief Financial Officer makes regular reports to the Audit and Risk Committee of the Board (the “Audit and Risk Committee”). The Audit and Risk Committee, in turn, briefs the full Board on significant financial matters arising from reports of the Chief Financial Officer and the external auditor.

The measures taken by the directors to secure compliance with the Company’s obligation to keep adequate accounting records include the use of appropriate systems and procedures and employment of competent persons. The accounting records are kept at Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6.

### **Corporate Governance**

The Company’s corporate governance policies and procedures are available on the Investors’ page of the Company’s website, [www.alkermes.com](http://www.alkermes.com).

## **Directors and Secretary**

The names of the persons who were directors or secretary of the Company at any time during the year ended December 31, 2020 or since December 31, 2020 are set out below.

<b><u>Directors</u></b>	<b><u>Date of Service as a Director or Secretary</u></b>
David W. Anstice	(Reappointed May 22, 2019)
Robert A. Breyer	(Reappointed May 22, 2019)
Shane M. Cooke	(Reappointed May 20, 2020)
David A. Daglio, Jr.	(Appointed December 9, 2020)
Wendy L. Dixon	(Reappointed May 22, 2019)
Richard B. Gaynor	(Reappointed May 20, 2020)
Brian P. McKeon	(Appointed December 9, 2020)
Paul J. Mitchell	(Reappointed May 20, 2020)
Richard F. Pops	(Reappointed May 20, 2020)
Nancy L. Snyderman	(Reappointed May 23, 2018)
Frank A. Wilson	(Appointed September 12, 2019)
Nancy J. Wysenski	(Reappointed May 23, 2018)
<b><u>Secretary</u></b>	
David J. Gaffin	(Appointed December 12, 2017)

## **Acquisition or Disposal of Own Shares**

Own shares held by the Company (par value, \$0.01 per share)  
(Value in thousands)

	<b>Number</b>	<b>Value</b>
January 1, 2020	2,710,886	\$ 118,386
Acquired during the year	397,193	7,701
December 31, 2020	<u>3,108,079</u>	<u>\$ 126,087</u>

The shares acquired during the year were received by the Company for the purchase of employee stock options or to satisfy minimum tax withholding obligations related to employee share-based awards.

## **Dividends**

No dividends have been paid on the ordinary shares to date, and we do not expect to pay cash dividends thereon in the foreseeable future (at December 31, 2020: none). We anticipate that we will retain all earnings, if any, to support our operations and our proprietary drug development programs. Any future determination as to the payment of dividends will be at the sole discretion of our Board and will depend on our financial condition, results of operations, capital requirements and other factors our Board deems relevant.



## **Directors' and Secretary's Interests in Shares**

No director, the secretary or any member of their immediate families had any interest in shares or debentures of any subsidiary. Directors' remuneration is set forth in Note 25, *Directors' Remuneration*, of the consolidated financial statements. The interests of the directors and secretary in office at January 1 and December 31, 2020 in the ordinary share capital of Alkermes plc are shown in the table below.

	Ordinary Shares <sup>(1)</sup> At December 31, 2020			Ordinary Shares <sup>(1)</sup> At January 1, 2020		
	Shares	Options	Restricted Share Units	Shares	Options	Restricted Share Units
<b>Directors</b>						
David W. Anstice	68,381	216,032	11,682	66,213	211,700	—
Robert A. Breyer	7,156	211,432	11,682	7,156	187,100	—
Shane M. Cooke	84,872	481,607	11,682	84,872	457,275	—
David A. Daglio, Jr.	45,000	—	—	—	—	—
Wendy L. Dixon	1,600	251,032	11,682	1,600	226,700	—
Richard Gaynor	—	97,332	11,682	—	73,000	—
Brian P. McKeon	—	—	—	—	—	—
Paul J. Mitchell	15,000	216,032	11,682	15,000	211,700	—
Richard F. Pops	759,094	3,236,666	360,017	716,433	3,203,200	273,975
Nancy L. Snyderman	—	122,032	11,682	—	97,700	—
Frank A. Wilson	—	97,332	11,682	—	73,000	—
Nancy J. Wysenski	11,242	207,282	11,682	4,302	182,950	—
<b>Company Secretary</b>						
David J. Gaffin	60,934	470,888	86,165	48,550	356,200	55,875

(1) All interests declared are in the ordinary shares of \$0.01 par value of Alkermes plc.

## **Political Donations**

No political contributions that require disclosure under S26(1) Electoral Act 1997 (as amended) were made during the financial year 2020.

## **Subsidiary Companies and Branches**

Information regarding our subsidiaries is provided in Note 27, *Subsidiaries*, to the consolidated financial statements.

## **Going Concern**

The Board formed a judgment at the time of approving these financial statements that there was a reasonable expectation that the Company has adequate resources to continue in operational existence for the next twelve months. In arriving at this conclusion, the board of directors has taken account of current and anticipated trading performance, together with the current and anticipated levels of net debt and the availability of the committed borrowing facilities. For this reason, the going concern basis continues to be adopted in the preparation of the Company's financial statements.

## **Audit and Risk Committee**

The Board has established an Audit and Risk Committee.

## **Statutory Auditors**

The Company's independent statutory auditors, PricewaterhouseCoopers, have indicated their willingness to continue in office and a resolution that they be re-appointed will be proposed at the Annual General Meeting.

## **Disclosure of Information to Auditors**

The directors in office at the date of this report have each confirmed that:

- As far as he/she is aware, there is no relevant audit information of which the Company's auditor is unaware; and

- He/she has taken all the steps that he/she ought to have taken as a director in order to make himself/herself aware of any relevant audit information and to establish that the Company’s auditor is aware of that information.

### **Non-Financial Statement**

The European Union (Disclosure of Non-Financial and Diversity Information by certain large undertakings and groups) Regulations 2017 (S.I. 360/2017) (as amended) require us to disclose certain non-financial information in our Directors’ Report.

A description of our business model can be found under “Business Overview” beginning on page 6 of this Directors’ Report and a description of our risks related to our business, including those related to environmental, social and governance issues can be found under “Principal Risks” on pages 29-47 of this Directors’ Report. The following is a summary of our key policies, actions and key performance indicators in the areas of: (a) Environmental Matters (including climate-related information); (b) Social and Employee Matters; (c) Human Rights; and (d) Bribery and Corruption. A description of matters relating to our supply chain can be found under the heading entitled “Manufacturing and Product Supply” on page 13 of this Directors’ Report. These policies and actions aim to ensure Alkermes manages risk in these areas and achieves its environmental, social and governmental goals.

The descriptions of our policies set forth in the sections below include references to our Code of Business Conduct and Ethics (the “Code of Conduct”). The Code of Conduct and certain other policies pertaining to our business are available on the Company’s website, [www.alkermes.com](http://www.alkermes.com). Our updated Corporate Responsibility Report is available on the Responsibility page of the Company’s website, [www.alkermes.com](http://www.alkermes.com).

#### ***Environmental Matters***

At Alkermes, our goal is to conduct our business activities in a manner that:

- Protects the health and safety of our employees;
- Minimizes the environmental impacts of our operations
- Promotes effective stewardship of environmental resources; and
- Maintains an unwavering focus on product quality and safety.

We are committed to complying with applicable laws, rules, and regulations and operating with the highest standards of conduct. As a global business, we ensure that our environmental performance meets all relevant local and national regulatory agencies’ requirements in the countries where we operate. All Alkermes facilities are subject to routine regulatory inspections for Environmental Health, Safety and Security (“EHSS”) and product quality and product safety to confirm compliance with applicable regulatory regimes.

We also go beyond compliance and strive to create a culture of sustainability throughout the organization. We work collaboratively across stakeholder groups and business units to identify ways to reduce our environmental impact, mitigate risk, and increase efficiencies.

Alkermes is committed to operating in a way that protects our employees, our environment, and our communities. We implement a variety of EHSS risk management strategies to help ensure compliance, proactively reduce risk, and drive awareness and improvement of our environmental impacts, priorities and risks. The core goals established by our EHSS function include to:

- Preserve and protect the viability of the business and the health and safety of our employees;
- Support safe, rapid, and sustainable innovation and growth; and
- Meet or exceed applicable environmental, health, and safety regulations and statutory obligations for the regions in which we operate.

Together with committed leadership and an engaged workforce, our operations are supported by teams of highly qualified and experienced EHSS professionals who provide strategic oversight and governance of EHSS activities and evaluate and establish appropriate EHSS performance goals for our operations.

Our EHSS strategy is integrated into all aspects of our business and spans the full scope of our enterprise, including our R&D, manufacturing, external operations, general and administrative functions, and our field sales teams. This strategy is supported by numerous EHSS initiatives ranging from our high-level, systemic compliance and risk management frameworks to programs more focused on creating a culture of EHSS risk awareness and active workforce engagement.

We maintain a robust, enterprise-wide EHSS Risk Management System (RMS), based on the structured principles of the international standards ISO14001:2015 (environmental management) and ISO45001:2018 (occupational health and safety management). Designed to rapidly identify existing and emerging risks and assign appropriate resources to ensure effective mitigation at each of our operating facilities, our RMS framework enables us to:

- Comply with statutory and regulatory requirements and Alkermes' internal policies, and adhere to the terms of our environmental permits and licenses;
- Proactively identify and prioritize EHSS risks and potential mitigations for internal and external operations;
- Maintain effective emergency response preparedness; and
- Drive continuous improvement across all of our operating areas.

Alkermes is committed to the safe and sustainable research, development, manufacturing scale-up and commercialization of medicines. We implement this commitment by integrating EHSS risk management requirements throughout the lifecycle of each of our products. Our approach to product stewardship oversight and control includes:

- Generation of occupational and environmental toxicology data, which is iterated and augmented as each product progresses through its lifecycle;
- Development and application of appropriate occupational health, safety, and environmental risk controls for each product based on scale, potency, task, and other processing considerations;
- Protocols and risk assessments to support safe and responsible technology transfers within Alkermes or to external contract manufacturing organizations (CMOs) or CROs or other third-parties;
- Development of "green chemistry" processes to eliminate or reduce the use or generation of hazardous substances in the design and manufacture of our products; and
- Implementation of a global program for process hazard management, with embedded controls as early as the discovery stage of development and through full commercial-scale manufacturing.

#### External Operations Risk Management

We have integrated certain EHSS risk management procedures and the formal RMS framework into our vendor management and governance processes and we collaborate directly with strategic partners to foster effective two-way risk management-focused communications. To ensure that our vendors operate to Alkermes' standards, EHSS risk considerations are embedded into our due diligence assessments, on-boarding procedures, technology transfers, and routine business reviews. We also incorporate enhanced EHSS provisions, as appropriate, into our standard service level agreements related to our products. Our vendor assessment tools, which we developed based on the Pharmaceutical Supply Chain Initiative's 'Pharmaceutical Industry Principles for Responsible Supply Chain Management,' address key areas such as: EHSS management systems; performance and regulatory compliance; environmental sustainability; occupational health and safety systems; process safety management controls; physical security; labor and ethics policies; business continuity systems; and capability to safely handle Alkermes products. We have conducted on-site audits or desk-top reviews to assess all external CMOs directly involved in the manufacture or packaging of proprietary Alkermes products, and use the information gained from these assessments to help us prioritize areas of focus for our ongoing risk management efforts.

#### Environmental Protection and Sustainability

We intend to continue to grow our business and operations in a manner that is both protective of the environment and sustainable in the long-term. We strive to create a culture of sustainability throughout our organization and work collaboratively across internal stakeholder groups and business units to identify ways to reduce our environmental impact, mitigate environmental and climate-related risks, and create sustainable business opportunities.

Cross-functional teams of employees at our facilities are focusing on sustainability initiatives such as waste stream evaluation and optimization and a forum of engineering leaders from each of our sites meets regularly to develop best practices for our facilities and utility systems. A sub-team of this group has been appointed to integrate sustainability principles and practices into the design of our capital projects, monitor Company-wide energy audits and develop a multi-year plan for energy reduction initiatives.

#### Control of Wastewater Emissions

Alkermes maintains strict controls over its wastewater emissions, adhering to the parameters of our applicable licenses and permits. We also continually evaluate opportunities to improve our wastewater control systems. For example, significantly advanced our wastewater emissions management system by gaining a deeper understanding of the

environmental toxicology of the products we manufacture and adapting our wastewater controls accordingly, in order to protect the environment in the most sustainable way possible.

#### Water Conservation

We recognize that water is a scarce and invaluable resource that we must endeavor to conserve and use efficiently and sustainably. We have implemented programs across our organization to assess, reduce and optimize our water consumption. The Athlone site is now largely self-sufficient in water consumption with substantially all water sourced and treated from onsite wells.

#### Waste Optimization

All Alkermes facilities have comprehensive waste management plans in place and we strive to reduce our generation of waste at the source. Our waste streams are fully segregated, and disposal methods are carefully evaluated to ensure compliance with statutory and permit requirements. For non-hazardous waste, our goal is to eliminate landfilling wherever feasible, and we actively implement recycling, composting and/or other re-use opportunities. We also employ other forms of responsible disposal, such as treatment in third-party “waste-to-energy” facilities. Similarly, for hazardous waste, we recognize that landfill is not an environmentally responsible disposal route. We actively explore recycling opportunities for our hazardous wastes and, when feasible, select disposal routes that include potential energy recovery benefits.

#### Sustainability Through Design

Reducing our carbon footprint and ensuring that Alkermes’ buildings and processes operate sustainably are major factors in the planning and decision-making processes for all new construction at our facilities. In addition, for existing infrastructure, our monitoring and targeting systems enable us to identify opportunities for further energy reduction or other sustainability improvements. Examples of our sustainability design efforts include:

- Installation of energy-saving fixtures such as low emissivity windows, LED lighting with motion sensors, and reflective roofing;
- Upgrade of HVAC systems to be more efficient and require lower energy consumption;
- Installation of variable speed drives and high efficiency motors;
- Institution of water conservation measures such as process cleaning optimization and low-flow restroom facilities; and
- Installation of sensors at fume hoods to reduce exhaust flow during unoccupied times.

#### ***Social and Employee Matters***

We recognize that all of our stakeholders are connected in a single environment and affect one another. This is particularly true of employees, healthcare providers, patients, caregivers, and the communities in which we live and work. Our employees are the foundation upon which our business is built. Their expertise, intelligence, and creativity drive our innovation, and their passion and commitment to excellence are the cornerstone of our success. Supporting our employees’ well-being in a transparent, diverse, inclusive, and collaborative culture and providing them with the training, support and resources they need to succeed professionally while appropriately balancing their professional and personal lives helps keep our employees connected and engaged and are critical to our success. Beyond our employees, we are committed to giving back to the communities where our employees live and work through volunteering opportunities and engagement with caregivers, patients and their loved ones. We also support advocacy efforts to raise awareness of patient needs and to increase access to medicines and other forms of treatment in support of patient health and well-being.

We have more than 2,000 employees across the U.S. and Ireland who are key to our ability to develop, produce and advance treatment options for patients. We are an equal opportunity employer and we are fundamentally committed to creating and maintaining a work environment in which employees are treated with respect and dignity. All human resources policies, practices and actions related to hiring, promotion, compensation, benefits and termination are administered in accordance with the principal of equal employment opportunity, meaning that they are made on the basis of individual skills, knowledge, abilities, job performance and other legitimate criteria and without regard to race, color, religion, sex, sexual orientation, gender expression or identity, ethnicity, national origin, ancestry, age, mental or physical disability, genetic information, any veteran status, any military status or application for military service, or membership in any other category protected under applicable law.

In 2020, employee health, safety and wellness were of particular focus and importance for the company. Following the emergence of the COVID-19 pandemic, we adapted our business practices to support uninterrupted supply of, and patient

access to, our marketed products for people living with addiction and serious mental illness. We also adopted a series of precautionary measures to protect and support our employees, including those performing essential tasks in our laboratories and manufacturing facilities who could not perform their work remotely. For additional information about actions taken by the Company to support its employees and other stakeholders in response to the COVID-19 pandemic, see the “COVID-19 Update” section included in this Directors’ Report.

### Diversity, Inclusion and Belonging

Across all of our sites, we actively cultivate a work environment that reflects our values of collaboration at our core, respect for each voice and unwavering commitment. In 2019, we created a global Diversity, Inclusion & Belonging Steering Committee, comprised of representatives from all of our locations, including our field-based employees, and a variety of functional areas to create connections and celebrate our diverse workforce by developing and advancing practices, tools and resources that can be used to strengthen the sense of belonging among our employee base. In 2020, we established three employee-led resource groups: Pride@Work, an LGBTQ+ and ally network; Mosaic, a multicultural network; and Women Inspired Network (WIN), a women’s network, with a common purpose of supporting and enhancing the inclusiveness of our company culture and providing opportunities for professional development, networking and building deeper connections within Alkermes based on cross-functional employee involvement.

### Professional Development

We are committed to the professional growth and development of our employees from their first day on the job and throughout their tenure at the Company. We conduct a comprehensive on-boarding experience that connects newly hired employees to our business, values, culture, and people. We organize frequent company-hosted trainings that cover topics including performance management, problem solving, leadership development, communication, and mentorship, as well as more specialized skills-based programs. We also encourage and support our employees in their efforts to seek out additional professional learning opportunities within Alkermes and externally.

We also conduct ongoing health and safety training in compliance with all federal, state, and local regulations.

### Culture of Employee Engagement

We strive to foster a strong culture of active employee engagement to ensure that employees feel part of our mission and that they have a voice in the Alkermes community. Since 2017, we have conducted annual employee engagement surveys to understand employee sentiment regarding, and satisfaction with, their work and experience at Alkermes. In 2020, nearly 75% of our employees participated in the employee engagement survey and we have used the data collected to help inform our human capital management strategy.

We also believe strongly in sharing and recognizing success as a team. Our RISE recognition program connects our employees across all locations and enables our employees to acknowledge and commend their colleagues’ outstanding performance through peer-to-peer recognition.

### Patient Engagement

We are inspired by the courage of individuals facing the unique challenges of living with CNS diseases, and the perspectives of those affected by these conditions are paramount to our work. Developing medicines for some of the most stigmatized and misunderstood CNS diseases requires thoughtful and sustained engagement with patients, caregivers, and patient advocacy groups. Alkermes works closely with patient organizations to integrate voices from the community into our business. Regular engagement with policymakers and leaders in the patient advocacy community allows us to better understand their perspectives and goals, and learnings from these interactions help inform our own policy and advocacy activities. Driven by our patient-centered ethos, we advocate for, among other things, improved access to treatments. However, we also understand that access to treatment options addresses only a portion of the needs of the patients, families, and communities for whom we develop our medicines. We are committed to working with the people affected by CNS diseases and the organizations that support them to better understand the complex system of care for diseases and to achieve our common goal of improving outcomes for such patients and their caregivers.

### Access

Alkermes believes that every patient deserves quality care and we are committed to collaborating with policy makers and other industry stakeholders to preserve and enhance access to important medicines. We strive to price our medicines in a responsible manner that facilitates broad access. We also offer programs, such as our Patient Assistance Program and our Co-Pay Savings Program, to provide support to eligible patients who are prescribed our medicines.

## Supporting Our Communities

Alkermes respects the culture, customs and values of the people in the communities in which we operate. We seek to support those communities and serve as a positive influence with grant programs, sponsorship contributions and volunteer support.

### Sponsorships

Alkermes is proud to be part of the broader healthcare community supporting those with mental illness and substance use disorder. We foster and maintain relationships with a variety of health-related and public policy organizations. In 2019 and 2020, we continued to work closely with non-profit organizations, such as the National Alliance on Mental Illness (NAMI), to help patients and their families and to bring awareness to programs and initiatives of organizations that work to improve the lives of persons affected by mental illness.

### Funding in Support of Research and Charitable Organizations

Innovative research and funding are urgently needed to support those who are living with serious mental illness and substance use disorders. Since 2017, Alkermes has proudly supported, and continues to support, not-for-profit organizations and independent researchers working in the areas of substance use disorders and serious mental health through its ALKERMES INSPIRATION GRANTS® initiative, its ALKERMES PATHWAYS RESEARCH AWARDS® program and its investigator-sponsored studies program. Information about past grant recipients can be found on the Responsibility page of the Company's website, [www.alkermes.com](http://www.alkermes.com).

In 2020, we established a COVID-19 Relief Fund, a special edition of the ALKERMES INSPIRATION GRANTS program, and awarded grants to 10 nonprofit organizations to assist in their work to rapidly address pandemic-related needs for people living with addiction, serious mental illness, or cancer.

### Community Engagement

Our employees are passionate about helping to care for people and the environment in the local communities in which we work, supporting not only organizations and programs that are connected to the diseases our medicines treat, but also causes for which they feel a personal connection through their own experience or that of loved ones.

#### ***United States***

Ten years ago, a group of employees started Alkermes in Action, an annual day of volunteering to support our local communities with hands-on activities that align with our values and embody our compassion. Over the past decade, over 5,000 volunteers have worked with more than 50 local community organizations and established a number of meaningful, long-term relationships between Alkermes and the organizations. In 2020, we adapted this volunteer program to make it entirely virtual, and our employees dedicated more than 400 volunteer hours to local organizations focused on education, caring for veterans, and providing for children and families in need.

#### ***Ireland***

Alkermes employees in Ireland proudly support local organizations that address a range of needs including mental health, cancer care, women and children refugees and homelessness, among others.

#### ***Respect for Human Rights***

We are committed to respecting human rights. At Alkermes, we believe that it is our responsibility to respect and uphold the human rights of our people and any other individuals we are in contact with across the globe. We believe this is evidenced by the information summarized above in *Social and Employee Matters* as well as in our EHSS and Procurement policies and practices.

At Alkermes, we work hard to foster a culture of respect, inclusion and equality supported by our Code of Conduct and the policies and programs championed by our human resources ("HR") organization.

Consistent with our Respect in the Workplace policy, we are fundamentally committed to creating and maintaining a work environment in which employees are treated fairly, with dignity, decency, respect, and in accordance with all applicable law. We believe that all employees have the right to work in an environment that is free of discrimination and harassment of any kind. Harassment or discriminatory behavior—whether by any Company personnel or third parties with whom we do business—is not tolerated. We also strive to uphold human rights in all of our business activities and support the principles in the United Nations Declaration on Human Rights, including the prohibition of human trafficking, child labor, and slavery of any kind.

We recognize that Diversity (the presence of difference) and Inclusion (welcoming, valuing, and leveraging differences) belong at the heart of all that we do and are key drivers of our success as an organization. Our approach to diversity and inclusion emphasizes engagement with colleagues, and policies and programs that reflect the diversity of our workforce and our belief in inclusiveness, including domestic partner benefits.

### ***Bribery and Corruption***

Integrity is a core Alkermes value and the foundation of the way we do business. Alkermes is dedicated to upholding legal, regulatory and ethical standards in every market in which we operate and to maintaining a strong culture of compliance. Our focus on compliance applies to all aspects of our business, beginning with pre-clinical research and continuing through clinical trials, manufacturing, and commercialization. This focus on compliance builds trust with healthcare professionals, institutional purchasers, relevant government agencies, and the public at large.

We believe compliance is a responsibility shared by all employees across all levels of the Company. We expect each individual to take ownership of compliance and to perform all activities and conduct all interactions with integrity and in accordance with the highest ethical standards.

Our commitment to compliance is embodied in our comprehensive compliance program which is built on the following core elements:

- Written policies and procedures address the compliance risk areas relevant to pharmaceutical manufacturers, including those identified in the guidance of the Office of Inspector General of the U.S. Department of Health & Human Services and the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals.
- The Chief Compliance Officer oversees the compliance program and reports directly to the Chief Executive Officer. The Corporate Compliance Committee helps oversee the Company's compliance program and assists with identifying any compliance issues that need to be brought to the attention of the Board.
- Alkermes conducts extensive training and education programs for all employees that begins with new hire training and includes regular, ongoing training on topics, processes, and policies relevant to their positions.
- Alkermes has established and continues to foster a culture of compliance that maintains effective lines of communication and encourages all employees to seek guidance on ethical or legal issues as they arise. This culture of compliance is further supported by a policy obligating employees to report possible compliance violations and a strong anti-retaliation policy (discussed below) that protects personnel who report issues in good faith.
- Regular monitoring and auditing of the compliance program enables Alkermes to detect and prevent potential non-compliance.
- The Company's policies and training ensure that all employees, including management, understand the consequences of failing to adhere to our compliance policies.
- Our compliance program is designed to promptly respond to and address, through corrective action, any detected instances of non-compliance.

Our Code of Conduct applies to all directors, officers and employees of the Company. Among other things, the Code of Conduct requires:

- honest and ethical conduct by directors, officers and employees of the Company, including the ethical handling of actual or apparent conflicts of interest;
- full, fair and understandable reports on the Company's activities in reports filed with the U.S. Securities and Exchange Commission (SEC) and in the Company's other public communications; and
- prompt internal reporting of any violation of the Code of Conduct to the Company's Chief Legal Officer or Chief Compliance Officer (which role is currently held by the Company's Chief Legal Officer).

The Code of Conduct also requires compliance with all applicable laws, rules, and regulations including, but not limited to, those guiding our interactions with government officials and health care providers. In this context, it expressly prohibits any bribes, kickbacks, or other improper payments, transfers, or receipts.

Our employees are obligated to raise concerns about any violations of our Code of Conduct, or any other ethics or conduct violations, with their supervisor, the Company's Chief Legal Officer or Chief Compliance Office, the Audit and Risk Committee and/or the Nominating and Corporate Governance Committee of the Board, or through the Company's Corporate Governance hotline. A current copy of the Reporting Procedures for Auditing and Accounting Internal Control Matters and

Illegal or Unethical Behaviors (the Whistleblower Policy) is available by visiting the Corporate Governance page of the Investors section of the Company's website, [www.alkermes.com](http://www.alkermes.com).

### **Subsequent Events**

In March 2021, the Company amended and extended the 2026 Term Loan, formerly referred to as the 2023 Term Loan, pursuant to which, among other things: (a) provided for a new class of replacement term loans equal to \$300.0 million; (b) extended the due date from March 26, 2023 to March 12, 2026; and (c) amended the interest payable from LIBOR plus 2.25% with no LIBOR floor to LIBOR plus 2.50%, with a LIBOR floor of 0.50% for LIBOR Rate Loans (as defined in the Amended Credit Agreement) and ABR plus 1.50%, with an ABR floor of 1.50% for ABR Loans (as defined in the Amended Credit Agreement).

### **Directors' Compliance Statement**

The directors acknowledge that they are responsible for securing the Company's compliance with its relevant obligations. The directors confirm that they have:

1. Drawn up a compliance policy statement setting out the Company's policies respecting compliance by the Company with its relevant obligations.
2. Put in place appropriate arrangements or structures that are designed to secure material compliance with the Company's relevant obligations.
3. Conducted a review, during the financial year ended 31 December 2020, of the arrangements and structures, referred to at 2 above.

On behalf of the directors

/s/ RICHARD F. POPS  
Richard F. Pops  
*Chairman*

/s/ PAUL J. MITCHELL  
Paul J. Mitchell  
*Director*

April 14, 2021



## ALKERMES PLC

### STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the directors' report and the financial statements in accordance with Irish law.

Irish law requires the directors to prepare financial statements for each financial year that give a true and fair view of the consolidated and Company's (as defined below) assets, liabilities and financial position and of the profit or loss of the Group (as defined below) for the financial year. Under that law the directors have prepared the consolidated financial statements in accordance with U.S. accounting standards, as defined in Section 279(1) of the Companies Act 2014, as amended (the "Companies Act"), to the extent that the use of those principles in the preparation of the consolidated financial statements does not contravene any provision of the Companies Act or of any regulations made thereunder and the standalone parent company financial statements in accordance with generally accepted accounting practice in Ireland (accounting standards issued by the Financial Reporting Council of the UK, including Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland and Irish law).

Under Irish law, the directors shall not approve the financial statements unless they are satisfied that they give a true and fair view of the Company's assets, liabilities and financial position as at the end of the financial year and the profit or loss of the Company for the financial year.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and estimates that are reasonable and prudent;
- state that the consolidated financial statements of Alkermes plc and its subsidiaries (the "Group") comply with accounting principles generally accepted in the United States of America ("U.S. GAAP") to the extent that it does not contravene Irish company law and that the standalone entity balance sheet of Alkermes plc (the "Company") comply with accounting standards issued by the Financial Reporting Council and Irish Law; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to:

- correctly record and explain the transactions of the Company;
- enable, at any time, the assets, liabilities, financial position and profit or loss of the Company to be determined with reasonable accuracy; and
- enable the directors to ensure that the financial statements comply with the Companies Act and enable those financial statements to be audited.

The directors are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the Company's website ([www.alkermes.com](http://www.alkermes.com)). Legislation in Ireland concerning the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.



## *Independent auditors' report to the members of Alkermes plc*

### **Report on the audit of the financial statements**

---

#### **Opinion**

In our opinion:

- Alkermes plc's consolidated financial statements and parent company financial statements (the "financial statements") give a true and fair view of the group's and the parent company's assets, liabilities and financial position as at 31 December 2020 and of the group's loss and cash flows for the year then ended;
- the consolidated financial statements have been properly prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"), as defined in Section 279 of the Companies Act 2014, to the extent that the use of those principles in the preparation of consolidated financial statements does not contravene any provision of Part 6 of the Companies Act 2014;
- the parent company financial statements have been properly prepared in accordance with Generally Accepted Accounting Practice in Ireland (accounting standards issued by the Financial Reporting Council of the UK, including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and Irish law); and
- the financial statements have been properly prepared in accordance with the requirements of the Companies Act 2014.

We have audited the financial statements, included within the Directors' Report and Consolidated Financial Statements (the "Annual Report"), which comprise:

- the Consolidated Balance Sheet as at 31 December 2020;
- the Parent Company Balance Sheet as at 31 December 2020;
- the Consolidated Profit and Loss account and Consolidated Statement of Comprehensive Loss for the year then ended;
- the Consolidated Statement of Cash Flows for the year then ended;
- the Consolidated Reconciliation of Movement in Shareholders' Funds for the year then ended;
- the Parent Company Reconciliation of Movement in Shareholders' Funds for the year then ended; and
- the notes to the financial statements, which include a description of the significant accounting policies.

---

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (Ireland) ("ISAs (Ireland)") and applicable law. Our responsibilities under ISAs (Ireland) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Independence**

We remained independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, which includes IAASA's Ethical Standard as applicable to listed entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

---

#### **Our audit approach**

##### *Overview*

	<p>Materiality</p> <ul style="list-style-type: none"><li>• \$7.5 million (2019: \$9.9 million) - Consolidated financial statements</li><li>• Based on c. 0.7% of Revenue (2019: c. 5% of loss before tax).</li></ul>
--	--



	<ul style="list-style-type: none"> <li>• \$30 million (2019: \$29 million) - Parent Company financial statements. Based on c. 1% of net assets of the parent company.</li> <li>• For group audit purposes the lower consolidated financial statements materiality of \$7.5 million was applied in testing balances that do not eliminate in the consolidated financial statements.</li> </ul>
	<p>Audit scope</p> <ul style="list-style-type: none"> <li>• The group has one reportable segment consisting of two primary geographic reporting components – United States (“U.S.”) and Ireland.</li> <li>• We conducted full scope audits on both reporting components.</li> </ul>
	<p>Key audit matters</p> <ul style="list-style-type: none"> <li>• Rebate Accruals - Medicaid Drug Rebate Program</li> </ul>

*The scope of our audit*

As part of designing our audit, we determined materiality and assessed the risks of material misstatement in the financial statements. In particular, we looked at where the directors made subjective judgements, for example in respect of significant accounting estimates that involved making assumptions and considering future events that are inherently uncertain. As in all of our audits we also addressed the risk of management override of internal controls, including evaluating whether there was evidence of bias by the directors that represented a risk of material misstatement due to fraud.

*Key audit matters*

Key audit matters are those matters that, in the auditors’ professional judgement, were of most significance in the audit of the financial statements of the current period and include the most significant assessed risks of material misstatement (whether or not due to fraud) identified by the auditors, including those which had the greatest effect on: the overall audit strategy; the allocation of resources in the audit; and directing the efforts of the engagement team. These matters, and any comments we make on the results of our procedures thereon, were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. This is not a complete list of all risks identified by our audit.

<i>Key audit matter</i>	<i>How our audit addressed the key audit matter</i>
<p><i>Rebate Accruals - Medicaid Drug Rebate Program</i></p> <p>Refer to note 2 "Summary of significant accounting policies and statement of compliance" and note 18 "Provisions for liabilities".</p> <p>As described in note 2 to the consolidated financial statements, revenue from product sales is recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, health care providers or payers.</p> <p>Accruals for rebates in the United States (“US”) under the Medicaid Drug Rebate Program are recorded as a reduction to product sales when the product is shipped into the distribution channel using the expected value method. As of December 31, 2020, total accrued Medicaid rebates amounted to \$182 million.</p>	<p>We tested the effectiveness of controls relating to rebate accruals for the Medicaid drug rebate program, including controls over the assumptions used to estimate the rebate accruals for the Medicaid Drug Rebate Program.</p> <p>We assessed the appropriateness of management’s methodology used to determine the accruals for the Medicaid Drug Rebate Program.</p> <p>We assessed the reasonableness of management’s forecast of the accruals for the Medicaid Drug Rebate Program by</p> <p>(i) developing an independent estimate of the rebate accruals for the Medicaid Drug Rebate Program by utilizing third-party data related to product sales, the historical trend of actual rebate claims paid and</p>



<p>The Company rebates individual States for all eligible units purchased under the Medicaid program based on a rebate per unit calculation, which is based on the Company’s average manufacturer prices. At the year end, management estimates unit sales and rebates per unit under the Medicaid program.</p> <p>We determined accruals for the Medicaid Drug Rebate Program to be a key audit matter due to the significant judgement exercised by management in developing the Medicaid Drug rebate accrual, including developing assumptions related to the estimates of units sold and rebates per unit under the Medicaid program.</p>	<p>(ii) consideration of contractual requirement changes and market events;</p> <p>(iii) comparing the independent estimate to management’s estimate; and</p> <p>testing rebate claims processed by the Company.</p> <p>We considered the historical accuracy of the accrual for the Medicaid Drug Rebate Program.</p>
---	--

**How we tailored the audit scope**

We tailored the scope of our audit to ensure that we performed enough work to be able to give an opinion on the financial statements as a whole, taking into account the structure of the group, the accounting processes and controls, and the industry in which the group operates. The group has one reportable segment consisting of two primary geographic reporting components – United States (“U.S.”) and Ireland. We conducted full scope audits on both reporting components.

**Materiality**

The scope of our audit was influenced by our application of materiality. We set certain quantitative thresholds for materiality. These, together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures on the individual financial statement line items and disclosures and in evaluating the effect of misstatements, both individually and in aggregate on the financial statements as a whole.

Based on our professional judgement, we determined materiality for the financial statements as a whole as follows:

	<i>Consolidated financial statements</i>	<i>Parent company financial statements</i>
<b>Overall materiality</b>	\$7.5 million (2019: \$9.9 million ).	\$30 million (2019: \$29 million ).
<b>How we determined it</b>	C. 0.7% of Revenue (2019: c. 5% of loss before tax).	C. 1% of net assets of the parent company.
<b>Rationale for benchmark applied</b>	We deem revenue to be an appropriate benchmark in the current year, having regard for the volatility in the loss before tax. This benchmark is utilised by management, analysts and the general market when assessing the results of the group.	As the parent company is a holding company we deem net assets to be the most appropriate benchmark to calculate materiality.

We agreed with the Audit Committee that we would report to them misstatements identified during our audit above \$0.56 million (group audit) (2019: \$0.7 million ) and \$1.5 million (parent company audit) (2019: \$1.5 million ) as well as misstatements below that amount that, in our view, warranted reporting for qualitative reasons.

**Conclusions relating to going concern**

Our evaluation of the directors’ assessment of the group and parent company’s ability to continue to adopt the going concern basis of accounting included:

- Evaluating management’s cashflow forecasts for the period of the going concern assessment (being the period of twelve months from the date on which the financial statements are authorised for issue), and evaluating these forecasts by considering the group’s historic performance and its past record of achieving strategic objectives.



- Considering whether the assumptions underlying the forecast were consistent with related assumptions considered in other parts of the audit, for example in testing for non-financial asset impairment;
- Considering available financing and maturity profile to assess liquidity and the covenants attaching to long term debt for the going concern assessment period;
- Testing management's controls which include the mathematical integrity of the forecasts.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's or the parent company's ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the group's or the parent company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

---

## Reporting on other information

The other information comprises all of the information in the Directors' Report and Consolidated Financial Statements other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Directors' Report, we also considered whether the disclosures required by the Companies Act 2014 (excluding the information included in the "Non Financial Statement" as defined by that Act on which we are not required to report) have been included.

Based on the responsibilities described above and our work undertaken in the course of the audit, ISAs (Ireland) and the Companies Act 2014 require us to also report certain opinions and matters as described below:

- In our opinion, based on the work undertaken in the course of the audit, the information given in the Directors' Report (excluding the information included in the "Non Financial Statement" on which we are not required to report) for the year ended 31 December 2020 is consistent with the financial statements and has been prepared in accordance with the applicable legal requirements.
- Based on our knowledge and understanding of the group and parent company and their environment obtained in the course of the audit, we have not identified any material misstatements in the Directors' Report (excluding the information included in the "Non Financial Statement" on which we are not required to report).

---

## Responsibilities for the financial statements and the audit

### *Responsibilities of the directors for the financial statements*

As explained more fully in the Directors' Responsibilities Statement set out on page 57, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view.

The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.



In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

### *Auditors' responsibilities for the audit of the financial statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Our audit testing might include testing complete populations of certain transactions and balances, possibly using data auditing techniques. However, it typically involves selecting a limited number of items for testing, rather than testing complete populations. We will often seek to target particular items for testing based on their size or risk characteristics. In other cases, we will use audit sampling to enable us to draw a conclusion about the population from which the sample is selected.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA website at:

[https://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description\\_of\\_auditors\\_responsibilities\\_for\\_audit.pdf](https://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf)

This description forms part of our auditors' report.

### *Use of this report*

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with section 391 of the Companies Act 2014 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

---

## **Other required reporting**

---

### **Companies Act 2014 opinions on other matters**

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the parent company were sufficient to permit the Parent Company financial statements to be readily and properly audited.
- The Parent Company Balance Sheet is in agreement with the accounting records.

---

### **Other exception reporting**

#### *Directors' remuneration and transactions*

Under the Companies Act 2014 we are required to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by sections 305 to 312 of that Act have not been made. We have no exceptions to report arising from this responsibility.



*Prior financial year Non Financial Statement*

We are required to report if the company has not provided the information required by Regulation 5(2) to 5(7) of the European Union (Disclosure of Non-Financial and Diversity Information by certain large undertakings and groups) Regulations 2017 in respect of the prior financial year. We have nothing to report arising from this responsibility.

A handwritten signature in blue ink, appearing to read 'Gareth Hynes', is written over a faint, light blue circular stamp or watermark.

Gareth Hynes  
for and on behalf of PricewaterhouseCoopers  
Chartered Accountants and Statutory Audit Firm  
Dublin  
14 April 2021

- The maintenance and integrity of the Alkermes plc website is the responsibility of the directors; the work carried out by the auditors does not involve consideration of these matters and, accordingly, the auditors accept no responsibility for any changes that may have occurred to the financial statements since they were initially presented on the website.
- Legislation in the Republic of Ireland governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**ALKERMES PLC**  
**CONSOLIDATED PROFIT AND LOSS ACCOUNT**

	Notes	Year Ended December 31,	
		2020	2019
		(In thousands, except per share amounts)	
Product sales, net	3	\$ 551,760	\$ 524,499
Manufacturing and royalty turnover	3	484,000	447,882
Research and development turnover	3	1,946	52,816
License turnover	3	1,050	145,750
Total turnover		1,038,756	1,170,947
Cost of sales		178,316	180,385
Gross profit		860,440	990,562
Research and development expense		394,588	512,833
Selling, general and administrative expense		538,827	599,449
Amortization of acquired intangible assets	5	39,452	40,358
Restructuring expense	6	—	13,401
Operating loss		(112,427)	(175,479)
Interest income		6,960	13,976
Interest expense	7	(8,659)	(13,601)
Change in the fair value of contingent consideration	8	3,945	(22,800)
Other income (expense), net		13,644	848
Total other expense, net		15,890	(21,577)
Loss before income taxes		(96,537)	(197,056)
(Provision) benefit for income taxes	9	(14,324)	436
Loss after income taxes		\$ (110,861)	\$ (196,620)
<b>LOSS PER ORDINARY SHARE:</b>			
Basic and diluted	10	\$ (0.70)	\$ (1.25)
<b>WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:</b>			
Basic and diluted	10	158,803	157,051

The accompanying notes are an integral part of these consolidated financial statements.



**ALKERMES PLC**  
**CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS**

	<u>Year Ended December 31,</u>	
	<u>2020</u>	<u>2019</u>
	<b>(In thousands, except per share amounts)</b>	
<b>NET LOSS</b>	<b>\$ (110,861)</b>	<b>\$ (196,620)</b>
Unrealized gains on marketable securities:		
Unrealized gains, net of tax	467	1,464
Unrealized gains on marketable securities	467	1,464
<b>COMPREHENSIVE LOSS</b>	<b>\$ (110,394)</b>	<b>\$ (195,156)</b>

The accompanying notes are an integral part of these consolidated financial statements.

**ALKERMES PLC**  
**CONSOLIDATED BALANCE SHEET**

	<u>Notes</u>	<u>December 31, 2020</u>	<u>December 31, 2019</u>
(In thousands, except share and per share amounts)			
<b>ASSETS</b>			
<i>Fixed Assets</i>			
Intangible assets—Goodwill	5	\$ 92,873	\$ 92,873
Intangible assets—Intellectual property	5	111,191	150,643
Tangible assets	11, 12	481,721	374,547
Financial assets	5, 15	30,991	85,302
Total fixed assets		<u>716,776</u>	<u>703,365</u>
<i>Current Assets</i>			
Stock	13	125,738	101,803
Debtors	14	472,189	465,256
Investments	15	362,066	331,208
Cash at bank and in-hand		272,961	203,771
Total current assets		<u>1,232,954</u>	<u>1,102,038</u>
<b>TOTAL ASSETS</b>		<u>\$ 1,949,730</u>	<u>\$ 1,805,403</u>
<b>LIABILITIES</b>			
<i>Capital and Reserves</i>			
Called-up share capital presented as equity	16	\$ 1,620	\$ 1,602
Share premium		597,651	589,296
Profit and loss account		(135,512)	(24,651)
Treasury shares	16	(126,087)	(118,386)
Other reserves		729,310	637,581
Total equity		<u>1,066,982</u>	<u>1,085,442</u>
<i>Provisions for liabilities</i>	18	229,008	167,754
<i>Creditors—amounts falling due within one year</i>			
Debt	7, 12	18,575	11,309
Creditors	19	211,870	235,555
<i>Creditors—amounts falling due after one year</i>			
Debt	7, 12	391,582	279,637
Creditors	19	31,713	25,707
Total for creditors		<u>653,740</u>	<u>552,208</u>
<b>TOTAL LIABILITIES</b>		<u>\$ 1,949,730</u>	<u>\$ 1,805,404</u>

The accompanying notes are an integral part of these consolidated financial statements.

The consolidated financial statements were approved by the board of directors on April 14, 2021 and signed on its behalf by:

/s/ RICHARD F. POPS  
Richard F. Pops  
Chairman

/s/ PAUL J. MITCHELL  
Paul J. Mitchell  
Director

**ALKERMES PLC**  
**CONSOLIDATED STATEMENT OF CASH FLOWS**

	Year Ended December 31,	
	2020	2019
(In thousands)		
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Loss after tax	\$ (110,861)	\$ (196,620)
Adjustments to reconcile net loss to after tax to cash flows from operating activities:		
Depreciation and amortization	81,854	80,413
Share-based compensation expense	90,164	100,977
Deferred income taxes	9,985	(319)
Change in the fair value of contingent consideration	(3,945)	22,800
Loss on debt refinancing	—	—
Payment made for debt refinancing	—	—
Impairment of property, plant and equipment	—	—
Other non-cash (credit)/charges	2,514	(580)
Changes in assets and liabilities, excluding the effect of acquisitions:		
Trade receivables	(18,050)	35,136
Contract assets	(6,015)	(5,156)
Stock	(22,933)	(13,077)
Prepaid expenses and other assets	4,022	(1,784)
Right-of-use assets	17,336	8,399
Creditors	50,600	34,847
Contract liabilities	(4,924)	16,140
Operating lease liabilities	(16,273)	(9,117)
Other long-term liabilities	9,368	18
Cash flows provided by operating activities	<u>82,842</u>	<u>72,077</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Additions to property, plant and equipment	(42,219)	(90,942)
Proceeds from the sale of equipment	643	900
Proceeds from contingent consideration	3,886	10,000
Purchases of investments	(229,543)	(277,518)
Sales and maturities of investments	253,001	224,602
Acquisition of Rodin Therapeutics, Inc.'s net assets, net of cash acquired	—	(8,875)
Cash flows used in investing activities	<u>(14,232)</u>	<u>(141,833)</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from the issuance of ordinary shares under share-based compensation arrangements	8,373	18,925
Employee taxes paid related to net share settlement of equity awards	(7,701)	(9,317)
Principal payments of long-term debt	(2,843)	(2,843)
Payment made in connection with debt refinancing	—	—
Cash flows provided by (used in) financing activities	<u>(2,171)</u>	<u>6,765</u>
<b>NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>66,439</b>	<b>(62,991)</b>
CASH AND CASH EQUIVALENTS—Beginning of period	203,771	266,762
CASH AND CASH EQUIVALENTS—End of period	<u>\$ 270,210</u>	<u>\$ 203,771</u>
<b>SUPPLEMENTAL CASH FLOW DISCLOSURE:</b>		
Cash paid for interest	\$ 8,288	\$ 13,254
Cash paid for taxes	\$ 620	\$ 2,508
Non-cash investing and financing activities:		
Purchased capital expenditures included in creditors	\$ 2,420	\$ 13,789

ALKERMES PLC

CONSOLIDATED RECONCILIATION OF MOVEMENT IN SHAREHOLDERS' FUNDS

	Share Capital	Share Premium	Profit and Loss Account	Treasury Shares	Other Reserves	Total
<b>(In thousands)</b>						
BALANCE — January 1, 2019	\$ 1,579	\$ 570,294	\$ 171,969	\$ (108,969)	\$ 536,412	\$ 1,171,285
Net loss	—	—	(196,620)	—	—	(196,620)
Other comprehensive income	—	—	—	—	1,464	1,464
Share-based payment reserve	—	—	—	—	99,705	99,705
Shares issued under employee stock plans	15	18,910	—	—	—	18,925
Receipt of Alkermes' shares for the purchase of stock options or to satisfy minimum tax withholding obligations related to share-based awards	8	92	—	(9,417)	—	(9,317)
BALANCE — December 31, 2019	\$ 1,602	\$ 589,296	\$ (24,651)	\$ (118,386)	\$ 637,581	\$ 1,085,442
Net loss	—	—	(110,861)	—	—	(110,861)
Other comprehensive income	—	—	—	—	467	467
Share-based payment reserve	—	—	—	—	91,262	91,262
Shares issued under employee stock plans	7	8,366	—	—	—	8,373
Receipt of Alkermes' shares for the purchase of stock options or to satisfy minimum tax withholding obligations related to share-based awards	11	(11)	—	(7,701)	—	(7,701)
BALANCE — December 31, 2020	\$ 1,620	\$ 597,651	\$ (135,512)	\$ (126,087)	\$ 729,310	\$ 1,066,982

The accompanying notes are an integral part of these consolidated financial statements.

**ALKERMES PLC**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**1. DESCRIPTION OF BUSINESS**

Alkermes plc (the “Company”) is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Headquartered in Dublin, Ireland, the Company has a research and development (“R&D”) center in Waltham, Massachusetts; R&D and manufacturing facilities in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

The registered office of the Company is located in Connaught House, 1 Burlington Road, Dublin 4 and its registration number is 498284.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE**

***Basis of Preparation***

Irish law requires the Company’s directors to prepare financial statements for each financial year that give a true and fair view of the consolidated and the standalone parent company’s assets, liabilities and financial position as at the end of the financial year and of the profit or loss of the group for the financial year. Under that law, the Company’s directors have prepared the consolidated financial statements in accordance with accounting standards generally accepted in the United States (“U.S. GAAP”), as defined in Section 279(1) of the Companies Act 2014, as amended (the “Companies Act”), to the extent that the use of those principles in the preparation of the financial statements does not contravene any provision of the Companies Act or of any regulations made thereunder and the standalone parent company financial statements in accordance with Generally Accepted Accounting Practice in Ireland (accounting standards issued by the Financial Reporting Council and Irish law).

The consolidated financial statements are prepared in accordance with Irish company law, to present to the shareholders of Alkermes plc and file with the Companies Registration Office in Ireland. Accordingly, these consolidated financial statements include disclosures required by the Companies Act in addition to those required under U.S. GAAP.

The preparation of the consolidated financial statements in conformity with U.S. GAAP accepted accounting principles requires management to use judgment in making estimates and assumptions based on the relevant information available at the end of each period. These estimates and assumptions have a significant effect on reported amounts of assets and liabilities, revenue and expenses as well as the disclosure of contingent assets and liabilities because they result primarily from the need to make estimates and assumptions on matters that are inherently uncertain. Actual results may differ from estimates.

***Going Concern***

The Board formed a judgment at the time of approving these financial statements that there was a reasonable expectation that the Company has adequate resources to continue in operational existence for the next twelve months. In arriving at this conclusion, the board of directors has taken account of current and anticipated trading performance, including current and anticipated uncertainties driven by the COVID-19 pandemic (as described in greater detail under the heading “Risks and Uncertainties” within this note), together with the current and anticipated levels of net debt and the availability of the committed borrowing facilities. The Company’s forecasts and projections, taking account of reasonably possible changes in trading performance, show that the Company should be able to operate within the level of its current facilities. After making enquiries, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the for a period of not less than 12 months from the date of approval of these financial statements. Therefore these financial statements have been prepared on a going concern basis.

***Principles of Consolidation***

The consolidated financial statements include the accounts of Alkermes plc and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated.

During the year ended December 31, 2020, Alkermes Finance S.à r.l, an indirect subsidiary of Alkermes plc, was liquidated and its net assets were transferred to its parent company, Alkermes Pharma Ireland Limited.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

##### *Use of Estimates*

The preparation of the Company's consolidated financial statements in accordance with U.S. GAAP requires that Company management make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates and judgments and methodologies, including those related to revenue from contracts with its customers and related allowances, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments, contingent consideration and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

##### *Cash at Bank and In-Hand*

The Company values its cash and cash equivalents at cost plus accrued interest, which the Company believes approximates their market value. The Company considers cash equivalents only those investments that are highly liquid, readily convertible into cash and so near their maturity, generally three months from the date of purchase, that they present insignificant risk of change in value because of interest rate changes.

##### *Investments*

The Company has investments in various types of securities, consisting primarily of United States ("U.S.") government and agency obligations, corporate debt securities and debt securities issued by foreign agencies and backed by foreign governments. The Company generally holds its interest-bearing investments with major financial institutions and in accordance with documented investment policies. The Company limits the amount of credit exposure to any one financial institution or corporate issuer. At December 31, 2020, substantially all these investments were classified as available-for-sale and were recorded at fair value.

Holding gains and losses on available-for-sale investments are considered "unrealized" and are reported within "Accumulated other comprehensive loss," a component of shareholders' equity. The Company uses the specific identification method for reclassifying unrealized gains and losses into earnings when investments are sold. The Company conducts periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments, as required by U.S. GAAP. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in "Accumulated other comprehensive loss."

For securities with unrealized losses, the Company performs an analysis to assess whether it intends to sell or whether it would more likely than not be required to sell the security before the expected recovery of its amortized cost basis. If the Company intends to sell a security, or may be required to do so, the security's decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is recorded within earnings as an impairment loss. Regardless of the Company's intent to sell a security, the Company performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

The Company's held-to-maturity investments are restricted investments held as collateral under letters of credit related to certain of the Company's agreements and are included in "Financial assets" in the accompanying consolidated balance sheets.

##### *Fair Value of Financial Instruments*

The Company's financial assets and liabilities are recorded at fair value and are classified as Level 1, 2 or 3 within the fair value hierarchy, as described in the accounting standards for fair value measurement. At December 31, 2020, the Company's financial assets consisted of cash equivalents, investments and contingent consideration and are classified within the fair value hierarchy as follows:

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

- *Level 1*—these valuations are based on a market approach using quoted prices in active markets for identical assets. Valuations of these products do not require a significant degree of judgment. Assets utilizing Level 1 inputs at December 31, 2020 included U.S. treasury securities, marketable securities classified as cash equivalents and a fixed term deposit account;
- *Level 2*—these valuations are based on quoted prices for identical or similar assets in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models. Assets utilizing Level 2 inputs at December 31, 2020 included U.S. government agency debt securities, debt securities issued by foreign agencies and backed by foreign governments and investments in corporate debt securities that are trading in the credit markets; and
- *Level 3*—these valuations are based on an income approach using certain inputs that are unobservable and are significant to the overall fair value measurement. Valuations of these products require a significant degree of judgment. At December 31, 2020, assets utilizing Level 3 inputs included contingent consideration and an investment in a corporate debt security.

The carrying amounts reflected in the consolidated balance sheets for cash at bank and in-hand, debtors and creditors approximate fair value due to their short-term nature.

**Stock**

Stock is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Included in stock are raw materials used in production of preclinical and clinical products, which have alternative future use and are charged to R&D expense when consumed. The cost elements included within stock include three primary categories for commercial products: cost of raw materials; direct labor; and overhead. Overhead is based on the normal capacity of the Company’s production facilities and does not include costs from abnormally low production or idle capacity, which are expensed directly to the consolidated profit and loss account.

The Company capitalizes stock costs associated with its products prior to regulatory approval when, based on management’s judgment, future commercialization of the product is considered probable and future economic benefit from such product is expected to be realized. The Company assesses the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety, efficacy or quality concerns, potential labeling restrictions and other potential impediments to approval. The Company also considers the shelf life of the product in relation to the expected timeline for approval and considers issues that may prevent or delay commercialization, including issues that may arise in relation to the manufacturing of the product. The Company expenses previously capitalized costs related to pre-approval stock upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by relevant regulatory agencies or other issues that may make the pre-approval stock batches less likely or unlikely to be commercialized and to result in future economic benefit.

**Tangible Fixed Assets**

Tangible fixed assets are recorded at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Expenditures for repairs and maintenance are charged to expense as incurred and major renewals and improvements are capitalized. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets:

Asset group	Term
Buildings and improvements	15 - 40 years
Furniture, fixtures and equipment	3 - 10 years
Leasehold improvements	Shorter of useful life or lease term

**Contingent Consideration**

The Company records contingent consideration it is entitled to receive at fair value on the acquisition date. The Company estimates the fair value of contingent consideration through valuation models that incorporate probability-adjusted assumptions related to the likelihood of achievement of milestones and of receipt of the related payments. The Company revalues its contingent consideration each reporting period, with changes in the fair value of contingent consideration recognized within the consolidated statements of operations and comprehensive loss. Changes in the fair value of contingent consideration can result from changes to one or multiple assumptions, including adjustments to discount rates, changes in the amount and timing of cash flows, changes in the assumed achievement and timing of any development and sales-based milestones and changes in the assumed probability associated with regulatory approvals and creditworthiness of the counterparty.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

The period over which the Company discounts its contingent consideration is based on the current development stage of the product candidate, the specific development plan for that product candidate, adjusted for the probability of completing the development steps, and when contingent payments would be triggered. In estimating the probability of success, the Company utilizes data regarding similar milestone events from several sources, including industry studies and the Company's own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment was employed in determining the appropriateness of these assumptions at the acquisition date and for each subsequent period. Accordingly, changes in assumptions described above could have a material impact on the increase or decrease in the fair value of contingent consideration recorded in any given period.

##### *Goodwill and Intangible Assets*

Goodwill represents the excess cost of the Company's investment in the net assets of acquired companies over the fair value of the underlying identifiable net assets at the date of acquisition. The Company's goodwill consists solely of goodwill created as a result of the Company's acquisition of Elan Drug Technologies ("EDT") from Elan Corporation, plc (the "Business Combination") in September 2011 and has been assigned to one reporting unit. A reporting unit is an operating segment or one level below an operating segment or a component to which goodwill is assigned when initially recorded.

Consistent with U.S. GAAP, goodwill is not amortized over an arbitrary period, but is reviewed for impairment on an annual basis, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable. The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of its reporting unit is less than its carrying amount, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative impairment test, the Company compares the fair value of its reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of its reporting unit, then the Company would record an impairment loss equal to the difference.

Irish law requires goodwill and indefinite lived intangible assets to be amortized. However, the Company does not believe this gives a true and fair view, as not all goodwill and intangible assets decline in value. In addition, since goodwill that does decline in value rarely does so on a straight-line basis, straight-line amortization of goodwill and indefinite lived intangible assets over an arbitrary period does not reflect the economic reality. Therefore, goodwill and indefinite lived intangible assets are not amortized.

The Company's finite-lived intangible assets, consisting of core developed technology and collaboration agreements acquired as part of the acquisition of EDT, were recorded at fair value at the time of their acquisition and are stated within the Company's consolidated balance sheets net of accumulated amortization. The finite-lived intangible assets are amortized over their estimated useful lives using the economic use method, which reflects the pattern that the economic benefits of the intangible assets are consumed as revenue is generated from the underlying patent or contract. The useful lives of the Company's intangible assets are primarily based on the legal or contractual life of the underlying patent or contract, which does not include additional years for the potential extension or renewal of the contract or patent.

In situations where the Company has significant influence, but not control, of an entity, it applies the equity method of accounting. Under the equity method of accounting, the Company's share of the investee's underlying net income or loss is recorded within "Other expense, net" in the accompanying consolidated profit and loss account. Refer to Note 5, *Goodwill, Intangible Assets and Associated Undertakings*, for further discussion of the Company's equity method investments.

##### *Impairment of Long-Lived Assets*

The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset; a significant change in the extent or manner in which an asset is used; a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset; a current-period operating or cash flow loss combined with a history of operating or cash-flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset; or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell them.



## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

In the fourth quarter of 2020, the Company determined that an impairment triggering event occurred and evaluated certain of its long-lived assets for impairment under a held-and-used model. The Company concluded that the long-lived assets evaluated for impairment were recoverable based on an analysis of the undiscounted net cash flows to be generated from the use of these assets.

##### *Turnover from Contracts with Customers*

The Company recognizes turnover in accordance with the requirements of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, *Revenue from Contracts with Customers* (“Topic 606”). When entering into arrangements with customers, the Company identifies whether its performance obligations under the arrangement represent a distinct good or service or a series of distinct goods or services. If a contract contains more than one performance obligation, the Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The fair value of performance obligations under the arrangement may be derived using an estimate of selling price if the Company does not sell the goods or services separately.

The Company recognizes turnover when or as it satisfies a performance obligation by transferring an asset or providing a service to a customer. Management judgment is required in determining the consideration to be earned under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. Steering committee services that are not inconsequential or perfunctory and that are determined to be performance obligations are combined with other research services or performance obligations required under an arrangement, if any, in determining the level of effort required in an arrangement and the period over which the Company expects to complete its aggregate performance obligations.

##### *Product Sales, Net*

The Company’s product sales, net consist of sales of VIVITROL<sup>®</sup>, ARISTADA<sup>®</sup> and ARISTADA INITIO<sup>®</sup> in the U.S. primarily to wholesalers, specialty distributors and pharmacies. Product sales, net are recognized when the customer obtains control of the product, which is when the product has been received by the customer.

Turnover from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, health care providers or payers. The Company’s process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative turnover recognized will not occur in a future period. Actual amounts may ultimately differ from the Company’s estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. The following are the Company’s significant categories of sales discounts and allowances:

- *Medicaid Rebates*—the Company records accruals for rebates to U.S. states under the Medicaid Drug Rebate Program as a reduction of sales when the product is shipped into the distribution channel using the expected value method. The Company rebates individual U.S. states for all eligible units purchased under the Medicaid program based on a rebate per unit calculation, which is based on the Company’s average manufacturer prices. The Company estimates expected unit sales to individuals covered by Medicaid and rebates per unit under the Medicaid program and adjusts its rebate accrual based on actual unit sales and rebates per unit and changes in trends in Medicaid utilization. To date, actual Medicaid rebates have not differed materially from the Company’s estimates;
- *Chargebacks*—discounts that occur when contracted indirect customers purchase directly from wholesalers and specialty distributors. Contracted customers generally purchase a product at its contracted price. The wholesaler or specialty distributor, in turn, then generally charges back to the Company the difference between the wholesale acquisition cost and the contracted price paid to the wholesaler or specialty distributor by the customer. The allowance for chargebacks is made using the expected value method and is based on actual and expected utilization of these programs. Chargebacks could exceed historical experience and the Company’s estimates of future participation in these programs. To date, actual chargebacks have not differed materially from the Company’s estimates;

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

- *Product Discounts*—cash consideration, including sales incentives, given by the Company under agreements with a number of wholesaler, distributor, pharmacy, and treatment provider customers that provide them with a discount on the purchase price of products. The reserve is made using the expected value method and to date, actual product discounts have not differed materially from the Company’s estimates;
- *Product Returns*—the Company records an estimate for product returns at the time its customers take control of their product. The Company estimates this liability using the expected returns of product sold based on historical return levels and specifically identified anticipated returns due to known business conditions and product expiry dates. Return amounts are recorded as a reduction of sales. Once product is returned, it is destroyed; and
- *Medicare Part D*—the Company records accruals for Medicare Part D liabilities under the Medicare Coverage Gap Discount Program (“CGDP”) as a reduction of sales. Under the CGDP, patients reaching the annual coverage gap threshold are eligible for reimbursement coverage for out-of-pocket costs for covered prescription drugs. Under an agreement with the Center for Medicare and Medicaid, manufacturers are responsible to reimburse prescription plan sponsors for the portion of out-of-pocket expenses not covered under their Medicare plans.

#### Collaborative Arrangements

The Company has entered into collaboration agreements with pharmaceutical companies including, among others, Janssen Pharmaceutica Inc. (“Janssen, Inc.”), Janssen Pharmaceutica International, a division of Cilag International AG (“Janssen International”), and Janssen Pharmaceutica N.V. (together with Janssen, Inc., Janssen International and their affiliates, “Janssen”) for INVEGA SUSTENNA®/XEPLION® and INVEGA TRINZA®/TREVICTA® as well as RISPERDAL CONSTA®, Acorda Therapeutics, Inc. (“Acorda”) for AMPYRA®/FAMPYRA® and Biogen Swiss Manufacturing GmbH (together with its affiliates, “Biogen”) for VUMERITY®. Substantially all of the products developed under these arrangements are currently being marketed as approved products for which the Company receives payments for manufacturing services and/or royalties on net product sales.

#### *Manufacturing Turnover*

The Company recognizes manufacturing turnover from the sale of products it manufactures for resale by its licensees. Manufacturing turnover for the Company’s partnered products, with the exception of those from Janssen related to RISPERDAL CONSTA, are recognized over time as products move through the manufacturing process, using a standard cost-based model as a measure of progress, which represents a faithful depiction of the transfer of control of the goods. The Company recognizes manufacturing turnover from these products over time as it determined, in each instance, that it would have a right to payment for performance completed to date if its customer were to terminate the manufacturing agreement for reasons other than the Company’s non-performance and the products have no alternative use. The Company invoices its licensees upon shipment with payment terms between 30 to 90 days.

The Company is the exclusive manufacturer of RISPERDAL CONSTA for commercial sale under its manufacturing and supply agreement with Janssen. The Company determined that it is appropriate to record turnover under this agreement at the point in time when control of the product passes to Janssen, which is determined to be when the product has been fully manufactured, since Janssen does not control the product during the manufacturing process and, in the event Janssen terminates the manufacturing and supply agreement, it is uncertain whether, and at what amount, the Company would be reimbursed for performance completed to date for product not yet fully manufactured. The manufacturing process is considered fully complete once the finished goods have been approved for shipment by both the Company and Janssen.

The sales price for certain of the Company’s manufacturing turnover is based on the end-market sales price earned by its licensees. As end-market sales generally occur after the Company has recorded manufacturing turnover, the Company estimates the sales price for such products based on information supplied to it by the Company’s licensees, its historical transaction experience and other third-party data. Differences between actual manufacturing turnover and estimated manufacturing turnover are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The difference between the Company’s actual and estimated manufacturing turnover has not been material to date.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

*Royalty Turnover*

The Company recognizes royalty turnover related to the sale by its licensees of products that incorporate the Company's technologies. Substantially all of the Company's royalties qualify for the sales-and-usage exemption under Topic 606 as (i) royalties are based strictly on the sales-and-usage by the licensee; and (ii) a license of intellectual property ("IP") is the sole or predominant item to which such royalties relate. Based on this exemption, these royalties are earned in the period the products are sold by the Company's partner and the Company has a present right to payment.

Certain of the Company's royalty turnover are recognized by the Company based on information supplied to the Company by its licensees and require estimates to be made. Differences between actual royalty turnover and estimated royalty turnover are reconciled and adjusted for in the period in which they become known, which is generally within the same quarter. The difference between the Company's actual and estimated royalty turnover has not been material to date.

*Research and Development Turnover*

R&D turnover consists of funding that compensates the Company for formulation, preclinical and clinical testing under R&D arrangements with its partners. The Company generally bills its partners under R&D arrangements using a full-time equivalent or hourly rate, plus direct external costs, if any. Turnover is recognized as the obligations under the R&D arrangements are performed.

*License Turnover*

The Company recognizes turnover from the grant of distinct, right-to-use licenses of IP when control of the license is transferred to the customer, which is the point in time the customer is able to direct the use of and obtain substantially all of the benefits from the license.

*Foreign Currency*

The Company's functional and reporting currency is the U.S. dollar. Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction. The resulting monetary assets and liabilities are translated into U.S. dollars at exchange rates prevailing on the subsequent balance sheet date. Gains and losses as a result of translation adjustments are recorded within "Other income (expense), net" in the accompanying consolidated profit and loss account. During the years ended December 31, 2020 and 2019, the Company recorded a gain (loss) on foreign currency translation of \$2.4 million and \$(0.9) million, respectively.

*Concentrations*

Financial instruments that potentially subject the Company to concentrations of credit risk are receivables and marketable securities. Billings to large pharmaceutical companies and pharmaceutical wholesalers account for the majority of the Company's receivables, and collateral is generally not required from these customers. To mitigate credit risk, the Company monitors the financial performance and credit worthiness of its customers. The following represents turnover and receivables from the Company's customers exceeding 10% of the total in each category as of and for the years ended December 31, 2020 and 2019:

Customer	Year Ended December 31,			
	2020		2019	
	Receivables	Turnover	Receivables	Turnover
Janssen	30%	33%	29%	28%
Biogen	*	*	*	17%
Cardinal Health	16%	21%	12%	*
AmerisourceBergen	11%	10%	10%	*
McKesson	*	14%	*	*

\* Indicates the turnover or receivables for the customer did not exceed 10% of the Company's total in each category as of or for the years ended December 31, 2020 and 2019, as noted.

The Company holds its interest-bearing investments with major financial institutions and, in accordance with documented investment policies, the Company limits the amount of credit exposure to any one financial institution or corporate issuer. The Company's investment objectives are, first, to ensure liquidity and conservation of capital and, second, to obtain investment income.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

*Geographic Information*

Company turnover by geographic location, as determined by the location of the customer, and the location of its assets, were as follows:

(In thousands)	Year Ended December 31,	
	2020	2019
Turnover by region:		
U.S.	\$ 838,995	\$ 966,929
Ireland	3,233	3,195
Rest of world	196,528	200,823
Assets by region:		
Current assets:		
U.S.	\$ 662,615	\$ 551,799
Ireland	448,356	407,791
Rest of world	—	2,381
Long-term assets:		
U.S.:		
Other	\$ 472,999	\$ 382,029
Ireland:		
Intangible assets	\$ 111,191	\$ 150,643
Goodwill	92,873	92,873
Other	161,696	217,887

*Research and Development Expenses*

For each of its R&D programs, the Company incurs both external and internal expenses. External R&D expenses include costs related to clinical and non-clinical activities performed by contract research organizations, consulting fees, laboratory services, purchases of drug product materials and third-party manufacturing development costs. Internal R&D expenses include employee-related expenses, occupancy costs, depreciation and general overhead. The Company tracks external R&D expenses for each of its development programs, however, internal R&D expenses, with the exception of those expenses related to VUMERITY, are not tracked by individual program as they benefit multiple programs or the Company's technologies in general.

*Selling, General and Administrative Expenses*

Selling, general and administrative ("SG&A") expenses are primarily comprised of employee-related expenses associated with selling and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising, financial and legal expenses and other general and administrative costs.

Advertising costs are expensed as incurred. During the years ended December 31, 2020 and 2019, advertising costs totaled \$25.5 million and \$31.1 million, respectively.

*Share-Based Compensation*

The Company's share-based compensation programs grant awards in the form of stock options and restricted stock unit awards ("RSUs"), which vest with the passage of time and/or vest based on the achievement of certain performance criteria. The Company issues new shares upon the exercise of stock options or the vesting of RSUs. Under the terms of the Company's stock option plans (the "Plans"), certain of the Company's employees may, at the discretion of the plan administrator, become eligible upon retirement for accelerated vesting of certain awards granted to them under the Plans. Since there are no effective future service requirements for such employees, the fair value of awards to such employees would be expensed in full on the grant date or upon meeting the retirement eligibility criteria, whichever is later.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

Time-Based Stock Options

Except as otherwise provided in the applicable Plan, stock option grants to employees expire ten years from the grant date and generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed with the Company during the applicable vesting period. Except as otherwise provided in the applicable Plan, stock option grants to non-employee directors expire ten years from the grant date and generally vest over a one-year period provided that the director continues to serve on the Company's board of directors through the vesting date. The estimated fair value of options is recognized over the requisite service period, which is generally the vesting period. Share-based compensation expense is based on awards ultimately expected to vest. Forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates.

The fair value of stock option grants is based on estimates as of the date of grant using a Black-Scholes option valuation model. The Company uses historical data as the basis for estimating stock option terms and forfeitures. Separate groups of employees that have similar historical stock option exercise and forfeiture behavior are considered separately for valuation purposes. The ranges of expected terms disclosed below reflect different expected behavior among certain groups of employees. Expected stock volatility factors are based on a weighted average of implied volatilities from traded options of the Company's ordinary shares and historical share price volatility of the Company's ordinary shares, which is determined based on a review of the weighted average of historical weekly price changes of the Company's ordinary shares. The risk-free interest rate for periods commensurate with the expected term of the stock option is based on the U.S. treasury yield curve in effect at the time of grant. The dividend yield on the Company's ordinary shares is estimated to be zero as the Company has not paid dividends, and does not expect to pay dividends in the near future. The exercise price of options granted is equal to the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant.

The fair value of each stock option grant was estimated on the grant date with the following weighted-average assumptions:

	Year Ended December 31,	
	2020	2019
Expected option term	5 - 7 years	5 - 7 years
Expected stock volatility	47 % - 54 %	46 % - 50 %
Risk-free interest rate	0.24 % - 1.69 %	1.34 % - 2.59 %
Expected annual dividend yield	—	—

*Performance-Based Stock Options*

Certain of the Company's granted stock options are subject to achievement of a specified market condition prior to vesting in addition to being subject to time-based vesting. The estimated fair value of these stock options that vest upon the achievement of a market condition was determined through the use of a Monte Carlo simulation model, which utilizes input variables that determine the probability of satisfying the market condition stipulated in the award and calculates the fair market value for the award. The Monte Carlo simulation model used the following assumptions:

Grant Date	Weighted-Average Expected Volatility	Cost of Equity	Risk-Free Interest Rate
February 21, 2019	45.0%	12.0%	2.69%

Compensation expense for the stock options that vest upon the achievement of a market condition is recognized over a derived service period as determined by the Monte Carlo simulation model. The vesting of these stock options is also subject to continued employment of the grantee.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

##### Time-Based Restricted Stock Unit Awards

Except as otherwise provided in the applicable Plan, time-based RSUs awarded to employees generally vest in four equal annual installments, commencing on the first anniversary of the date of grant, provided the employee remains continuously employed with the Company during the applicable vesting period. Shares subject to these RSUs are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of time-based RSUs is equal to the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.

##### Performance-Based Restricted Stock Unit Awards

Performance-based RSUs awarded to employees vest upon the achievement of certain performance criteria, typically during or at the end of a specified performance period. The estimated fair value of these RSUs are generally based on the closing price of the Company's ordinary shares traded on the Nasdaq Global Select Market on the date of grant, unless the RSU is also subject to a market condition. In that case, the fair value of the RSU is based on a Monte Carlo simulation model. Compensation expense for performance-based RSUs is recognized from the date the Company determines the performance criteria probable of being achieved to the date the award, or relevant portion of the award, is expected to vest. Cumulative adjustments are recorded on a quarterly basis to reflect subsequent changes to the estimated outcome of the performance criteria until the date results are determined.

##### *Other Reserves*

Other reserves includes: a share-based payment reserve, which represents the share-based compensation expense for the cost of the awards granted to the Company's subsidiaries' employees less an additional capital contribution made by the Company's subsidiaries to the Company equal to the fair value of the Company's ordinary shares on the date options are exercised or RSU's vest, less the proceeds received; and unrealized gains (losses) on marketable securities.

##### *Income Taxes*

The Company recognizes income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. In evaluating the Company's ability to recover its deferred tax assets, the Company considers all available positive and negative evidence including its past operating results, the existence of cumulative income in the most recent fiscal years, changes in the business in which the Company operates and its forecast of future taxable income. In determining future taxable income, the Company is responsible for assumptions utilized including the amount of Irish and foreign pre-tax operating income, the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates that the Company is using to manage the underlying business.

The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates its tax position on a quarterly basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.

##### *Comprehensive Loss*

Comprehensive loss consists of net loss and other comprehensive loss. Other comprehensive loss includes changes in equity that are excluded from net loss, such as unrealized holding gains and losses on available-for-sale marketable securities.

##### *Loss Per Share*

Basic loss per share is calculated based upon net loss available to holders of ordinary shares divided by the weighted average number of ordinary shares outstanding. For the calculation of diluted earnings per share, the Company uses the weighted average number of ordinary shares outstanding, as adjusted for the effect of potential dilutive securities, including stock options and RSUs.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

##### *Segment Information*

The Company operates as one business segment, which is the business of developing, manufacturing and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. The Company's chief decision maker, the Chairman and Chief Executive Officer, reviews the Company's operating results on an aggregate basis and manages the Company's operations as a single operating unit.

##### *Employee Benefit Plans*

###### 401(k) Plan

The Company maintains a 401(k) retirement savings plan (the "401(k) Plan"), which covers substantially all of its U.S. based employees. Eligible employees may contribute up to 100% of their eligible compensation, subject to certain Internal Revenue Service ("IRS") limitations. The Company matches 100% of employee contributions up to the first 5% of employee pay, up to IRS limits. Employee and Company contributions are fully vested when made. During the years ended December 31, 2020 and 2019, the Company contributed \$14.7 million and \$14.8 million, respectively, to match employee deferrals under the 401(k) Plan.

###### Defined Contribution Plan

The Company maintains a defined contribution plan for its Ireland-based employees (the "Defined Contribution Plan"). The Defined Contribution Plan provides for eligible employees to contribute up to a maximum of 40%, depending upon their age, of their total taxable earnings subject to an earnings cap of €115,000. The Company provides a match of up to 18% of taxable earnings depending upon an individual's contribution level. During the years ended December 31, 2020 and 2019, the Company contributed \$4.4 million and \$4.1 million, respectively, in contributions to the Defined Contribution Plan.

##### *Risks and Uncertainties*

In March 2020, COVID-19 was declared a global pandemic by the World Health Organization. To date, COVID-19 has surfaced in nearly all regions around the world and resulted in travel restrictions and business slowdowns and/or shutdowns in affected areas. All U.S. states, and many local jurisdictions and countries around the world, including Ireland, have, at times during the pandemic, issued "shelter-in-place" orders, quarantines, executive orders and similar government orders, restrictions, and recommendations for their residents to control the spread of COVID-19. Such orders, restrictions and/or recommendations, and/or the perception that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses, including healthcare systems that serve people living with opioid dependence, alcohol dependence and schizophrenia, work stoppages, slowdowns and/or delays, work-from-home policies and travel restrictions, among other effects.

The Company continues to closely monitor and rapidly respond to the ongoing impact of COVID-19 on its employees, communities and business operations. Due to numerous uncertainties surrounding the ongoing COVID-19 pandemic, the actual impact on the Company's financial condition and operating results resulting from the pandemic may differ from current projections. These uncertainties include, among other things, the ultimate severity and duration of the pandemic; governmental, business or other actions that have been, are being or will be, taken in response to the pandemic, including restrictions on travel and mobility, business closures and operating restrictions, and imposition of social distancing measures; impacts of the pandemic on the Company's employees, the vendors or distribution channels in the Company's supply chain and on the Company's ability to continue to manufacture its products; impacts of the pandemic on the conduct of the Company's clinical trials, including with respect to enrollment rates, availability of investigators and clinical trial sites, and monitoring of data; impacts of the pandemic on healthcare systems that serve people living with opioid dependence, alcohol dependence and schizophrenia; impacts of the pandemic on the regulatory agencies with which the Company interacts in the development, review, approval and commercialization of its medicines; impacts of the pandemic on reimbursement for the Company's products, including the Company's Medicaid rebate liability, and for services related to the use of its products; and impacts of the pandemic on the U.S., Irish and global economies more broadly.

The Company relies upon third parties for many aspects of its business, including the provision of goods and services related to the manufacture of its clinical products and its and its partners' marketed products, the conduct of its clinical trials, and the sale of marketed products from which the Company receives manufacturing and royalty turnover. Any prolonged material disruption to the third parties on which the Company relies could negatively impact the Company's ability to conduct business in the manner and on the timelines presently planned, which could have a material adverse impact on the Company's business, results of operations and financial condition.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)

The marketed products from which the Company derives turnover, including manufacturing and royalty turnover, are primarily injectable medications administered by healthcare professionals. Given developments that have transpired to date, and may continue to transpire, in response to the pandemic, including the implementation of “shelter-in-place” policies, social distancing requirements and other restrictive measures, commercial sales of these marketed products have been adversely impacted to varying degrees and the Company expects commercial sales of these marketed products to continue to be adversely impacted while the pandemic persists.

During the year ended December 31, 2020, we took actions to support uninterrupted access to our proprietary marketed products. However, we currently expect commercial sales of our marketed products, particularly VIVITROL, to be impacted by the COVID-19 pandemic into 2021. The impact COVID-19 had on our proprietary marketed products during the year ended December 31, 2020 is discussed in greater detail later in the “Results of Operations” section of this Directors’ Report.

The Company continues to operate its manufacturing facilities and supply its medicines. While the Company continues to conduct R&D activities, including its ongoing clinical trials, the COVID-19 pandemic has impacted, and may continue to impact, the timelines of certain of its early-stage discovery efforts and clinical trials. The Company is working with its internal teams, its clinical investigators, R&D vendors and critical supply chain vendors to continually assess, and mitigate, any potential adverse impacts of COVID-19 on its manufacturing operations and R&D activities.

#### *New Accounting Pronouncements*

From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

#### Recently Adopted Accounting Pronouncements

The Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases (“Topic 842”), as of January 1, 2019, using the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and did not restate prior periods.

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments, to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in this ASU replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This ASU was adopted by the Company in the year ended December 31, 2020. This standard primarily impacts how firms account for credit losses and requires an impairment model, known as the current expected credit loss model (“CECL”), that is based on expected losses rather than incurred losses. Companies are required to carry an allowance for expected credit losses for most debt instruments (except those carried at fair value), trade receivables, certain lease receivables, reinsurance receivables, financial guarantee contracts and loan commitments. Available-for-sale debt securities are largely scoped out of this guidance. The Company’s investment portfolio primarily consists of available-for-sale securities carried at fair value. Further, the Company’s trade receivables do not have abnormally long terms and the Company has rarely ever written off trade receivables. The adoption of this ASU did not have an impact on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which aims to improve the effectiveness of fair value measurement disclosures. The amendments in this ASU modify the disclosure requirements on fair value measurements based on the concepts in FASB Concepts Statement, Conceptual Framework for Financial Reporting - Chapter 8: Notes to Financial Statements, including the consideration of costs and benefits. This ASU was adopted by the Company in the year ended December 31, 2020 and did not have a material impact on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU also requires the entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. This ASU was adopted by the



**ALKERMES PLC**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND STATEMENT OF COMPLIANCE (Continued)**

Company in the year ended December 31, 2020, using the prospective transition method, whereby it applied the requirements to any eligible costs incurred after adoption. The adoption of this ASU did not have an impact on the Company's consolidated financial statements.

In November 2018, the FASB issued ASU 2018-18, Clarifying the Interaction Between Topic 808 and Topic 606, which clarifies when transactions between participants in a collaborative arrangement are within the scope of the FASB's turnover standard, Topic 606. This ASU was adopted by the Company in the year ended December 31, 2020 and after review of its collaborative arrangements, the Company determined that there are no collaborative arrangements that are considered within the scope of this standard.

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles of ASC 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. Depending on the amendment, adoption may be applied on a retrospective, modified retrospective or prospective basis. This ASU was adopted by the Company in the year ended December 31, 2020 and the adoption of this ASU did not have a material impact on the Company's consolidated financial statements.

New Accounting Pronouncements not Adopted

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform, which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. This amendment applies to all entities, subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This ASU became effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. The Company is currently assessing the impact that this ASU may have on its consolidated financial statements.

**3. TURNOVER FROM CONTRACTS WITH CUSTOMERS**

During the years ended December 31, 2020 and 2019, the Company recorded product sales, net, as follows:

(In thousands)	Year Ended December 31,	
	2020	2019
VIVITROL	\$ 310,722	\$ 335,365
ARISTADA and ARISTADA INITIO	241,038	189,134
Total product sales, net	<u>\$ 551,760</u>	<u>\$ 524,499</u>

During the years ended December 31, 2020 and 2019, the Company recorded manufacturing and royalty turnover from its collaborative arrangements as follows:

(In thousands)	Year Ended December 31, 2020		
	Manufacturing Turnover	Royalty Turnover	Total
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA	\$ —	\$ 274,200	\$ 274,200
RISPERDAL CONSTA	56,893	14,468	71,361
AMPYRA/FAMPYRA	26,909	20,984	47,893
Other	35,232	55,314	90,546
	<u>\$ 119,034</u>	<u>\$ 364,966</u>	<u>\$ 484,000</u>

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

3. TURNOVER FROM CONTRACTS WITH CUSTOMERS (Continued)

(In thousands)	Year Ended December 31, 2019		
	Manufacturing Turnover	Royalty Turnover	Total
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA	\$ —	\$ 256,947	\$ 256,947
RISPERDAL CONSTA	50,433	15,950	66,383
AMPYRA/FAMPYRA	22,071	15,170	37,241
Other	31,750	55,561	87,311
	<u>\$ 104,254</u>	<u>\$ 343,628</u>	<u>\$ 447,882</u>

The research and development turnover and license turnover recorded during the years ended December 31, 2020 and 2019 primarily related to turnover earned under the Company’s license and collaboration agreement with Biogen for VUMERITY. In addition to the research and development revenue and license revenue, during the year ended December 31, 2020 and 2019 the Company recognized \$22.5 million and \$1.0 million, respectively, of manufacturing and royalty revenue related to VUMERITY.

Under a license and collaboration agreement with Biogen, which the Company entered into in November 2017 and amended in October 2018, January 2019 and October 2019, the Company granted Biogen a worldwide, exclusive, sublicensable license to develop, manufacture and commercialize VUMERITY and other products covered by patents licensed to Biogen under the agreement.

Upon entering into the license and collaboration agreement, the Company received an up-front cash payment of \$28.0 million and was also eligible to receive additional payments upon achievement of developmental milestones with respect to VUMERITY. In June 2018, the Company received an additional cash payment of \$50.0 million following Biogen’s review of preliminary gastrointestinal tolerability data from the clinical development program for VUMERITY. In November 2019, the Company received an additional payment of \$150.0 million following the U.S. Food and Drug Administration’s (“FDA”) approval of the New Drug Application (“NDA”) for VUMERITY and transfer of such NDA to Biogen. The Company is also eligible to receive additional payments upon achievement of developmental milestones with respect to the first two products other than VUMERITY covered by patents licensed to Biogen under the license and collaboration agreement. Biogen paid a portion of the VUMERITY development costs the Company incurred in 2017 and, in January 2018, Biogen became responsible for all VUMERITY development costs that the Company incurred, subject to annual budget limitations. Following FDA approval of the NDA for VUMERITY in October 2019, the NDA and any further development responsibilities with respect to VUMERITY were transferred to Biogen.

The Company evaluated the license and collaboration agreement under Topic 606 and determined that it had four deliverables: (i) the grant of a distinct, right-to-use license of IP to Biogen; (ii) future development services; (iii) clinical supply; and (iv) participation on a joint steering committee with Biogen. The Company’s participation on the joint steering committee was considered to be perfunctory and thus not recognized as a performance obligation. The deliverables, aside from the participation in the joint steering committee which was considered to be perfunctory, were determined to be separate performance obligations as the license is separately identifiable from the development services and clinical supply, and the development services are not expected to significantly modify or customize the IP.

The Company allocated the arrangement consideration to each performance obligation using the standalone selling prices based on its estimate of selling price for the license and other deliverables. The Company used a discounted cash flow model to estimate the standalone selling price of the license in order to allocate the consideration to the performance obligations. To estimate the standalone selling price of the license, the Company assessed the likelihood of the FDA’s approval of VUMERITY and estimated the expected future cash flows assuming FDA approval and maintenance of the IP protecting VUMERITY. The Company then discounted these cash flows using a discount rate of 8.0%, which it believes captures a market participant’s view of the risk associated with the expected cash flows. The estimate of selling price of the development services and clinical supply were determined through third-party evidence. The Company believes that a change in the assumptions used to determine its estimate of selling price for the license most likely would not have a significant effect on the allocation of consideration transferred.

Under Topic 606, the Company allocated the \$28.0 million up-front payment and the \$50.0 million June 2018 payments as follows: \$27.0 million and \$48.3 million to the delivery of the license; \$0.9 million and \$1.5 million to future development services; and \$0.1 million and \$0.2 million to clinical supply, respectively.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 3. TURNOVER FROM CONTRACTS WITH CUSTOMERS (Continued)

The Company allocated the \$150.0 million milestone payment received in November 2019 to the relevant performance obligations as follows: \$144.8 million to the delivery of the license; and \$5.2 million to future development services and clinical supply. The amounts allocated to the license were recognized upon receipt of the payments as delivery of the license occurred upon entry into the agreement in 2017. The amounts allocated to the development services and clinical supply were recognized over the course of the development work and as clinical supply was delivered to Biogen in 2020.

In addition, the Company receives a 15% royalty on worldwide net sales of VUMERITY, subject to, under certain circumstances, minimum annual payments for the first five years following FDA approval of VUMERITY. The Company is also entitled to receive royalties on net sales of products other than VUMERITY covered by patents licensed to Biogen under the license and collaboration agreement, at tiered royalty rates calculated as percentages of net sales ranging from high-single digits to sub-teen double digits. All royalties are payable on a product-by-product and country-by-country basis until the later of (i) the last-to-expire patent right covering the applicable product in the applicable country and (ii) a specified period of time from the first commercial sale of the applicable product in the applicable country. Royalties for all products and the minimum annual payments for VUMERITY are subject to customary reductions, as set forth in the license and collaboration agreement.

The Company determined that the future development milestones and sales-based royalties that it may be entitled to receive are variable consideration. The Company is using the most likely amount method for estimating the variable consideration to be received related to the milestones under this arrangement. The royalties are subject to the sales-based exception and are recorded when the corresponding sale occurs.

Under the license and collaboration agreement, Biogen appointed the Company as the toll manufacturer of clinical and commercial supplies of VUMERITY, subject to Biogen's right to manufacture or have manufactured commercial supplies as a back-up manufacturer and subject to good faith agreement by the parties on the terms of such manufacturing arrangements. In October 2019, the Company entered into a commercial supply agreement with Biogen for the commercial supply of VUMERITY, an amendment to such commercial supply agreement and an amendment to the November 2017 license and collaboration agreement with Biogen. Under these agreements, Biogen has an option to assume responsibility, subject to a transition period, for the manufacture (itself or through a designee) of clinical supplies of VUMERITY and up to 100% of commercial supplies of VUMERITY in exchange for an increase in the royalty rate to be paid by Biogen to the Company on net sales of that portion of product that is manufactured by Biogen or its designee. The Company evaluated the commercial supply agreement and the related amendments under Topic 606 and determined that these agreements should be combined and accounted for as a separate contract since the commercial supply agreement and amendment to the November 2017 license and collaboration agreement were negotiated together to achieve a common economic objective and the additional performance obligations under the commercial supply agreement are considered distinct obligations priced at their standalone selling prices. The Company determined that it had two separate performance obligations, the commercial supply of VUMERITY and, upon an election by Biogen to commence a transfer of technology relating to the manufacture of VUMERITY (the "Tech Transfer"), services to be performed by the Company in connection with such Tech Transfer. There are other deliverables under the agreements that were determined to be perfunctory or immaterial.

In connection with the entry into the commercial supply agreement and the related amendments, the Company received payments in the aggregate amount of \$5.8 million in the fourth quarter of 2019 and the Company will be eligible to receive an additional \$5.0 million payment upon the earlier of successful completion of the Tech Transfer or a date in the fourth quarter of 2022. The \$5.8 million received in the fourth quarter of 2019 plus amounts received in connection with the Tech Transfer will be allocated to each of the performance obligations using the standalone selling prices based on the Company's estimate of selling price for the commercial supply of VUMERITY and the services related to the Tech Transfer, and this additional arrangement consideration will be recognized as the Company delivers commercial supply of VUMERITY and/or provides services relating to the Tech Transfer. The Company began performing under this commercial supply agreement in 2020.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 4. COLLABORATIVE ARRANGEMENTS

The Company has entered into several collaborative arrangements to develop and commercialize products and, in connection with such arrangements, to access technologies, financial, marketing, manufacturing and other resources. Refer to the “Patents and Proprietary Rights” section of this Directors’ Report for information with respect to IP protection for these products. The collaboration revenue the Company has earned in the years ended December 31, 2020 and 2019 is summarized in Note 3, *Turnover from Contracts with Customers* within these “Notes to Consolidated Financial Statements” in this Directors’ Report.

The Company’s significant collaborative arrangements are described below:

##### *Janssen*

##### INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA

Under a license agreement with Janssen Pharmaceutica N.V., the Company granted Janssen a worldwide exclusive license under its NanoCrystal technology to develop, commercialize and manufacture INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA and related products.

Under this license agreement, the Company received milestone payments upon the achievement of certain development goals from Janssen; there are no further milestones to be earned under this agreement. The Company receives tiered royalty payments between 5% and 9% of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA end-market net sales in each country where the license is in effect, with the exact royalty percentage determined based on aggregate worldwide net sales. The tiered royalty payments consist of a patent royalty and a know how royalty, both of which are determined on a country-by-country basis. The patent royalty, which equals 1.5% of net sales, is payable in each country until the expiration of the last of the patents claiming the product in such country. The know-how royalty is a tiered royalty of 3.5%, 5.5% and 7.5% on aggregate worldwide net sales of below \$250 million, between \$250 million and \$500 million, and greater than \$500 million, respectively. The know how royalty rate resets to 3.5% at the beginning of each calendar year and is payable until 15 years from first commercial sale of a product, subject to the expiry of the license agreement. These royalty payments may be reduced in any country based on patent litigation or on competing products achieving certain minimum sales thresholds. The license agreement expires upon the expiration of the last of the patents subject to the agreement. After expiration, Janssen retains a non-exclusive, royalty free license to develop, manufacture and commercialize the products.

Janssen may terminate the license agreement in whole or in part upon three months’ notice to the Company. The Company and Janssen have the right to terminate the agreement upon a material breach of the other party, which is not cured within a certain time period, or upon the other party’s bankruptcy or insolvency.

##### RISPERDAL CONSTA

Under a product development agreement, the Company collaborated with Janssen on the development of RISPERDAL CONSTA. Under the development agreement, Janssen provided funding to the Company for the development of RISPERDAL CONSTA and Janssen is responsible for securing all necessary regulatory approvals for the product.

Under two license agreements, the Company granted Janssen and an affiliate of Janssen exclusive worldwide licenses to use and sell RISPERDAL CONSTA. Under its license agreements with Janssen, the Company receives royalty payments equal to 2.5% of Janssen’s end-market net sales of RISPERDAL CONSTA in each country where the license is in effect based on the quarter when the product is sold by Janssen. This royalty may be reduced in any country based on lack of patent coverage and significant competition from generic versions of the product. Janssen can terminate the license agreements upon 30 days’ prior written notice to the Company. Either party may terminate the license agreements by written notice following a breach which continues for 90 days after the delivery of written notice thereof or upon the other party’s insolvency. The licenses granted to Janssen expire on a country-by-country basis upon the later of: (i) the expiration of the last patent claiming the product in such country; or (ii) 15 years after the date of the first commercial sale of the product in such country, provided that in no event will the license granted to Janssen expire later than the twentieth anniversary of the first commercial sale of the product in each such country, with the exception of Canada, France, Germany, Italy, Japan, Spain and the United Kingdom, in each case where the fifteen-year minimum shall pertain regardless. After expiration, Janssen retains a non-exclusive, royalty-free license to manufacture, use and sell RISPERDAL CONSTA.

The Company exclusively manufactures RISPERDAL CONSTA for commercial sale. Under its manufacturing and supply agreement with Janssen, the Company records manufacturing turnover when the product is fully manufactured and approved for shipment, by both Janssen and the Company. Turnover is based on a percentage of Janssen’s net unit sales price for RISPERDAL CONSTA for the applicable calendar year. This percentage is determined based on Janssen’s unit demand for such calendar year and varies based on the volume of units shipped, with a minimum manufacturing fee of 7.5%.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 4. COLLABORATIVE ARRANGEMENTS (Continued)

Either party may terminate the manufacturing and supply agreement upon a material breach by the other party, which is not resolved within 60 days after receipt of a written notice specifying the material breach or upon written notice in the event of the other party's insolvency or bankruptcy. Janssen may terminate the agreement upon six months' written notice to the Company. In the event that Janssen terminates the manufacturing and supply agreement without terminating the license agreements, the royalty rate payable to the Company on Janssen's net sales of RISPERDAL CONSTA would increase from 2.5% to 5.0%.

##### *Acorda*

Under an amended and restated license agreement, the Company granted Acorda an exclusive worldwide license to use and sell and, solely in accordance with its supply agreement, to make or have made AMPYRA/FAMPYRA. The Company receives certain commercial and development milestone payments, license revenues and a royalty of approximately 10% based on net selling price of AMPYRA and FAMPYRA by Acorda and its sub-licensee, Biogen, respectively. This royalty payment may be reduced in any country based on lack of patent coverage, competing products achieving certain minimum sales thresholds and whether Alkermes manufactures the product.

In June 2009, the Company entered into an amendment of the amended and restated license agreement and the supply agreement with Acorda and, pursuant to such amendment, consented to the sublicense by Acorda to Biogen of Acorda's rights to use and sell FAMPYRA in certain territories outside of the U.S. (to the extent that such rights were to be sublicensed to Biogen pursuant to its separate collaboration and license agreement with Acorda). Under this amendment, the Company agreed to modify certain terms and conditions of the amended and restated license agreement and the supply agreement with Acorda to reflect the sublicense by Acorda to Biogen.

Acorda has the right to terminate the amended and restated license agreement upon 90 days' written notice. The Company has the right to terminate the amended and restated license agreement for countries in which Acorda fails to launch a product within a specified time after obtaining the necessary regulatory approval or fails to file regulatory approvals within a commercially reasonable time after completion of and receipt of positive data from all pre-clinical and clinical studies required for filing a marketing authorization application. Either party has the right to terminate the amended and restated license agreement by written notice following a material breach of the other party, which is not cured within a certain time period, or upon the other party's entry into bankruptcy or dissolution proceedings. If the Company terminates Acorda's license in any country, the Company is entitled to a license from Acorda of its patent rights and know-how relating to the product as well as the related data, information and regulatory files, and to market the product in the applicable country, subject to an initial payment equal to Acorda's cost of developing such data, information and regulatory files and to ongoing royalty payments to Acorda. Subject to the termination of the amended and restated license agreement, licenses granted under the license agreement terminate on a country-by-country basis upon the expiration of the last to expire of our patents or the existence of a threshold level of competition in the marketplace.

Under its commercial manufacturing supply agreement with Acorda, the Company manufactures and supplies AMPYRA/FAMPYRA for Acorda (and its sub-licensee, Biogen). Under the terms of the agreement, Acorda may obtain up to 25% of its total annual requirements of product from a second-source manufacturer. The Company receives manufacturing royalties equal to 8% of net selling price (or higher under certain circumstances) for all product manufactured by it and a compensating payment for product manufactured and supplied by a third party. The Company may terminate the commercial manufacturing supply agreement upon 12 months' prior written notice to Acorda and either party may terminate the commercial manufacturing supply agreement following a material and uncured breach of the commercial manufacturing supply agreement or amended and restated license agreement or the entry into bankruptcy or dissolution proceedings by the other party. In addition, subject to early termination of the commercial manufacturing supply agreement noted above, the commercial manufacturing supply agreement terminates upon the expiry or termination of the amended and restated license agreement.

The Company is entitled to receive the following milestone payments under its amended and restated license agreement with Acorda for each of the third and fourth new indications of the product developed thereunder: (i) initiation of a phase 3 clinical trial: \$1.0 million; (ii) acceptance of an NDA by the FDA: \$1.0 million; (iii) approval of the NDA by the FDA: \$1.5 million; and (iv) the first commercial sale: \$1.5 million.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 4. COLLABORATIVE ARRANGEMENTS (Continued)

##### *Biogen*

Under a license and collaboration agreement with Biogen, which the Company entered into in November 2017 and amended in October 2018, January 2019 and October 2019, the Company granted Biogen a worldwide, exclusive, sublicensable license to develop, manufacture and commercialize VUMERITY and other products covered by patents licensed to Biogen under the agreement.

Under this license and collaboration agreement, the Company received an upfront cash payment of \$28.0 million in November 2017, and milestone payments of \$50.0 million, \$150.0 million and \$5.0 million in June 2018, November 2019 and December 2019, respectively, upon the achievement of certain developmental milestones, including FDA approval of the NDA for VUMERITY in October 2019, and amendment of the license and collaboration agreement in October 2019. The Company is also eligible to receive additional payments upon achievement of milestones with respect to the first two products, other than VUMERITY, covered by patents licensed to Biogen under the license and collaboration agreement.

In addition, the Company receives a 15% royalty on worldwide net sales of VUMERITY, subject to, under certain circumstances, minimum annual payments for the first five years following FDA approval of VUMERITY. The Company is also entitled to receive royalties on net sales of products other than VUMERITY covered by patents licensed to Biogen under the license and collaboration agreement, at tiered royalty rates calculated as percentages of net sales ranging from high-single digits to sub-teen double digits. All royalties are payable on a product-by-product and country-by-country basis until the later of (i) the last-to-expire patent right covering the applicable product in the applicable country and (ii) a specified period of time from the first commercial sale of the applicable product in the applicable country. Royalties for all products and the minimum annual payments for VUMERITY are subject to customary reductions, as set forth in the license and collaboration agreement.

Except in limited circumstances, we were responsible for the development of VUMERITY until it was approved by the FDA. Following FDA approval of VUMERITY in October 2019 and except for the manufacturing responsibilities discussed below, Biogen is now responsible for all development and commercialization activities for VUMERITY and all other products covered by patents licensed to Biogen.

Under the license and collaboration agreement, Biogen appointed the Company as the toll manufacturer of clinical and commercial supplies of VUMERITY, subject to Biogen's right to manufacture or have manufactured commercial supplies as a back-up manufacturer and subject to good faith agreement by the parties on the terms of such manufacturing arrangements. In October 2019, the Company entered into a commercial supply agreement with Biogen for the commercial supply of VUMERITY, an amendment to such commercial supply agreement and an amendment to the November 2017 license and collaboration agreement with Biogen. Biogen has elected to initiate a technology transfer and, following a transition period, assume responsibility for the manufacture (itself or through a designee) of clinical supplies of VUMERITY and up to 100% of commercial supplies of VUMERITY in exchange for an increase in the royalty rate to be paid by Biogen to the Company on net sales of that portion of product that is manufactured by Biogen or its designee.

If VUMERITY discontinuations due to gastrointestinal adverse events in VUMERITY's long-term safety clinical trial exceed a certain pre-defined threshold, then "GI Inferiority" shall be deemed to exist, and (i) Biogen shall have the right to recapture from the Company its \$50.0 million option payment through certain temporary reductions in royalty rates, and (ii) the minimum annual payments Biogen owes to the Company shall terminate.

Unless earlier terminated, the license and collaboration agreement will remain in effect until the expiry of all royalty obligations. Biogen has the right to terminate the license and collaboration agreement at will, on a product-by-product basis or in its entirety upon 180 days' prior notice to the Company. Either party has the right to terminate the license and collaboration agreement following any governmental prohibition of the transactions effected by the agreement, or in connection with an insolvency event involving the other party. Upon termination of the license and collaboration agreement by either party, then, at the Company's request, the VUMERITY program will revert to the Company.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

5. GOODWILL, INTANGIBLE ASSETS AND ASSOCIATED UNDERTAKINGS

Goodwill and intangible assets consist of the following:

(In thousands)	Goodwill	Intangible Assets—Intellectual Property			Total
		Collaboration Agreements	NanoCrystal Technology	OCR Technology	
<b>Cost:</b>					
At January 1, 2020	\$ 92,873	\$ 465,590	\$ 74,600	\$ 42,560	\$ 582,750
At December 31, 2020	\$ 92,873	\$ 465,590	\$ 74,600	\$ 42,560	\$ 582,750
<b>Accumulated Depreciation:</b>					
At January 1, 2019	\$ —	\$ (319,311)	\$ (38,942)	\$ (33,496)	\$ (391,749)
Expensed during the year	—	(29,284)	(7,831)	(3,243)	(40,358)
At December 31, 2019	—	(348,595)	(46,773)	(36,739)	(432,107)
Expensed during the year	—	(29,132)	(7,618)	(2,702)	(39,452)
At December 31, 2020	\$ —	\$ (377,727)	\$ (54,391)	\$ (39,441)	\$ (471,559)
<b>Net Book Amount:</b>					
At December 31, 2020	\$ 92,873	\$ 87,863	\$ 20,209	\$ 3,119	\$ 111,191
At December 31, 2019	\$ 92,873	\$ 116,995	\$ 27,827	\$ 5,821	\$ 150,643

The Company's finite-lived intangible assets consist of collaborative agreements and the NanoCrystal and OCR technologies acquired as part of the EDT acquisition. The Company recorded \$39.5 million and \$40.4 million of amortization expense related to its finite-lived intangible assets during the years ended December 31, 2020 and 2019, respectively. Based on the Company's most recent analysis, amortization of intangible assets included within its consolidated balance sheets at December 31, 2020 is expected to be approximately \$40.0 million, \$35.0 million, \$35.0 million, \$1.0 million and none in the years ending December 31, 2021 through 2025, respectively. Although the Company believes such available information and assumptions are reasonable, given the inherent risks and uncertainties underlying its expectations regarding such future turnover, there is the potential for the Company's actual results to vary significantly from such expectations. If turnover are projected to change, the related amortization of the intangible assets will change in proportion to the change in turnover.

The Company performed its annual goodwill impairment test as of October 31, 2020. The Company elected to perform a quantitative impairment test and determined that the fair value of the reporting unit exceeded its carrying value.

Associated Undertakings

In May 2014, the Company entered into an agreement whereby it is committed to provide up to €7.4 million to a partnership, Fountain Healthcare Partners II, L.P. of Ireland ("Fountain"), which was created to carry on the business of investing exclusively in companies and businesses engaged in the healthcare, pharmaceutical and life sciences sectors. As of December 31, 2020, the Company's total contribution in Fountain was equal to €7.0 million, and its commitment represented approximately 7% of the partnership's total funding. The Company is accounting for its investment in Fountain under the equity method.

During the year ended December 31, 2020, two of the companies within the Fountain portfolio were acquired by third parties. The Company's proportional share of the proceeds from these transactions was \$11.1 million, of which \$10.4 million was received in September 2020 and \$0.7 million is being held in escrow. The Company expects to collect the funds in escrow in 2021. The transactions were accounted for under the cumulative earnings approach whereby the return on investment of \$8.3 million was recorded as a gain within "Other income (expense), net" in the accompanying consolidated statements of operations and comprehensive loss and the return of investment of \$2.8 million was recorded as a reduction in the Company's net investment in Fountain. The Company's net investment in Fountain was \$6.2 million and \$5.9 million at December 31, 2020 and 2019, respectively, and was included within "Other assets" in the accompanying consolidated balance sheets.

During the years ended December 31, 2020 and 2019, the Company recorded an increase in its investment in Fountain of \$0.3 million and a reduction of \$0.4 million, respectively, which represented the Company's proportional share of Fountain's net gains (losses) for such periods.

**ALKERMES PLC**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**6. RESTRUCTURING**

On October 18, 2019, the Company approved a restructuring plan following a review of its operations, cost structure and growth opportunities (the “Restructuring”). The Restructuring included a reduction in headcount of approximately 160 employees across the Company. The Company recorded a charge of \$13.4 million in the fourth quarter of 2019 as a result of the Restructuring, which consisted of one-time termination benefits for employee severance, benefits and related costs, all of which are resulted in cash expenditures and substantially all of which were paid out by December 31, 2020. Restructuring activity during the year ended December 31, 2020 was as follows:

<b>(In thousands)</b>	
Balance, January 1, 2020	\$ 9,201
Amounts paid during the period:	
Severance	(7,354)
Outplacement services	(108)
Benefits	(1,277)
Balance, December 31, 2020	<u>\$ 462</u>

At December 31, 2020 and 2019, \$0.5 million and \$9.0 million of the restructuring accrual were included within “Creditors” in the accompanying consolidated balance sheets, respectively, and none and \$0.2 million of the restructuring accrual were included within “Other long-term liabilities” in the accompanying consolidated balance sheets, respectively.

**7. LONG-TERM DEBT**

Long-term debt consists of the following:

<b>(In thousands)</b>		<b>December 31,</b>	<b>December 31,</b>
		<b>2020</b>	<b>2019</b>
2023 Term Loans, due March 26, 2023	\$	274,961	\$ 277,138
Less: current portion		(2,843)	(2,843)
Long-term debt	\$	<u>272,118</u>	<u>\$ 274,295</u>

**2023 Term Loans**

In March 2018, the Company amended and refinanced its existing term loan, previously referred to as Term Loan B-1 (as so amended and refinanced, the “2023 Term Loans”), in order to, among other things, extend the due date of the loan from September 25, 2021 to March 26, 2023, reduce the interest payable from LIBOR plus 2.75% with a LIBOR floor of 0.75% to LIBOR plus 2.25% with a 0% LIBOR floor and increase covenant flexibility (the “Refinancing”).

The Refinancing involved multiple lenders who were considered members of a loan syndicate. In determining whether the Refinancing was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether creditors remained the same or changed and whether the changes in debt terms were substantial. A change in the debt terms was considered to be substantial if the present value of the remaining cash flows under the new terms of the 2023 Term Loans was at least 10% different from the present value of the remaining cash flows under the former Term Loan B-1 (commonly referred to as the “10% Test”). The Company performed a separate 10% Test for each individual creditor participating in the loan syndication. With the exception of one lender, who owned 1% of the total outstanding principal amount of Term Loan B-1 at the date of the Refinancing and was accounted for as a debt extinguishment, the Refinancing was accounted for as a debt modification.

Scheduled maturities with respect to the 2023 Term Loans are as follows (in thousands):

<b>Year Ending December 31:</b>	
2021	\$ 2,843
2022	2,843
2023	270,747
2024	—
2025	—
Total	<u>\$ 276,433</u>



ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

7. LONG-TERM DEBT (Continued)

The Company is subject to mandatory prepayments of principal if certain excess cash flow thresholds, as defined in the 2023 Term Loans, are met. To date, the Company has not been required to make any such mandatory prepayments.

The 2023 Term Loans have an incremental facility capacity in an amount of \$175.0 million, plus additional amounts as long as the Company meets certain conditions, including a specified leverage ratio. The 2023 Term Loans include a number of restrictive covenants that, among other things and subject to certain exceptions and baskets, impose operating and financial restrictions on the Company and certain of its subsidiaries. The 2023 Term Loans also contain customary affirmative covenants and events of default. The Company was in compliance with its debt covenants at December 31, 2020.

At December 31, 2020, the Company's balance of unamortized deferred financing costs and unamortized original issue discount costs were \$0.4 million and \$1.0 million, respectively. These costs are being amortized to interest expense over the estimated repayment period of the 2023 Term Loans using the effective interest method. During each the years ended December 31, 2020 and 2019, the Company had amortization expense of \$0.7 million related to deferred financing costs and original issue discount.

8. FAIR VALUE

The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy and the valuation techniques the Company utilized to determine such fair value:

(In thousands)	December 31, 2020	Level 1	Level 2	Level 3
<b>Assets:</b>				
Cash equivalents	\$ 41,849	\$ 41,849	\$ —	\$ —
U.S. government and agency debt securities	103,345	73,451	29,894	—
Corporate debt securities	184,956	—	183,979	977
International government agency debt securities	94,871	—	94,871	—
Contingent consideration	32,451	—	—	32,451
Total	<u>\$ 457,472</u>	<u>\$ 115,300</u>	<u>\$ 308,744</u>	<u>\$ 33,428</u>

(In thousands)	December 31, 2019	Level 1	Level 2	Level 3
<b>Assets:</b>				
Cash equivalents	\$ 8,064	\$ 8,064	\$ —	\$ —
U.S. government and agency debt securities	117,376	73,795	43,581	—
Corporate debt securities	195,855	—	193,902	1,953
International government agency debt securities	93,779	—	93,779	—
Contingent consideration	32,400	—	—	32,400
Total	<u>\$ 447,474</u>	<u>\$ 81,859</u>	<u>\$ 331,262</u>	<u>\$ 34,353</u>

The Company transfers its financial assets and liabilities, measured at fair value on a recurring basis, between the fair value hierarchies at the end of each reporting period.

There were no transfers of any securities between levels during the year ended December 31, 2020. The following table is a rollforward of the fair value of the Company's investments whose fair value was determined using Level 3 inputs at December 31, 2020:

(In thousands)	Fair Value
Balance, January 1, 2020	\$ 34,353
Change in the fair value of contingent consideration	3,945
Milestone and royalty payments received by the Company related to contingent consideration	(3,886)
Royalty payments due to the Company related to contingent consideration	(7)
Impairment of corporate debt security	(977)
Balance, December 31, 2020	<u>\$ 33,428</u>

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 8. FAIR VALUE (Continued)

The Company's investments in U.S. government and agency debt securities, international government agency debt securities and corporate debt securities classified as Level 2 within the fair value hierarchy were initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing market-observable data. The market-observable data included reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validated the prices developed using the market-observable data by obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active.

In April 2015, the Company sold its Gainesville, GA manufacturing facility, the related manufacturing and royalty revenue associated with certain products manufactured at the facility, and the rights to IV/IM and parenteral forms of Meloxicam to Recro Pharma, Inc. ("Recro") and Recro Gainesville LLC (such transaction the "Gainesville Transaction"). The Gainesville Transaction included in the purchase price contingent consideration tied to low double digit royalties on net sales of the IV/IM and parenteral forms of Meloxicam and any other product with the same active ingredient as Meloxicam IV/IM that is discovered or identified using certain of the Company's IP to which Recro was provided a right of use, through license or transfer, pursuant to the Gainesville Transaction (such products, the "Meloxicam Products"), and milestone payments upon the achievement of certain regulatory and sales milestones related to the Meloxicam Products.

In November 2019, Recro spun out its acute care segment to Baudax Bio, Inc. ("Baudax"), a publicly-traded pharmaceutical company. As part of this transaction, Recro's obligations to pay certain contingent consideration from the Gainesville Transaction were assigned and/or transferred to Baudax.

In Baudax's Quarterly Report on Form 10-Q for the period ended September 30, 2020, Baudax included disclosures around its ability to continue as a going concern. At December 31, 2020, the Company determined the fair value of the contingent consideration to be received as follows:

- The Company received \$3.8 million and \$10.0 million in milestone payments during 2020 and 2019, respectively, and is due to receive an additional \$1.5 million in June 2021 related to the FDA approval in February 2020 of the NDA for ANJESO, the first Meloxicam Product, and \$45.0 million in seven equal, annual installments beginning in February 2021, which is the first anniversary of such approval;
- The Company is entitled to receive future royalties on net sales of Meloxicam Products; and
- The Company is entitled to receive payments of up to \$80.0 million upon achieving certain sales milestones on future sales of the Meloxicam Products. The fair value of the sales milestones was determined through the use of a real options approach, where net sales are simulated in a risk-neutral world. To employ this methodology, the Company used a risk-adjusted expected growth rate based on its assessments of expected growth in net sales of the approved Meloxicam Product, adjusted by an appropriate factor capturing their respective correlation with the market.

In order to address the substantial doubt about Baudax's ability to continue as a going concern, the Company split its fair value analysis into two scenarios and applied an equal weighting to each. In the first scenario, the amounts above were all discounted using a rate of 13%, which the Company believes captures a market participant's view of the risk associated with the expected payments assuming Baudax is able to continue as a going concern. In the second scenario, the Company used the undiscounted values derived from the amounts summarized above and applied a recovery rate of 18%, based on an analysis performed by Moody's Investor Service regarding recoveries in a pandemic-driven default cycle.

At December 31, 2020 and 2019, the Company determined that the fair value of the contingent consideration was \$32.5 million and \$32.4 million, respectively. At December 31, 2020 and 2019, \$7.8 million and none, respectively, of the fair value of the contingent consideration was included within "Prepaid expenses and other current assets" in the accompanying consolidated balance sheets, and \$24.7 million and \$32.4 million, respectively, of the fair value of the contingent consideration was included within "Contingent consideration" in the accompanying consolidated balance sheets. The Company recorded an increase of \$3.9 million and a decrease of \$22.8 million during the years ended December 31, 2020 and 2019, respectively, within "Change in the fair value of contingent consideration" in the accompanying consolidated statements of operations and comprehensive loss.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

8. FAIR VALUE (Continued)

The carrying amounts reflected in the accompanying consolidated balance sheets for cash and cash equivalents, accounts receivable, contract assets, other current assets, creditors, approximate fair value due to their short-term nature. The estimated fair value of the Company's long-term debt under the 2023 Term Loans, which was based on quoted market price indications (Level 2 in the fair value hierarchy) and which may not be representative of actual values that could have been, or will be, realized in the future, was \$275.1 million and \$277.9 million at December 31, 2020 and 2019, respectively. Please refer to Note 7, *Long-Term Debt* within these "Notes to Consolidated Financial Statements" in this Directors' Report.

9. INCOME TAXES

The Company's (provision) benefit for income taxes is comprised of the following:

(In thousands)	Year Ended December 31,	
	2020	2019
Current income tax (provision) benefit:		
U.S. federal	\$ (2,943)	\$ 471
U.S. state	(1,396)	(354)
Rest of world	—	—
Deferred income tax (provision) benefit:		
U.S. federal	(9,876)	1,503
U.S. state	(109)	(881)
Ireland	—	(303)
Total tax (provision) benefit	<u>\$ (14,324)</u>	<u>\$ 436</u>

The income tax provision in 2020 and the income tax benefit in 2019 were primarily due to U.S. federal and state taxes. The unfavorable change in income taxes in 2020, as compared to 2019, was primarily due to a significant benefit recorded in 2019 relating to the foreign derived intangible income ("FDII") proposed regulations issued by the U.S. Department of the Treasury and the U.S. Internal Revenue Service in March 2019.

On March 27, 2020 the Coronavirus Aid, Relief and Economic Security ("CARES") Act was passed by the U.S. Congress and signed into law by the President of the United States. The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits have limited impact on the Company's income tax provision.

No provision for income tax has been provided on undistributed earnings of the Company's foreign subsidiaries because such earnings are indefinitely reinvested in the foreign operations. Cumulative unremitted earnings of overseas subsidiaries totaled approximately \$369.0 million at December 31, 2020. In the event of a repatriation of those earnings in the form of dividends or otherwise, the Company may be liable for income taxes, subject to adjustment, if any, for foreign tax credits and foreign withholding taxes payable to foreign tax authorities. The Company estimates that approximately \$38.0 million of income taxes would be payable on the repatriation of the unremitted earnings to Ireland.

The distribution of the Company's loss before the (provision) benefit for income taxes by geographical area consisted of the following:

(In thousands)	Year Ended December 31,	
	2020	2019
Ireland	\$ (138,070)	\$ (141,869)
U.S.	41,599	(55,102)
Rest of world	(66)	(85)
Loss before (provision) benefit for income taxes	<u>\$ (96,537)</u>	<u>\$ (197,056)</u>

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

9. INCOME TAXES (Continued)

The components of the Company's net deferred tax assets (liabilities) were as follows:

(In thousands)	December 31, 2020	December 31, 2019
Deferred tax assets:		
NOL carryforwards	\$ 233,755	\$ 227,872
Tax credits	59,098	57,385
Accrued expenses and reserves	49,730	20,337
Share-based compensation	44,480	45,214
Other	6,651	8,756
Less: valuation allowance	(253,649)	(242,059)
Total deferred tax assets	140,065	117,505
Deferred tax liabilities:		
Property, plant and equipment	(52,707)	(19,926)
Other	(1,697)	(1,590)
Total deferred tax liabilities	(54,404)	(21,516)
Net deferred tax assets	<u>\$ 85,661</u>	<u>\$ 95,989</u>

The activity in the valuation allowance associated with deferred taxes consisted of the following:

(In thousands)	Balance at Beginning of Period	Additions <sup>(1)</sup>	Balance at End of Period
Deferred tax asset valuation allowance for the year ended December 31, 2019	\$ (219,093)	\$ (22,966)	\$ (242,059)
Deferred tax asset valuation allowance for the year ended December 31, 2020	\$ (242,059)	\$ (11,590)	\$ (253,649)

- (1) The additions in each of the periods presented relate primarily to Irish net operating losses ("NOLs"). Additionally, in 2019 the Company's valuation allowance was increased by \$3.0 million as a result of the attributes acquired as part of the acquisition of Rodin.

At December 31, 2020, the Company maintained a valuation allowance of \$20.9 million against certain U.S. state deferred tax assets and \$232.8 million against certain Irish deferred tax assets as the Company has determined that it is more-likely-than-not that these net deferred tax assets will not be realized. If the Company demonstrates consistent profitability in the future, the evaluation of the recoverability of these deferred tax assets could change and the remaining valuation allowances could be released in part or in whole. If the Company incurs losses in the U.S. in the future, or experiences significant excess tax benefits arising from the future exercise of stock options and/or the vesting of RSUs, the evaluation of the recoverability of the U.S. deferred tax assets could change and a valuation allowance against the U.S. deferred tax assets may be required in part or in whole.

As of December 31, 2020, the Company had \$1.6 billion of Irish NOL carryforwards, \$33.3 million of U.S. federal NOL carryforwards, \$43.2 million of state NOL carryforwards, \$48.6 million of federal R&D credits and \$23.0 million of state tax credits which will either expire on various dates through 2040 or can be carried forward indefinitely. These loss and credit carryforwards are available to reduce certain future Irish and foreign taxable income and tax. These loss and credit carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. These loss and credit carryforwards, which may be utilized in a future period, may be subject to limitations based upon changes in the ownership of the Company's ordinary shares.

As a result of the acquisition of Rodin, the Company acquired \$51.3 million of U.S. federal NOL carryforwards, \$43.2 million of state NOL carryforwards, \$0.7 million of U.S. federal R&D credit carryforwards and \$0.4 million of state R&D credit carryforwards. These attributes are subject to multiple limitations based upon prior changes in the ownership of the ordinary shares of Rodin.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

9. INCOME TAXES (Continued)

A reconciliation of the Company's statutory tax rate to its effective tax rate is as follows:

(In thousands, except percentage amounts)	Year Ended December 31,	
	2020	2019
Statutory tax rate	12.5 %	12.5 %
Loss before income taxes at statutory rate	\$ (12,067)	\$ (24,632)
Change in valuation allowance	11,590	19,882
Share-based compensation	8,972	6,287
Foreign rate differential <sup>(1)</sup>	7,798	5,390
Intercompany amounts <sup>(2)</sup>	6,234	(1,125)
U.S. state income taxes, net of U.S. federal benefit	1,298	1,051
Irish rate differential <sup>(3)</sup>	2,511	(146)
Uncertain tax positions	811	776
Non deductible lobbying expenses	683	736
Federal tax law change <sup>(4)</sup>	248	(8,111)
In-process R&D <sup>(5)</sup>	84	10,824
Foreign derived intangible income	(3,125)	(3,450)
R&D credit	(11,198)	(8,846)
Other permanent items <sup>(6)</sup>	485	928
Income tax provision (benefit)	\$ 14,324	\$ (436)
Effective tax rate	(14.8) %	0.2 %

- (1) Represents income or losses of non-Irish subsidiaries, including U.S. subsidiaries, subject to tax at a rate other than the Irish statutory rate.
- (2) Intercompany amounts include cross-territory eliminations, the pre-tax effect of which has been eliminated in arriving at the Company's consolidated loss before taxes.
- (3) Represents income or losses of Irish companies subject to tax at a rate other than the Irish statutory rate.
- (4) During the year ended December 31, 2019, federal tax law change represents federal income tax benefit related to the foreign derived intangible income deductions for 2018 following the publications by the IRS and the Department of Treasury of proposed regulations in March 2019.
- (5) Represents the tax effect of the research and development expense recorded on the acquisition of Rodin.
- (6) Other permanent items include, but are not limited to, non-deductible meals and entertainment expenses and non-deductible compensation of senior officers of the Company.

A reconciliation of the beginning and ending amount of unrecognized tax benefits was as follows:

(In thousands)	Unrecognized Tax Benefits
Balance, December 31, 2018	\$ 6,081
Additions based on tax positions related to prior periods	38
Additions based on tax positions related to the current period	738
Balance, December 31, 2019	\$ 6,857
Additions based on tax positions related to prior periods	15
Additions based on tax positions related to the current period	796
Balance, December 31, 2020	\$ 7,668

The unrecognized tax benefits at December 31, 2020, if recognized, would affect the Company's effective tax rate. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease within the next 12 months. The Company has elected to include interest and penalties related to uncertain tax positions as a component of its provision for taxes. For the years ended December 31, 2020 and 2019, the Company's accrued interest and penalties related to uncertain tax positions were not material.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

9. INCOME TAXES (Continued)

The Company's major taxing jurisdictions include Ireland and the U.S. (federal and state). These jurisdictions have varying statutes of limitations. In the U.S., the 2017 through 2020 fiscal years remain subject to examination by the respective tax authorities. In Ireland, the years 2016 to 2020 remain subject to examination by the Irish tax authorities. Additionally, because of the Company's Irish and U.S. loss carryforwards and credit carryforwards, certain tax returns from fiscal years 1999 onward may also be examined. These years generally remain open for three to four years after the loss carryforwards and credit carryforwards have been utilized.

The years ended December 31, 2018 and 2017 for Alkermes Finance S.à.r.l are currently under examination by the Tax Authorities in Luxembourg. There are no uncertain tax positions or adjustments associated with the audit at this time.

10. LOSS PER SHARE

Basic loss per ordinary share is calculated based upon net loss available to holders of ordinary shares divided by the weighted average number of shares outstanding. For the years ended December 31, 2020 and 2019, as the Company was in a net loss position, the diluted loss per share did not assume conversion or exercise of stock options and awards as they would have had an anti-dilutive effect on loss per share.

The following potential ordinary share equivalents were not included in the net loss per ordinary share calculation because the effect would have been anti-dilutive:

(In thousands)	Year Ended December 31,	
	2020	2019
Stock options	15,274	13,814
Restricted stock units	3,279	3,177
Total	18,553	16,991

11. TANGIBLE FIXED ASSETS

Tangible fixed assets consists of the following:

(In thousands)	Land and Buildings	Furniture, Fixtures and Equipment	Leasehold Improvements	Construction in Progress	Total
<b>Cost:</b>					
At January 1, 2019	\$ 163,539	\$ 314,831	\$ 20,105	\$ 88,983	\$ 587,458
Additions at cost	20,120	23,835	632	49,108	93,695
Transfers	—	3,408	—	(3,408)	—
Disposals	(12)	(1,928)	—	—	(1,940)
At December 31, 2019	\$ 183,647	\$ 340,146	\$ 20,737	\$ 134,683	\$ 679,213
Additions at cost	1,107	28,462	31,836	(30,529)	30,876
Transfers	—	1,321	—	(1,321)	—
Disposals	—	(3,878)	(65)	—	(3,943)
At December 31, 2020	\$ 184,754	\$ 366,051	\$ 52,508	\$ 102,833	\$ 706,146
<b>Accumulated Depreciation:</b>					
At January 1, 2019	\$ (64,874)	\$ (198,307)	\$ (14,290)	\$ —	\$ (277,471)
Charged during the year	(6,189)	(31,023)	(2,925)	—	(40,137)
Disposals	3	560	—	—	563
At December 31, 2019	\$ (71,060)	\$ (228,770)	\$ (17,215)	\$ —	\$ (317,045)
Charged during the year	(6,198)	(31,124)	(5,106)	—	(42,428)
Disposals	—	3,265	65	—	3,330
At December 31, 2020	\$ (77,258)	\$ (256,629)	\$ (22,256)	\$ —	\$ (356,143)
<b>Net Book Amount:</b>					
At December 31, 2020	\$ 107,496	\$ 109,422	\$ 30,252	\$ 102,833	\$ 350,003
At December 31, 2019	\$ 112,587	\$ 111,376	\$ 3,522	\$ 134,683	\$ 362,168

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 11. TANGIBLE FIXED ASSETS (Continued)

Depreciation expense was \$42.4 million and \$40.1 million for the years ended December 31, 2020 and 2019, respectively. Also, during the years ended December 31, 2020 and 2019, the Company wrote off furniture, fixtures and equipment that had an approximate carrying value of less than \$0.1 million and \$0.9 million, respectively, at the time of disposition.

Amounts included as construction in progress in the consolidated balance sheets primarily include capital expenditures at the Company's manufacturing facility in Wilmington, Ohio. Approximately \$24.2 million of the construction in progress balance at December 31, 2020 relates to certain building and equipment that the Company would place into service upon approval by the FDA of the NDA for LYBALVI. The Company continues to evaluate its manufacturing capacity based on expectations of demand for its products and will continue to record such amounts within construction in progress until such time as the underlying assets are placed into service. The Company continues to periodically evaluate whether facts and circumstances indicate that the carrying value of its long-lived assets to be held and used may not be recoverable.

On November 18, 2019, the Company entered into a definitive agreement to acquire Rodin Therapeutics, Inc. ("Rodin"), a privately held biopharmaceutical company focused on developing novel, small molecule therapeutics for synaptopathies. The acquisition was completed on November 25, 2019 and, under the terms of the agreement, the Company made an upfront cash payment of \$98.1 million to Rodin's former security holders and may make up to \$850.0 million in future payments, \$225.0 million of which are triggered upon achievement by the development candidates acquired in the acquisition of Rodin of certain specified clinical milestones, \$300.0 million of which are triggered by the development candidates acquired in the acquisition of Rodin of certain regulatory milestones and \$325.0 million of which are triggered upon the attainment of certain sales thresholds.

The Company accounted for the transaction, as an asset acquisition as substantially all of the fair value of Rodin's gross assets acquired were concentrated in its in-process research and development ("IPR&D"), which was largely in the preclinical stage. As the IPR&D was determined to not have an alternative future use, the Company recorded a charge to R&D expense in the accompanying consolidated statements of operations and comprehensive loss of \$86.6 million, which was the amount determined to be the relative fair value of the \$98.1 million payment attributed to the acquired IPR&D. The Company has not recorded any of the \$850.0 million in contingent consideration as a liability in the accompanying consolidated balance sheet as none of the future events which would trigger a milestone payment were considered probable of occurring at December 31, 2020.

The following were the amounts allocated to the assets acquired, liabilities assumed and amounts expensed at the acquisition date based on their respective fair values:

<b>(In thousands)</b>	
Cash	2,658
Prepaid expenses and other current assets	461
Deferred tax assets	11,642
Right-of-use assets	637
Other assets	137
Accounts payable and accrued expenses	(3,364)
Operating lease liabilities—short-term	(400)
Operating lease liabilities—long-term	(237)
Research and development expense	86,594

#### 12. LEASES

Leases are recorded in accordance with FASB ASU 842, Leases, ("Topic 842"), which the Company adopted on January 1, 2019 under the modified retrospective transition method. The Company determines if an arrangement includes a lease at the inception of the agreement. For each of the Company's lease arrangements, a right-of-use asset representing its right to use an underlying asset for the lease term and a lease liability representing its obligation to make lease payments are recorded. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the term of the lease. The Company did not assume lease extension options would be exercised in its right-of-use asset and lease liability amounts.

**ALKERMES PLC**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**12. LEASES (Continued)**

The Company determined that the identified operating leases did not contain non-lease components and required no further allocation of the total lease cost. Additionally, the agreements in place did not contain information to determine the rate implicit in the leases. As such, the Company calculated the incremental borrowing rate based on the assumed remaining lease term for each lease in order to calculate the present value of the remaining lease payments. At December 31, 2020, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were 5.25% and 12.6 years, respectively.

In July 2020, the Company entered into an amendment to its existing lease at 852 Winter Street, Waltham, Massachusetts (as amended, the “852 Winter Street Lease”). The amendment became effective on October 7, 2020. The 852 Winter Street Lease governs approximately 180,000 square feet of corporate office space, administrative areas and laboratories. The amendment served to, among other things, extend the term of the 852 Winter Street Lease for a period of approximately five years, to commence in March 2021 and expire in April 2026 with respect to approximately 163,000 square feet of the 852 Winter Street Lease premises (the “Base Premises”) and to commence in September 2021 and expire in October 2026 with respect to approximately 17,000 square feet of the 852 Winter Street Lease premises (the “Additional Premises”). The Company expects to make annual lease payments of approximately \$5.7 million for the Base Premises and \$0.5 million for the Additional Premises, subject to annual increases. Under the terms of the 852 Winter Street Lease, the Company will have the option to extend the term for an additional five-year period. The Company determined that the amendment did not grant an additional right-of-use and therefore was not deemed to be a separate new lease and that the 852 Winter Street Lease should be reassessed and remeasured as of the effective date of the amendment. The Company accounted for the amendment prospectively.

In March 2018, the Company entered into a lease agreement for approximately 220,000 square feet of office and laboratory space located in a building that was to be built at 900 Winter Street, Waltham, Massachusetts (the “900 Winter Street Lease”). The initial term of the lease commenced on January 20, 2020 (the “Commencement Date”) and includes an option to extend the term of an additional ten-year period. As the lease had not commenced as of December 31, 2019 and the Company: (a) did not have the right to obtain or control the leased premises during the construction period; (b) did not have the right of payment for the partially constructed assets, and thus, the partially constructed assets could have potentially been leased to another tenant; and (c) did not legally own or control the land on which the property improvements were being constructed, the lease assets were not included as right-of-use assets at December 31, 2019. The future lease payments outlined below do not include the 900 Winter Street Lease payments as of December 31, 2019 under Topic 842.

As of December 31, 2020 and 2019, right-of-use assets arising from operating leases were \$131.7 million and \$12.4 million, respectively. Right-of-use assets as of December 31, 2020 consisted of the following:

(In thousands)	Right-of-Use Assets
Balance, January 1, 2019	\$ 20,140
Addition of operating lease in 2019	638
Amortization	(8,399)
Balance, December 31, 2019	\$ 12,379
Addition of operating lease in 2020	136,675
Amortization	(17,336)
Balance, December 31, 2020	\$ 131,718

At December 31, 2020 and 2019, liabilities arising from operating leases were \$135.2 million and \$13.8 million, respectively, of which \$15.7 million and \$8.5 million fall due within one year, respectively, and \$119.5 million and \$5.3 million fall due after more than one year, respectively. During the year ended December 31, 2020 and 2019, cash paid for amounts included for the measurement of lease liabilities was \$17.3 million and \$9.1 million, respectively. The Company recorded operating lease expense of \$16.3 million and \$8.1 million for the years ended December 31, 2020 and 2019, respectively.



ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

12. LEASES (Continued)

Future lease payments under non-cancelable leases as of December 31, 2020 consisted of the following:

(In thousands)	December 31, 2020
2021	\$ 16,882
2022	17,001
2023	17,266
2024	17,536
2025	17,810
Thereafter	109,311
Total lease payments	\$ 195,806
Less: imputed interest	(60,610)
Total operating lease liabilities	<u>\$ 135,196</u>

For comparable purposes, future lease payments under non-cancelable leases as of December 31, 2019 consisted of the following:

(In thousands)	December 31, 2019
2020	\$ 9,053
2021	2,727
2022	500
2023	509
2024	520
Thereafter	2,579
Total lease payments	\$ 15,888
Less: imputed interest	(2,080)
Total operating lease liabilities	<u>\$ 13,808</u>

13. STOCK

Stock consists of the following:

(In thousands)	December 31, 2020	December 31, 2019
Raw materials	\$ 44,944	\$ 34,577
Work in process	53,243	54,061
Finished goods <sup>(1)</sup>	27,551	13,165
Total stock	<u>\$ 125,738</u>	<u>\$ 101,803</u>

- (1) At December 31, 2020 and 2019, the Company had \$26.5 million and \$7.6 million, respectively, of finished goods stock located at its third-party warehouse and shipping service provider.

In November 2020, the Company received a complete response letter, which included a request for information, from the FDA regarding the LYBALVI (formerly referred to as ALKS 3831) NDA, following the FDA's remote review of manufacturing records to the manufacture of LYBALVI at the Company's Wilmington, Ohio facility. The NDA was resubmitted in December 2020 and assigned a Prescription Drug User Fee Act target action date of June 1, 2021.

In the third quarter of 2020, the Company capitalized a total of \$15.3 million of LYBALVI stock in advance of regulatory approval, of which \$6.3 million was subsequently expensed in the fourth quarter of 2020 as the Company determined that certain lots were no longer probable of being sold commercially. As of December 31, 2020 and 2019, the carrying value of stock included \$13.8 million and none, respectively, associated with LYBALVI, which was capitalized in advance of regulatory approval.

The estimated replacement cost of stocks did not differ significantly from the amounts shown above. The Company performs periodic assessments to determine the existence of obsolete, slow-moving and non-saleable stock and records provisions to reduce such stock to net-realizable value. At December 31, 2020 and 2019, the Company had a provision for stock obsolescence of less than \$0.1 million and \$0.1 million, respectively.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

14. DEBTORS

(In thousands)	December 31, 2020	December 31, 2019
<i>Amounts falling due within one year</i>		
Trade receivables	\$ 275,143	\$ 257,086
Contract assets	14,401	8,386
Prepaid expenses and other current assets	60,662	59,716
	<u>\$ 350,206</u>	<u>\$ 325,188</u>
<i>Amounts falling due after more than one year</i>		
Contingent consideration	\$ 24,651	\$ 32,400
Deferred income taxes	86,228	96,558
Other debtors	11,104	11,110
Total	<u>\$ 472,189</u>	<u>\$ 465,256</u>

Included in trade receivable at December 31, 2020 and 2019, are unbilled receivables of \$110.9 million and \$89.7 million, respectively, and related primarily to royalty turnover. The Company maintains an allowance for doubtful accounts to provide for the estimated amounts of trade receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience and age of trade receivables. The allowance for doubtful accounts was approximately \$0.1 million and \$0.2 million at December 31, 2020 and 2019, respectively.

Contract assets include unbilled amounts resulting from sales under certain of the Company's manufacturing contracts where turnover is recognized over time. The manufacturing related amounts included in the contract assets table below complete the manufacturing process in ten days to eight weeks and are classified as current, except for \$5.0 million of consideration related to the Company's collaboration with Biogen related to VUMERITY, which the Company expects to receive in approximately two years.

Contract assets consisted of the following:

(In thousands)	Contract Assets
Contract assets at January 1, 2019	\$ 8,230
Additions	37,911
Transferred to receivables, net	(32,755)
Contract assets at December 31, 2019	13,386
Additions	46,325
Transferred to receivables, net	(40,310)
Contract assets at December 31, 2020	<u>\$ 19,401</u>

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

15. INVESTMENTS

Investments consist of the following:

December 31, 2020	Amortized Cost	Gains	Gross Unrealized Losses		Allowance for Credit Losses	Estimated Fair Value
			Less than One Year	Greater than One Year		
<b>Short-term investments:</b>						
Available-for-sale securities:						
Corporate debt securities	\$ 176,937	\$ 1,105	\$ (7)	\$ —	\$ (977)	\$ 177,058
U.S. government and agency debt securities	103,011	336	(2)	—	—	103,345
International government agency debt securities	79,346	469	(6)	—	—	79,809
	<u>359,294</u>	<u>1,910</u>	<u>(15)</u>	<u>—</u>	<u>(977)</u>	<u>360,212</u>
Held-to-maturity securities:						
Fixed term deposit account	1,667	187	—	—	—	1,854
Total short-term investments	<u>360,961</u>	<u>2,097</u>	<u>(15)</u>	<u>—</u>	<u>(977)</u>	<u>362,066</u>
<b>Long-term investments:</b>						
Available-for-sale securities:						
Corporate debt securities	7,908	—	(10)	—	—	7,898
International government agency debt securities	15,077	—	(15)	—	—	15,062
	<u>22,985</u>	<u>—</u>	<u>(25)</u>	<u>—</u>	<u>—</u>	<u>\$ 22,960</u>
Held-to-maturity securities:						
Certificates of deposit	1,820	—	—	—	—	1,820
Total long-term investments	<u>24,805</u>	<u>—</u>	<u>(25)</u>	<u>—</u>	<u>—</u>	<u>24,780</u>
Total investments	<u>\$ 385,766</u>	<u>\$ 2,097</u>	<u>\$ (40)</u>	<u>\$ —</u>	<u>\$ (977)</u>	<u>\$ 386,846</u>
<b>December 31, 2019</b>						
<b>Short-term investments:</b>						
Available-for-sale securities:						
Corporate debt securities	\$ 144,161	\$ 676	\$ —	\$ —	\$ —	\$ 144,837
U.S. government and agency debt securities	112,948	434	(1)	(1)	—	113,380
International government agency debt securities	72,753	248	(10)	—	—	72,991
Total short-term investments	<u>329,862</u>	<u>1,358</u>	<u>(11)</u>	<u>(1)</u>	<u>—</u>	<u>331,208</u>
<b>Long-term investments:</b>						
Available-for-sale securities:						
Corporate debt securities	51,070	—	(45)	(7)	—	\$ 51,018
International government agency debt securities	20,806	—	(18)	—	—	20,788
U.S. government and agency debt securities	4,000	—	(4)	—	—	3,996
	<u>75,876</u>	<u>—</u>	<u>(67)</u>	<u>(7)</u>	<u>—</u>	<u>75,802</u>
Held-to-maturity securities:						
Certificates of deposit	1,820	—	—	—	—	1,820
Fixed term deposit account	1,667	102	—	—	—	1,769
	<u>3,487</u>	<u>102</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>3,589</u>
Total long-term investments	<u>79,363</u>	<u>102</u>	<u>(67)</u>	<u>(7)</u>	<u>—</u>	<u>79,391</u>
Total investments	<u>\$ 409,225</u>	<u>\$ 1,460</u>	<u>\$ (78)</u>	<u>\$ (8)</u>	<u>\$ —</u>	<u>\$ 410,599</u>

At December 31, 2020, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were other-than-temporary. Investments with unrealized losses consisted primarily of corporate debt securities and debt securities issued by foreign agencies and backed by foreign governments. In making the determination whether the decline in fair value of these securities was other-than-temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

15. INVESTMENTS (Continued)

If the Company intends to sell a security, or it is more likely than not that the Company would be required to sell a security prior to recovering its amortized cost basis, an other-than-temporary impairment is deemed to have occurred. The amount of an other-than-temporary impairment related to a credit loss, or investments that the Company intends to sell before recovery, is recognized in earnings. The amount of an other-than-temporary impairment on available-for-sale investments related to other factors is recorded as a component of accumulated other comprehensive income.

In September 2019, the Company purchased \$1.9 million of convertible promissory notes from Synchronicity Pharma, Inc. (“Synchronicity”), a related party. The notes mature on the earlier of June 30, 2021 or the closing of a preferred equity financing or closing of a merger, business combination or sale of stock resulting in Synchronicity’s stockholders owning less than 50% of the surviving entity. The note is classified as a corporate debt instrument and is classified as available-for-sale. During the year ended December 31, 2020, the Company recorded an other-than-temporary credit loss of \$1.0 million against the value of this investment. The loss was recorded within “Other income (expense), net” in the accompanying consolidated statements of operations and comprehensive loss.

Realized gains and losses on the sales and maturities of marketable securities, which were identified using the specific identification method, were as follows:

(In thousands)	Year Ended December 31,	
	2020	2019
Proceeds from the sales and maturities of marketable securities	\$ 253,001	\$ 224,602
Realized gains	\$ 76	\$ 997
Realized losses	\$ 977	\$ 497

The Company’s available-for-sale and held-to-maturity securities at December 31, 2020 had contractual maturities in the following periods:

(In thousands)	Available-for-sale		Held-to-maturity	
	Amortized Cost	Estimated Fair Value	Amortized Cost	Estimated Fair Value
Within 1 year	\$ 242,605	\$ 242,365	\$ 3,487	\$ 3,674
After 1 year through 5 years	139,674	140,807	—	—
Total	\$ 382,279	\$ 383,172	\$ 3,487	\$ 3,674

16. SHARE CAPITAL PRESENTED AS EQUITY

*Share Capital*

(In thousands, except per share amounts)	December 31,	
	2020	2019
Authorized:		
40,000 ordinary shares of €1 par value	\$ 40,000	\$ 40,000
50,000,000 preferred shares of \$0.01 par value	500,000	500,000
450,000,000 ordinary shares of \$0.01 par value	4,500,000	4,500,000
Share Capital	\$ 5,040,000	\$ 5,040,000

The Company’s board of directors is authorized to allot and issue all or any of the authorized but unissued preferred shares from time to time in one or more classes or series, and to fix for each such class or series such voting powers (full or limited or without voting powers), designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof as are stated and expressed, or in any resolution or resolutions providing for the issue of such class or series adopted by the Company’s board of directors as hereinafter provided, including, without limitation, and subject to the Company’s Articles of Incorporation (“Articles”) and applicable law, the authority to provide that any such class or series may be:

- redeemable at the option of the Company, with the manner of the redemption to be set by the Company’s board of directors, and redeemable at such time or times, including upon a fixed date, and at such price or prices;
- entitled to receive dividends (which may be cumulative or non-cumulative) at such rates, on such conditions at such times and in respect of such dividend periods (the “Dividend Periods”), and payable in preference to, or in such relation to, the dividends payable on any other class or classes of shares or any other series;
- entitled to such rights upon the dissolution of, or upon any distribution of the assets of, the Company; or

**ALKERMES PLC**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**16. SHARE CAPITAL PRESENTED AS EQUITY (Continued)**

- convertible into, or exchangeable for, shares of any other class or classes of shares, or of any other series of the same or any other class or classes of shares, of the Company at such price or prices or at such rates of exchange and with such adjustments as the Company's board of directors determines, which rights and restrictions may be as stated in such resolution or resolutions of the Company's board of directors as determined by it in accordance with this Article 14. The Company's board of directors may at any time before the allotment of any preferred share by further resolution in any way amend the designations, preferences, rights, qualifications, limitations or restrictions, or vary or revoke the designations of such preferred shares.

The holders of ordinary shares shall be:

- entitled to dividends on a *pro rata* basis in accordance with the relevant provisions of these Articles;
- entitled to participate *pro rata* in the total assets of the Company in the event of the Company's winding up; and
- entitled, subject to the right of the Company, to set record dates for the purpose of determining the identity of holders of ordinary shares entitled to notice of and/or vote at a general meeting, to attend general meetings of the Company and shall be entitled to one vote for each ordinary share registered in their name in the Register of Members, both in accordance with the relevant provisions of these Articles.

**Issued Ordinary Shares (par value, \$0.01 per share)  
(Value in thousands)**

	Number	Value
Balance at January 1, 2019	158,180,833	\$ 1,579
Issuance of ordinary shares under employee stock plans	2,309,055	23
Balance at December 31, 2019	160,489,888	\$ 1,602
Issuance of ordinary shares under employee stock plans	1,779,332	18
Balance at December 31, 2020	<u>162,269,220</u>	<u>\$ 1,620</u>

***Share Repurchase Program***

On September 16, 2011, the board of directors authorized the continuation of the Alkermes, Inc. share repurchase program to repurchase up to \$215.0 million of the Company's ordinary shares at the discretion of management from time to time in the open market or through privately negotiated transactions. At December 31, 2020, approximately \$101.0 million was available to repurchase ordinary shares pursuant to the repurchase program. All shares repurchased are recorded as treasury stock. The repurchase program has no set expiration date and may be suspended or discontinued at any time. During the years ended December 31, 2020 and 2019, the Company did not acquire any ordinary shares under the repurchase program.

***Treasury Shares***

**Treasury Shares (par value, \$0.01 per share)  
(Value in thousands)**

	Number	Value
Balance at January 1, 2019	2,423,489	\$ 108,969
Acquired during the year	287,397	9,417
Balance at December 31, 2019	2,710,886	\$ 118,386
Acquired during the year	397,193	7,701
Balance at December 31, 2020	<u>3,108,079</u>	<u>\$ 126,087</u>

The shares acquired during the year were received by the Company for the purchase of employee stock options or to satisfy minimum tax withholding obligations related to employee share-based awards.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

17. SHARE-BASED COMPENSATION

*Share-Based Compensation Expense*

The following table presents share-based compensation expense included in the Company's consolidated statements of operations and comprehensive loss:

(In thousands)	Year Ended December 31,	
	2020	2019
Cost of goods manufactured and sold	\$ 8,430	\$ 9,948
Research and development	26,408	29,924
Selling, general and administrative	55,326	61,105
Total share-based compensation expense	\$ 90,164	\$ 100,977

During the years ended December 31, 2020 and 2019, \$2.6 million and \$1.5 million of share-based compensation expense was capitalized and recorded as "Stock" in the accompanying consolidated balance sheets.

*Share-Based Compensation Plans*

The Company has one share-based compensation plan pursuant to which awards are currently being made: the 2018 Stock Option and Incentive Plan, as amended (the "2018 Plan"). The Company has two share-based compensation plans pursuant to which outstanding awards have been made, but from which no further awards can or will be made: the Alkermes plc Amended and Restated 2008 Stock Option and Incentive Plan, as amended, (the "2008 Plan") and the Alkermes plc 2011 Stock Option and Incentive Plan, as amended (the "2011 Plan"). Effective May 20, 2020, the 2018 Plan was amended such that any shares underlying any outstanding awards granted under the 2011 Plan or the 2008 Plan that are forfeited, canceled, repurchased or otherwise terminated (other than by exercise) from and after such date will become available for issuance pursuant to the 2018 Plan, notwithstanding anything to the contrary in the terms of the 2011 Plan or the 2008 Plan.

The 2018 Plan allows for the issuance of non-qualified and incentive stock options, restricted stock, restricted stock units, cash-based awards and performance shares to employees, officers and directors of, and consultants to, the Company in such amounts and with such terms and conditions as may be determined by the compensation committee of the Company's board of directors, subject to the provisions of the 2018 Plan, as applicable.

At December 31, 2020, there were 13.9 million ordinary shares available for issuance in the aggregate under the 2018 Plan. The 2018 Plan provides that awards other than stock options will be counted against the total number of shares available under the plan in a 1.8-to-1 ratio.

*Stock Options*

A summary of stock option activity is presented in the following table:

	Number of Shares	Weighted Average Exercise Price
Outstanding, January 1, 2020	15,235,845	\$ 40.34
Granted	3,799,952	\$ 20.20
Exercised	(682,122)	\$ 12.27
Expired	(1,266,999)	\$ 49.81
Forfeited	(974,487)	\$ 36.28
Outstanding, December 31, 2020	16,112,189	\$ 36.27
Exercisable, December 31, 2020	9,842,531	\$ 40.08

The weighted average grant date fair value of stock options granted during the years ended December 31, 2020 and 2019 was \$9.52 and \$15.57, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was \$2.0 million and \$21.3 million, respectively.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

17. SHARE-BASED COMPENSATION (Continued)

At December 31, 2020, there were 6.1 million stock options expected to vest with a weighted average exercise price of \$30.46 per share, a weighted average contractual remaining life of 8.5 years with an aggregate intrinsic value of \$0.2 million. At December 31, 2020, the aggregate intrinsic value of stock options exercisable was \$6.9 million with a weighted average remaining contractual term of 4.3 years. The number of stock options expected to vest was determined by applying the pre-vesting forfeiture rate to the total outstanding options. The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price of the stock option.

At December 31, 2020, there was \$34.6 million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted average period of 1.8 years. Included within the outstanding stock option balances at December 31, 2020 was 0.4 million performance-based stock options that were granted in 2019 and valued using a Monte Carlo simulation model. The weighted average grant date fair value of such performance-based stock options was \$16.78. The unrecognized compensation cost related to these performance-based stock options was \$1.9 million at December 31, 2020 and is included in the unrecognized compensation cost noted above. Cash received from option exercises under the Company's award plans during the years ended December 31, 2020 and 2019 was \$8.4 million and \$18.9 million, respectively.

*Time-Based Restricted Stock Unit Awards*

A summary of time-based RSU vesting activity is presented in the following table:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested, January 1, 2020	3,744,800	\$ 38.99
Granted	3,494,759	\$ 20.22
Vested	(1,097,210)	\$ 41.84
Forfeited	(587,087)	\$ 31.16
Unvested, December 31, 2020	<u>5,555,262</u>	<u>\$ 27.45</u>

The weighted average grant date fair value of time-vested RSUs granted during the years ended December 31, 2020 and 2019 were \$20.22 and \$30.47, respectively. The total fair value of time-vested RSUs that vested during the years ended December 31, 2020 and 2019, was \$45.9 million and \$42.4 million, respectively.

At December 31, 2020, there was \$61.0 million of total unrecognized compensation cost related to unvested time-vested RSUs, which will be recognized over a weighted average remaining contractual term of 1.8 years.

*Performance-Based Restricted Stock Unit Awards*

In February 2020, the compensation committee of the Company's board of directors approved awards of performance-based RSUs to employees of the Company at the Senior Vice President level and above, in each case subject to vesting on the achievement of certain commercial and R&D performance criteria to be assessed over a performance period of three years from the date of the grant, and subject, at the end of such three-year performance period, to upward or downward adjustment based on a market condition tied to relative share price performance over the three-year performance period.

A summary of performance-based RSU activity is presented in the following table:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested, January 1, 2020	543,554	\$ 54.75
Granted	529,578	\$ 23.43
Forfeited	(574,148)	\$ 53.08
Vested	—	\$ —
Unvested, December 31, 2020	<u>498,984</u>	<u>\$ 23.43</u>

**ALKERMES PLC**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**17. SHARE-BASED COMPENSATION (Continued)**

As the performance-based RSUs granted in February 2020 are subject to a market condition, the grant date fair value for such RSUs was based on a Monte Carlo simulation model. At December 31, 2020, the Company believed it probable that commercial performance criteria underlying the RSUs will be met and, accordingly, has recognized share-based compensation expense related to this portion of the performance-based RSUs. At December 31, 2020, the Company did not consider it probable that the performance criteria related to the R&D portion of the awards will be met and has not recognized any additional share-based compensation expense related to this portion of the performance-based RSUs. At December 31, 2020, there was \$10.4 million of unrecognized compensation cost related to the R&D portion of the performance-based RSUs, which would be recognized in accordance with the terms of the award when the Company deems it probable that the performance criteria will be met. The unvested awards will expire if it is determined that the performance criteria have not been met on or before December 31, 2022.

In February 2017, the compensation committee of the Company's board of directors approved awards of RSUs to all employees employed by the Company during 2017, in each case subject to vesting on the achievement of certain performance criteria which were to be assessed over a performance period of three years from the date of the grant (the "2017 Performance Awards"). The grant date fair value of the 2017 Performance Awards was equal to the closing price of the Company's stock on the Nasdaq Global Select Market on the dates of grant.

In December 2018, the Company achieved one such performance criteria, resulting in the vesting of a portion of the 2017 Performance Awards. In the first quarter of 2020, the compensation committee of the Company's board of directors determined the two remaining performance criteria of the 2017 Performance Awards were not achieved. The unvested portion of the 2017 Performance Awards expired as the performance conditions were not met on or before the three year anniversary of the grant date.

**18. PROVISIONS FOR LIABILITIES**

Provisions for liabilities consists of the following:

(In thousands)	Medicaid Rebates	Product Returns	Other	Total
Balance, January 1, 2019	\$ 123,429	\$ 21,900	\$ 18,561	\$ 163,890
Additions	237,059	8,535	74,142	319,736
Amounts utilized	(234,495)	(5,823)	(75,554)	(315,872)
Balance, December 31, 2019	\$ 125,993	\$ 24,612	\$ 17,149	\$ 167,754
Additions	291,084	6,019	91,470	388,573
Amounts utilized	(235,118)	(6,936)	(85,265)	(327,319)
Balance, December 31, 2020	<u>\$ 181,959</u>	<u>\$ 23,695</u>	<u>\$ 23,354</u>	<u>\$ 229,008</u>

The category "Other" in the table above includes certain other provisions for sales discounts and allowances that are not individually significant.



ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

19. CREDITORS

(In thousands)	December 31, 2020	December 31, 2019
Amounts falling due within one year		
Accrued expenses	\$ 153,591	\$ 159,546
Trade creditors	46,034	54,261
Contract liabilities	7,513	6,766
Payroll taxes	2,834	2,657
Restructuring	462	8,977
Accrued interest on long-term debt	203	498
Value added tax	548	1,731
Corporate tax	38	19
Other taxes	647	1,100
	<u>\$ 211,870</u>	<u>\$ 235,555</u>
Amounts falling due after more than one year		
Deferred income taxes	\$ 567	\$ 569
Contract liabilities	16,397	22,067
Accrued vacation	8,957	—
Restructuring	—	224
Other long-term liabilities	5,792	2,846
Total	<u>\$ 243,583</u>	<u>\$ 261,261</u>

Trade and other creditors are payable at various dates in the next three months in accordance with the suppliers' usual and customary credit terms. Tax amounts are repayable at various dates over the coming months in accordance with the applicable statutory provisions.

The Company's contract liabilities consist of contractual obligations related to deferred revenue.

Contract liabilities consisted of the following:

(In thousands)	Contract Liabilities
Contract liabilities at January 1, 2019	\$ 12,694
Additions	18,677
Amounts recognized into revenue	(2,537)
Contract liabilities at December 31, 2019	28,834
Additions	—
Amounts recognized into revenue	(4,925)
Contract liabilities at December 31, 2020	<u>\$ 23,909</u>

20. COMMITMENTS AND CONTINGENT LIABILITIES

*Litigation*

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company would accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on the Company's best estimates, utilizing all available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results. At December 31, 2020, there were no potential material losses from claims, asserted or unasserted, or legal proceedings that the Company determined were probable of occurring.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 20. COMMITMENTS AND CONTINGENT LIABILITIES (Continued)

##### **INVEGA SUSTENNA ANDA Litigation**

Janssen Pharmaceuticals NV and Janssen Pharmaceuticals, Inc. initiated patent infringement lawsuits in the U.S. District Court for the District of New Jersey (the “NJ District Court”) in January 2018 against Teva Pharmaceuticals USA, Inc. (“Teva”) and Teva Pharmaceuticals Industries, Ltd. (“Teva PI”), in August 2019 against Mylan Laboratories Limited (“Mylan Labs”), Mylan Pharmaceuticals Inc. (“Mylan”), and Mylan Institutional LLC and in December 2019 against Pharmascience, Inc. (“Pharmascience”), Mallinckrodt plc, and SpecGX LLC, following the respective filings by each of Teva, Mylan Labs, and Pharmascience of an Abbreviated New Drug Application (“ANDA”) seeking approval from the FDA to market a generic version of INVEGA SUSTENNA before the expiration of U.S. Patent No. 9,439,906. In October 2020, a trial was held in the lawsuit between the Janssen entities and the Teva entities. Requested judicial remedies in each of the lawsuits included recovery of litigation costs and injunctive relief. The Company is not a party to any of these proceedings.

##### **INVEGA TRINZA ANDA Litigation**

In September 2020, Janssen Pharmaceuticals NV, Janssen Pharmaceuticals, Inc., and Janssen Research & Development, LLC, initiated a patent infringement lawsuit in the NJ District Court against Mylan Labs, Mylan, and Mylan Institutional LLC following the filing by Mylan Labs of an ANDA seeking approval from the FDA to market a generic version of INVEGA TRINZA before the expiration of U.S. Patent No. 10,143,693. Requested judicial remedies include recovery of litigation costs and injunctive relief. The Company is not a party to this proceeding.

##### **RISPERDAL CONSTA European Opposition Proceedings**

In December 2016, Nanjing Luye Pharmaceutical Co., Ltd., Pharmathen SA, Teva PI and Dehns Ltd (a law firm representing an unidentified opponent) filed notices of opposition with the European Patent Office (the “EPO”) in respect of EP 2 269 577 B (the “EP ’577 Patent”), which is a patent directed to certain risperidone microsphere compositions, including RISPERDAL CONSTA. Following a hearing on the matter in January 2019, the EPO issued a written decision revoking the EP’577 Patent in April 2019. The Company filed a notice of appeal of the decision to the EPO’s Technical Boards of Appeal in June 2019. Pharmathen SA submitted a reply on November 5, 2019 and Nanjing Luye Pharmaceutical Co Ltd. and Teva Pharmaceutical Industries Ltd. submitted replies on December 20, 2019. The Company will continue to vigorously defend the EP ’577 Patent.

##### **VIVITROL ANDA Litigation**

In September 2020, Alkermes, Inc. and Alkermes Pharma Ireland Limited filed a patent infringement lawsuit in the NJ District Court against Teva and Teva PI following the filing by Teva of an ANDA seeking approval from the FDA to engage in the commercial manufacture, use or sale of a generic version of VIVITROL (naltrexone for extended-release injectable suspension) before the expiration of the Company’s U.S. Patent No. 7,919,499. Teva filed its Answer on November 16, 2020, which included counterclaims against the Company. The Company filed its Reply to Teva’s counterclaims on December 7, 2020. The Company intends to vigorously defend its intellectual property. The filing of the lawsuit triggered a stay of FDA approval of the ANDA for up to 30 months in accordance with the U.S. Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act).

##### **Government Matters**

The Company has received a subpoena and civil investigative demands from U.S. state and Federal governmental authorities for documents related to VIVITROL. The Company is cooperating with the investigations.

## ALKERMES PLC

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

#### 20. COMMITMENTS AND CONTINGENT LIABILITIES (Continued)

##### Securities Litigation

In December 2018 and January 2019, purported stockholders of the Company filed putative class actions against the Company and certain of its officers in the U.S. District Court for the Eastern District of New York (the “EDNY District Court”) captioned *Karimian v. Alkermes plc, et al., No. 1:18-cv-07410* and *McDermott v. Alkermes plc, et al., No. 1:19-cv-00624*, respectively. In March 2019, the EDNY District Court consolidated the two cases and appointed a lead plaintiff. The plaintiff filed an amended complaint on July 9, 2019 naming one additional officer of the Company and one former officer of the Company as defendants. The amended complaint was filed on behalf of a putative class of purchasers of Alkermes securities during the period of July 31, 2014 through November 1, 2018 and alleges violations of Sections 10(b) and 20(a) of the Exchange Act based on allegedly false or misleading statements and omissions regarding the Company’s clinical methodologies and regulatory submission for ALKS 5461 and the FDA’s review and consideration of that submission. The lawsuit seeks, among other things, unspecified money damages, prejudgment and postjudgment interest, reasonable attorneys’ fees, expert fees and other costs. In August 2019, the defendants filed a pre-motion letter (in respect of a requested motion to dismiss filing) with the EDNY District Court and plaintiff filed a response. On November 27, 2019, the defendants served the plaintiff with a motion to dismiss, and on December 27, 2019, the plaintiff served the defendants with its opposition to such motion. On January 17, 2020, the defendants filed the fully-briefed motion, including a reply to the plaintiff’s opposition, with the EDNY District Court.

##### Product Liability and Other Legal Proceedings

The Company is also involved in product liability cases and other legal proceedings incidental to its normal business activities, including product liability cases alleging that the FDA-approved VIVITROL labeling was inadequate and caused the users of the product to suffer from opioid overdose and death. The Company intends to vigorously defend itself in these matters. While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing matters would have a material adverse effect on the Company’s business or financial condition.

#### 21. CAPITAL EXPENDITURE COMMITMENTS

The Company’s board of directors has authorized the Company to spend \$40.0 million for capital expenditures in the year ending December 31, 2020.

#### 22. RELATED PARTY DISCLOSURES

The principal related party relationships requiring disclosure in the consolidated financial statements pertain to the existence of subsidiaries and associates and transactions with these entities entered into by the Group and the identification of key management personnel as addressed in greater detail below.

##### *Subsidiaries and Associates*

The consolidated financial statements include the results of operations, financial positions and cash flows of the Company and its subsidiaries and associates over which the Company has control. A listing of principal subsidiaries and associates is provided in Note 27, *Subsidiaries*, to the consolidated financial statements.

##### *Trading Transactions*

There were no transactions requiring disclosure under Sch. 3, Section 67(1) of the Companies Act.

##### *Compensation of Key Management Personnel of the Group*

Key management personnel are the Company’s executive and non-executive directors and their compensation is disclosed in Note 25, *Directors’ Remuneration*.

#### 23. LOANS TO DIRECTORS

Irish company law prohibits the Group from making a loan or a quasi-loan to a director of the Group unless certain conditions are met. No loans or quasi-loans have been made to any director of the Group during the financial year.

**ALKERMES PLC**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**24. EMPLOYEES**

The average number of persons employed by the Company during the years ended December 31, 2020 and 2019, respectively, was as follows:

	December 31, 2020	December 31, 2019
Manufacturing	806	773
Research and development	460	531
Selling, general and administrative	989	971
Total	<u>2,255</u>	<u>2,275</u>

Employee costs included in profit and loss during the years ended December 31, 2020 and 2019 consisted of the following:

(In thousands)	December 31, 2020	December 31, 2019
Wages and salaries	\$ 389,915	\$ 389,475
Share-based compensation	90,164	100,977
Social insurance costs <sup>(1)</sup>	55,812	61,038
Defined contribution plan contributions	20,387	20,047
Total	<u>\$ 556,278</u>	<u>\$ 571,537</u>

(1) Social insurance costs include social security costs, employer paid payroll taxes and other employee benefits paid by the Company.

During the years ended December 31, 2020 and 2019, the Company capitalized \$0.5 million and \$0.1 million, respectively, as part of its tangible fixed assets and \$67.6 million and \$61.4 million, respectively, as part of its stock.

**25. DIRECTORS' REMUNERATION**

Directors' remuneration is set forth in the table below. Mr. Pops, the Company's Chairman and Chief Executive Officer ("CEO"), is not compensated for his services as a director. Accordingly, the amounts below include compensation for Mr. Pops' service as CEO (referred to as "Managerial Services") as well as compensation for all non-employee directors in their capacities as such (referred to as "Director Services").

(In thousands)	December 31, 2020	December 31, 2019
<b>Managerial Services:</b>		
Emoluments	\$ 1,986	\$ 2,017
Benefits under long term incentive schemes	1,498	1,816
Company contribution to 401(k) plan	15	14
Total	<u>\$ 3,499</u>	<u>\$ 3,847</u>
<b>Director Services:</b>		
Fees paid in cash	\$ 835	\$ 782
Total	<u>\$ 835</u>	<u>\$ 782</u>

The aggregate intrinsic value resulting from the exercise of stock options by the directors, including the Company's Chairman and CEO, during the year ended December 31, 2020 was \$0.9 million (December 31, 2019: \$10.5 million). The Company considers its directors to be key management personnel.

ALKERMES PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

26. AUDITORS' REMUNERATION

Total auditors' remuneration, including expenses, accrued and paid to PricewaterhouseCoopers and its affiliated firms for the years ended December 31, 2020 and 2019, respectively, were as follows:

(In thousands)	December 31, 2020	December 31, 2019
Audit and review of group financial statements <sup>(1)</sup>	\$ 2,396	\$ 2,262
Audit-related fees <sup>(2)</sup>	9	8
Tax fees <sup>(3)</sup>	472	639
All other fees <sup>(4)</sup>	3	3
<b>Total</b>	<b>\$ 2,880</b>	<b>\$ 2,912</b>

- (1) Consists of fees for services related to the audit of the Company's annual consolidated financial statements, statutory audits and the review of the Company's quarterly consolidated financial statements, including the review of the Company's internal controls over financial reporting, and other engagements related to the fiscal year. Included in the years ended December 31, 2020 and 2019 are expenses of \$2 thousand and \$8 thousand, respectively.
- (2) Consists of assurance services related to employee benefit plan audits.
- (3) Consists of fees for tax compliance and tax advisory services, other than those related to the audit of our annual consolidated financial statements and review of our quarterly consolidated financial statements. Included in the years ended December 31, 2020 and 2019 are expenses of \$none and \$37 thousand, respectively.
- (4) Consists of fees for access to the PricewaterhouseCoopers on-line accounting research database.

Total fees paid to PricewaterhouseCoopers Ireland in respect of the audit of the group financial statements were \$0.6 million and \$0.5 million during the years ended December 31, 2020 and 2019, respectively. In addition, PricewaterhouseCoopers Ireland received \$0.1 million for tax advisory services during both the years ended December 31, 2020 and 2019.

**ALKERMES PLC**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**27. SUBSIDIARIES**

The subsidiaries of Alkermes plc are wholly-owned by Alkermes plc or one of its subsidiaries.

Name	Nature of Business	Registered Office and Country of Incorporation	Percent of Ownership
Alkermes Ireland Holdings Limited	Holding Company	Connaught House, 1 Burlington Road Dublin 4, Republic of Ireland	100%
Alkermes Pharma Ireland Limited	Manufacturing and R&D	Connaught House, 1 Burlington Road Dublin 4, Republic of Ireland	100%
Alkermes Finance Ireland Limited	Finance Company	Connaught House, 1 Burlington Road Dublin 4, Republic of Ireland	100%
Daravita Pharma Ireland Limited	Holding Company	Connaught House, 1 Burlington Road Dublin 4, Republic of Ireland	100%
Alkermes Finance Ireland (No.2) Limited	Finance Company	Connaught House, 1 Burlington Road Dublin 4, Republic of Ireland	100%
Alkermes Finance Ireland (No.3) Limited	Finance Company	Connaught House, 1 Burlington Road Dublin 4, Republic of Ireland	100%
Daravita Limited	Non-Operating	Connaught House, 1 Burlington Road Dublin 4, Republic of Ireland	100%
Alkermes Science Four Limited	Non-Operating	Connaught House, 1 Burlington Road Dublin 4, Republic of Ireland	100%
Alkermes Science Five Limited	Non-Operating	Connaught House, 1 Burlington Road Dublin 4, Republic of Ireland	100%
Alkermes U.S. Holdings, Inc.	Holding Company	852 Winter Street, Waltham, MA 02451 United States	100%
Alkermes, Inc.	Manufacturing and R&D	852 Winter Street, Waltham, MA 02451 United States	100%
Alkermes Controlled Therapeutics, Inc.	Non-Operating	852 Winter Street, Waltham, MA 02451 United States	100%
Alkermes Europe, Ltd.	Non-Operating	c/o Mitre house, 160 Aldersgate Street London EC1A 4DD, United Kingdom	100%
Rodin Therapeutics, Inc.	R&D	852 Winter Street, Waltham, MA 02451 United States	100%

**28. SUBSEQUENT EVENTS**

In March 2021, the Company amended and extended the 2026 Term Loan, formerly referred to as the 2023 Term Loan, pursuant to which, among other things: (a) provided for a new class of replacement term loans equal to \$300.0 million; (b) extended the due date from March 26, 2023 to March 12, 2026; and (c) amended the interest payable from LIBOR plus 2.25% with no LIBOR floor to LIBOR plus 2.50%, with a LIBOR floor of 0.50% for LIBOR Rate Loans (as defined in the Amended Credit Agreement) and ABR plus 1.50%, with an ABR floor of 1.50% for ABR Loans (as defined in the Amended Credit Agreement).

**ALKERMES PLC**  
**PARENT COMPANY BALANCE SHEET**

(In thousands)	Note	December 31, 2020	December 31, 2019
<b>ASSETS</b>			
<i>Fixed Assets</i>			
Financial assets	7	\$ 2,118,764	\$ 2,054,461
Associated undertakings	8	4,859	5,912
Total fixed assets		<u>2,123,623</u>	<u>2,060,373</u>
<i>Current Assets</i>			
Debtors	9	848,995	806,614
Cash at bank and in-hand		55,437	72,150
<b>TOTAL ASSETS</b>		<u>\$ 3,028,055</u>	<u>\$ 2,939,137</u>
<b>LIABILITIES</b>			
<i>Creditors</i>			
Creditors—amounts falling due within one year	10	\$ 40,015	\$ 41,244
Total for creditors		<u>40,015</u>	<u>41,244</u>
<i>Equity Shareholders' Funds</i>			
Share capital, \$0.01 par value	11	1,620	1,602
Share premium	12	594,045	585,679
Profit and loss account	12	1,803,290	1,805,088
Treasury shares	12	(126,087)	(118,386)
Other reserves	12	715,172	623,910
Total equity shareholders' funds		<u>\$ 2,988,040</u>	<u>\$ 2,897,893</u>
<b>TOTAL EQUITY AND LIABILITIES</b>		<u>\$ 3,028,055</u>	<u>\$ 2,939,137</u>

The accompanying notes are an integral part of these financial statements.

The Parent Company financial statements were approved by the Parent Company's board of directors on April 14, 2021 and signed on its behalf by:

/s/ RICHARD F. POPS  
Richard F. Pops  
*Chairman*

/s/ PAUL J. MITCHELL  
Paul J. Mitchell  
*Director*

ALKERMES PLC

PARENT COMPANY RECONCILIATION OF MOVEMENT IN SHAREHOLDERS' FUNDS

	Share Capital	Share Premium	Profit and Loss Account	Treasury Shares	Other Reserves	Total
(In thousands)						
BALANCE—January 1, 2019	\$ 1,579	\$ 566,670	\$ 1,825,243	\$ (108,969)	\$ 524,205	\$ 2,808,728
Net loss	—	—	(20,155)	—	—	(20,155)
Share-based payment reserve	—	—	—	—	99,705	99,705
Shares issued under employee stock plans	15	18,917	—	—	—	18,932
Receipt of Alkermes' shares for the purchase of share options or to satisfy minimum tax withholding obligations related to share based awards	8	92	—	(9,417)	—	(9,317)
BALANCE—December 31, 2019	\$ 1,602	\$ 585,679	\$ 1,805,088	\$ (118,386)	\$ 623,910	\$ 2,897,893
Net loss	—	—	(1,798)	—	—	(1,798)
Share-based payment reserve	—	—	—	—	91,262	91,262
Shares issued under employee stock plans	7	8,366	—	—	—	8,373
Receipt of Alkermes' shares for the purchase of share options or to satisfy minimum tax withholding obligations related to share based awards	11	—	—	(7,701)	—	(7,690)
BALANCE—December 31, 2020	\$ 1,620	\$ 594,045	\$ 1,803,290	\$ (126,087)	\$ 715,172	\$ 2,988,040

The accompanying notes are an integral part of these financial statements.



**ALKERMES PLC**  
**NOTES TO THE PARENT COMPANY FINANCIAL STATEMENTS**

**1. General Information**

Alkermes plc (the “Parent Company”) is a public limited company incorporated in Ireland. The address of its registered office is Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6. The registered number of the Parent Company is: 498284.

On May 9, 2011, Alkermes plc, Alkermes, Inc., Elan and certain of their respective subsidiaries entered into the Business Combination Agreement and Plan of Merger (the “Business Combination Agreement”) pursuant to which Alkermes, Inc., and EDT agreed to combine their businesses under the Parent Company in a cash and share transaction (the “Business Combination”). EDT, which operated as a business unit of Elan with its principal assets predominantly located in Ireland, developed and manufactured pharmaceutical products using its proprietary drug technologies in collaboration with pharmaceutical companies worldwide. On May 4, 2011, the Parent Company was incorporated by Elan as Antler Science Two plc in connection with the negotiation and execution of the Business Combination Agreement solely to effect the Business Combination. Following the execution of the Business Combination Agreement, Elan contributed the assets and legal entities that comprised the EDT business to the Parent Company through a combination of asset transfers, share transfers and other intercompany transactions, following which the EDT business was contained in several subsidiaries under the Parent Company. On September 14, 2011, the Parent Company changed its name to Alkermes plc.

On September 16, 2011, the business of Alkermes, Inc., and EDT were combined under the Parent Company. As part of the Business Combination, a wholly owned subsidiary of the Parent Company merge with and into Alkermes, Inc., with Alkermes, Inc., surviving as a wholly-owned subsidiary of the Parent Company.

**2. Statement of Compliance**

The entity financial statements have been prepared on the going concern basis and in accordance with Irish GAAP (accounting standards issued by the Financial Reporting Council of the UK and the Companies Act). The entity financial statements comply with Financial Reporting Standard 102, ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ (“FRS 102”) and the Companies Act.

**3. Summary of Significant Accounting Policies**

***Basis of Preparation***

The financial statements of the Parent Company present the balance sheet and the reconciliation of movement in shareholders’ funds on a stand-alone basis, including related party transactions.

The financial statements have been prepared under the historical cost convention.

The preparation of financial statements in conformity with FRS 102 requires the use of certain key assumptions concerning the future, and other key sources of estimation uncertainty at the end of the financial year. It also requires the Parent Company’s board of directors to exercise its judgment in the process of applying the Parent Company’s accounting policies. The areas involving a higher degree of judgment or areas where assumptions and estimates have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are disclosed in Note 5, *Critical Accounting Judgments and Estimation Uncertainty*.

***Going Concern***

As the Parent Company’s operational existence relies on the activities of the Parent Company and its subsidiaries as a group (collectively, the “Group”), a going concern assessment performed at the Group level was deemed relevant to support the Parent Company’s ability to continue as a going concern. The Parent Company meets its day-to-day working capital requirements through its bank facilities. The Parent Company’s forecasts and projections, taking account of reasonably possible changes in trading performance, show that the Parent Company should be able to operate within the level of its current facilities. After making enquiries, the directors have a reasonable expectation that the Parent Company has adequate resources to continue in operational existence for the foreseeable future. Therefore these entity financial statements have been prepared on a going concern basis.

The Parent Company’s board of directors formed a judgment at the time of approving these financial statements that there was a reasonable expectation that the Parent Company has adequate resources to continue in operational existence for the next twelve months. In arriving at this conclusion, the Parent Company’s board of directors took account of current and anticipated uncertainties driven by the COVID-19 pandemic (as described in greater detail under the heading “*Risks and*

## ALKERMES PLC

### NOTES TO THE PARENT COMPANY FINANCIAL STATEMENTS (Continued)

#### 3. Summary of Significant Accounting Policies (Continued)

*Uncertainties*” within Note 2, *Summary of Significant Accounting Policies and Statement of Compliance*, within the “Notes to Consolidated Financial Statements” in this Directors’ Report.) in its going concern assessment and believed that these uncertainties would not have a material impact on the Parent Company’s ability to continue as a going concern.

For this reason, the going concern basis continues to be adopted in the preparation of the Parent Company’s financial statements.

#### *Disclosure Exemptions for Qualifying Entities Under FRS 102*

FRS 102 allows a qualifying entity certain disclosure exemptions. As a qualifying entity the Parent Company has availed of a number of exemptions from the disclosure requirements of FRS 102 in the preparation of the entity financial statements.

In accordance with FRS 102, the Parent Company has availed of an exemption from the following paragraphs of FRS 102:

- Exemption from the requirements of Section 7 of FRS 102 and FRS 102 paragraph 3.17(d) to present a statement of cash flows;
- Exemption from the financial instrument disclosure requirements of Section 11 paragraphs 11.39 to 11.48A and Section 12 paragraphs 12.26 to 12.29A of FRS 102 providing the equivalent disclosures are included in the consolidated financial statements of the group in which the entity is consolidated;
- Exemption from certain disclosure requirements of Section 26 of FRS 102 (paragraphs 26.18(b), 26.19 to 26.21 and 26.23), in respect of share-based payments; and
- Exemption from the requirement of FRS 102 paragraph 33.7 to disclose key management personnel compensation in total.

#### *Foreign Currency*

##### Functional and presentation currency

The Parent Company’s functional and presentation currency is the U.S. dollar, denominated by the symbol “\$” and unless otherwise stated, the financial statements have been presented in thousands.

##### Transactions and balances

Transactions during the period denominated in foreign currencies have been translated at the rates of exchange ruling at the dates of the transactions. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars at the rates of exchange at the balance sheet date. The resulting profits or losses are dealt with in the profit and loss account.

#### *Financial Assets*

Investments in group undertakings in the financial statements of the Parent Company are carried at historical cost less accumulated impairment losses. See Note 7, *Financial Assets*, below for further information.

#### *Associated Undertakings*

The Parent Company accounts for its associated undertakings at cost, less impairment. Refer to Note 8, *Associated Undertakings*, for further discussion.

#### *Dividend Income from Shares in Group Undertakings*

Dividend income from group undertakings is recognized in the period in which it is received.

#### *Share Premium*

The difference between the proceeds received on issue of shares and the nominal value of the shares is credited to the share premium account.

## ALKERMES PLC

### NOTES TO THE PARENT COMPANY FINANCIAL STATEMENTS (Continued)

#### 3. Summary of Significant Accounting Policies (Continued)

##### *Taxation*

Corporation tax is provided on taxable profits at current rates. Deferred taxation is accounted for in respect of all timing differences at tax rates enacted or substantially enacted at the balance sheet date. Timing differences arise from the inclusion of items of income and expenditure in tax computation in periods different from those in which they are included in the financial statements. A deferred tax asset is only recognized when it is more likely than not the asset will be recoverable in the foreseeable future out of suitable taxable profits from which the underlying timing differences can be recovered.

##### *Share Capital Presented as Equity*

Equity shares issued are recognized at the proceeds received. Incremental costs directly attributable to the issue of new equity shares or options are shown in equity as a deduction, net of tax, from the proceeds.

##### *Treasury Shares*

These represent shares of Alkermes plc acquired from employees for the purchase of employee stock options or to satisfy minimum tax withholding obligations related to employee share based awards. Treasury shares are treated as a deduction from the profit and loss reserves until the shares are cancelled, reissued or disposed of. When such shares are subsequently sold or reissued, any consideration received, increases shareholders' funds.

At December 31, 2020, the Parent Company has approximately \$101.0 million available to repurchase ordinary shares pursuant to a share repurchase program. All shares repurchased are recorded as treasury stock. The repurchase program has no set expiration date and may be suspended or discontinued at any time. The Parent Company has not repurchased any ordinary shares under this program since September 16, 2011.

##### *Share-Based Payments*

The Parent Company and its subsidiaries operate equity-settled share-based compensation plans. The fair value of the employee services received in exchange for the grant of the options has been valued using the Black-Scholes option pricing model. In accordance with Section 26 of FRS 102 'Share-based Payments', the resulting cost for the Parent Company's employees is charged to the profit and loss account over the vesting period. The value of the charge is adjusted to reflect expected and actual levels of awards vesting. The cost for awards granted to the Parent Company's subsidiaries' employees represents additional capital contributions by the Parent Company to its subsidiaries. An additional investment in subsidiaries has been recorded in respect of those awards granted to the Parent Company's subsidiaries' employees, with a corresponding increase in the Parent Company's shareholder equity. The additional capital contribution is based on the fair value at the grant date of the awards issued, allocated over the life of the underlying grant's vesting period. Proceeds received from employees, if any, for the exercise of share-based instruments increase the share capital and share premium accounts of the Parent Company. The Parent Company has an arrangement in place with its subsidiaries whereby the subsidiary will remit an amount to the Parent Company equal to the difference between the market value of the equity and the amount paid by the employee. Amounts remitted by the subsidiaries to the Parent Company are reflected as a decrease in the Parent Company's "Investment in Subsidiaries". To the extent cash received from the vesting of restricted stock units and stock option exercises exceeds the fair value of restricted stock units and stock options on the date of grant, this amount is recorded in the Parent Company's statement of operations.

Note 17, *Share-Based Compensation*, of the 2020 Alkermes plc consolidated financial statements provides additional details of the Group's share-based compensation plans.

##### *Contingencies*

Contingent liabilities, arising as a result of past events, are not recognized as a liability because (i) it is not probable that the Parent Company will be required to transfer economic benefits in settlement of the obligation or the amount cannot be reliably measured at the end of the financial year. Possible but uncertain obligations are not recognized as liabilities but are contingent liabilities. Contingent liabilities are disclosed in the financial statements unless the probability of an outflow of resources is remote.

Contingent assets are not recognized. Contingent assets are disclosed in the financial statements when an inflow of economic benefits is probable.

## ALKERMES PLC

### NOTES TO THE PARENT COMPANY FINANCIAL STATEMENTS (Continued)

#### 3. Summary of Significant Accounting Policies (Continued)

##### *Financial Instruments*

The Parent Company has chosen to adopt Sections 11 and 12 of FRS 102 in respect of financial instruments.

##### Financial assets

Basic financial assets, including trade and other receivables and cash and bank balances, are initially recognized at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Such assets are subsequently carried at amortized cost using the effective interest method. At the end of each reporting period financial assets measured at amortized cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognized in profit or loss. If there is decrease in the impairment loss arising from an event occurring after the impairment was recognized the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognized. The impairment reversal is recognized in profit or loss.

Financial assets are derecognized when (a) the contractual rights to the cash flows from the asset expire or are settled, (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

##### Financial liabilities

Basic financial liabilities, including trade and other payables and loans from fellow group companies, are initially recognized at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if payment is due within one year or less. If not, they are presented within creditors amounts falling due after more than one year.

Financial liabilities are derecognized when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

##### *Cash and Cash Equivalents*

Cash and cash equivalents includes cash in hand, deposits held at call with banks, other short term highly liquid investments with original maturities of three months or less. Bank overdrafts are shown within borrowings in current liabilities. Cash and cash equivalents are initially measured at transaction price and subsequently measured at amortised cost. Bank deposits which have original maturities of more than three months are not cash and cash equivalents and are presented as current asset investments.

#### 4. Loss for the Financial Year

In accordance with section 304 (2) of the Companies Act and Section 341 of the Companies Act, the Parent Company is availing of the exemption from presenting its individual profit and loss account to the Annual General Meeting and from filing it with the Registrar of Companies. The Parent Company's net loss for the financial years ended December 31, 2020 and 2019, determined in accordance with Irish GAAP, was \$1.8 million and \$20.2 million, respectively.

#### 5. Critical Accounting Judgments and Estimation Uncertainty

The preparation of the Parent Company's financial statements requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, turnover and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Parent Company evaluates its estimates and judgments and methodologies, including those related to the carrying value of investments in subsidiaries and measurement of share-based compensation. The Parent Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. The key judgement identified by the Parent Company's board of directors relates to the impairment of the Parent Company's investments in its subsidiaries. Consequently, the Parent Company assesses at each reporting date whether there is any indication that an investment in a subsidiary has been impaired. If such indication exists, the Parent Company is required to undertake a review for impairment and estimate the recoverable amount of the asset.

ALKERMES PLC

NOTES TO THE PARENT COMPANY FINANCIAL STATEMENTS (Continued)

6. Employees and Directors

The Parent Company had no employees during the year. The Parent Company's directors are not employees but are remunerated for their service by the Parent Company. See Note 25, *Directors' Remuneration* of the notes to the consolidated financial statements for a summary of their remuneration.

7. Financial Assets

Financial assets relate to investments in subsidiaries.

	(In thousands)
Balance—January 1, 2019, at cost	\$ 2,005,008
Capital contribution in respect of share-based payment plans	96,088
Reduction—equity recharge from subsidiaries	(46,635)
Balance—December 31, 2019, at cost	\$ 2,054,461
Capital contribution in respect of share-based payment plans	87,536
Reduction—equity recharge from subsidiaries	(23,232)
Balance—December 31, 2020, at cost	<u>\$ 2,118,765</u>

The Parent Company's only direct subsidiary is Alkermes Ireland Holdings Limited ("AIHL") of which it owns 100%. AIHL is a holding company, incorporated in the Republic of Ireland and a registered office located at Connaught House, 1 Burlington Road, Dublin 4, Ireland D04 C5Y6. See Note 27, *Subsidiaries*, in the consolidated financial statements for the list of direct subsidiaries.

8. Associated Undertakings

In May 2014, the Parent Company entered into an agreement whereby it is committed to provide up to €7.4 million to a partnership, Fountain Healthcare Partners II, L.P. of Ireland ("Fountain"), which was created to carry on the business of investing exclusively in companies and businesses engaged in the healthcare, pharmaceutical and life sciences sectors. As of December 31, 2020, the Parent Company's total contribution in Fountain was equal to €7.0 million, and its commitment represents approximately 7% of the partnership's total funding. The Parent Company is accounting for its investment in Fountain under the cost method. At December 31, 2020 and 2019, the Parent Company's investment is equal to \$4.9 million and \$5.9 million, respectively, which is included within "Associated undertakings" in the accompanying balance sheets.

	(In thousands)
Balance—January 1, 2019, at cost	\$ 5,463
Contribution to associated undertakings	815
Foreign exchange	(366)
Balance—December 31, 2019, at cost	\$ 5,912
Contributions to associated undertakings	87
Distributions from associated undertakings	(1,659)
Foreign exchange	519
Balance—December 31, 2020, at cost	<u>\$ 4,859</u>

9. Debtors

(In thousands)	December 31, 2020	December 31, 2019
<i>Amounts falling due within one year</i>		
Trade receivables	\$ —	\$ 146
Prepaid expenses and other current assets	717	3,923
Intercompany notes and loans receivable	71,878	87,145
	<u>\$ 72,595</u>	<u>\$ 91,214</u>
<i>Amounts falling due after one year</i>		
Intercompany loans receivable	776,400	715,400
Total	<u>\$ 848,995</u>	<u>\$ 806,614</u>

ALKERMES PLC

NOTES TO THE PARENT COMPANY FINANCIAL STATEMENTS (Continued)

9. Debtors (Continued)

The Parent Company's intercompany notes and loans receivable due within one year consisted of the following:

Borrower	Maturity	Interest Rate	Balance at December 31,	
			2020	2019
(in thousands)				
Daravita Pharma Ireland Limited	Repayable upon demand	None	\$ 3,600	\$ 3,600
Alkermes Finance Ireland No.3 Limited	Repayable upon demand	Variable	68,278	83,545
Total			<u>\$ 71,878</u>	<u>\$ 87,145</u>

The Parent Company's intercompany loans receivable with a maturity greater than one year consisted of the following loans:

Borrower	Maturity	Interest Rate	Balance at December 31,	
			2020	2019
(in thousands)				
Alkermes Pharma Ireland Limited	July 8, 2022	7.00%	\$ 291,000	\$ 291,000
Alkermes Pharma Ireland Limited	September 27, 2022	7.00%	435,400	424,400
Alkermes Pharma Ireland Limited	January 1, 2024	9.00%	50,000	—
Total			<u>\$ 776,400</u>	<u>\$ 715,400</u>

10. Creditors

(In thousands)	December 31, 2020	December 31, 2019
<i>Amounts falling due within one year</i>		
Accrued expenses	\$ 2,779	\$ 736
Trade creditors	47	87
Intercompany payables	37,189	40,421
Total	<u>\$ 40,015</u>	<u>\$ 41,244</u>

Trade and other creditors are payable at various dates in the next three months in accordance with the suppliers' usual and customary credit terms. Intercompany payables are amounts due to subsidiaries related to transactions in the normal course of business, are interest free and are expected to be repaid in the next three months.

11. Share Capital

(In thousands, except per share amounts)	December 31,	
	2020	2019
Authorized:		
40,000 ordinary shares of €1 par value	\$ 40,000	\$ 40,000
50,000,000 preferred shares of \$0.01 par value	500,000	500,000
450,000,000 ordinary shares of \$0.01 par value	4,500,000	4,500,000
Share Capital	<u>\$ 5,040,000</u>	<u>\$ 5,040,000</u>

Issued Ordinary Shares (par value, \$0.01 per share) (Value in thousands)	Number	Value
Balance at January 1, 2019	158,180,833	\$ 1,579
Issuance of ordinary shares under employee stock plans	2,309,055	23
Balance at December 31, 2019	160,489,888	1,602
Issuance of ordinary shares under employee stock plans	1,779,332	18
Balance at December 31, 2020	<u>162,269,220</u>	<u>\$ 1,620</u>

See Note 16, *Share Capital Presented as Equity*, to the Consolidated Financial Statements for additional information regarding equity shareholder's funds.

## ALKERMES PLC

### NOTES TO THE PARENT COMPANY FINANCIAL STATEMENTS (Continued)

#### 12. Reserves

The Parent Company's reserves consisted of the following:

- Share premium—includes amounts received by the Parent Company for the excess of the fair value over par value for the issuance of its common stock; the excess of the fair value over the cost of employee share options; and the par value of shares received from employees for the purchase of share options.
- Profit and loss account—includes the Parent Company's accumulated net income or loss.
- Treasury shares—includes shares of Alkermes plc acquired from employees for the purchase of employee stock options or to satisfy minimum tax withholding obligations related to employee share based awards. Treasury shares are treated as a deduction from the profit and loss reserves until the shares are cancelled, reissued or disposed of. When such shares are subsequently sold or reissued, any consideration received, increases shareholders' funds.
- Other reserves—includes a share-based payment reserve, which represents the share-based compensation expense for the cost of the awards granted to the Parent Company's subsidiaries' employees less amounts remitted to the Parent Company, equal to the fair value of the Parent Company's ordinary shares on the date options are exercised or RSU's vest, less the proceeds received.

#### 13. Related Party Transactions

The Parent Company has not disclosed any other related party transactions as it has availed of the exemption available under the provisions of FRS 102 Section 33.1A "Related Party Disclosures" which exempts disclosure of transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned by a member of that group.

#### 14. Contingencies

From time to time, the Parent Company may be subject to legal proceedings and claims in the ordinary course of business. On a quarterly basis, the Parent Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Parent Company would accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on the Parent Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Parent Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Parent Company's operating results. At December 31, 2020, there were no potential losses from claims, asserted or unasserted, or legal proceedings the Parent Company felt were probable of occurring (at December 31, 2019: none).

#### 15. Auditors' Remuneration

Remuneration, including expenses, for the statutory audit and other services carried out for the Parent Company by the Parent Company's auditors was as follows:

(In thousands)	Year Ended	
	December 31, 2020	December 31, 2019
Audit of the Parent Company's individual financial statements	\$ 25	\$ 25
Other assurance services	—	—
Tax advisory services	—	—
Other non-audit services	—	—
<b>Total</b>	<b>\$ 25</b>	<b>\$ 25</b>

See Note 26, *Auditors' Remuneration*, to the Consolidated Financial Statements for additional information regarding fees paid to PricewaterhouseCoopers and its affiliated firms by the Parent Company.

#### 16. Approval of the Financial Statements

The financial statements were approved and authorized for issue by the Parent Company's board of directors on April 14, 2021 and were signed on its behalf on that day.

